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Abstract 
 
At present mammalian cell factories are being employed for recombinant protein production. 
However, the yields of proteins produced from such systems are often poor.  This thesis 
describes experiments to study the effects of altering targeting signals (signal peptide) and 3’ 
untranslated regions (3’UTR) in an expression vector on protein expression.  A variety of 
gene constructs containing Gaussia princeps luciferase as reporter were created using a 
seamless cloning method.  In these constructs a variety of signal peptides, some with altered 
hydrophobicity, were combined with the Gaussia luciferase coding region and either the 
native Gaussia luciferase or human albumin 3’UTR.  These were then transfected into CHO 
AA8 Tet-Off cells to measure how modification of the signal peptide/3’UTR affects protein 
expression.  The results indicate that the Albumin 3’UTR, in conjunction with an appropriate 
signal peptide, boosts protein production by approximately 3 fold compared to the native 
Gaussia luciferase 3’UTR.  Deletion analysis of the Albumin 3’UTR showed that deletion of 
regions ∆1-50, ∆1-100, ∆1-150, ∆101-150 significantly reduces protein production compared 
with deletion of regions ∆51-100, ∆51-150 and ∆1-50&101-150.  Interestingly, mRNA 
abundance levels were significantly decreased for constructs containing deletions in regions 
1-50, 1-150 and 1-50&101-150. UV Cross linking and electrophoretic mobility gel shift 
competition assays showed strong competition by RNA transcripts from the deletion construct 
∆1-50, which was then used as bait for isolating bound protein/s from a CHO cell extract. 
Three proteins, including CUG-BP1 an RNA-binding protein involved in mRNA stability and 
translation were identified by mass spectrophotometry analysis.  Knock down of CUG-BP1 
expression using siRNA, led to impairment of complex formation between CHO cell protein 
extract and Albumin 3’UTR RNA transcripts, and in addition it led to an increase in the 
  
iv 
reporter activity and mRNA expression level in cells expressing the reporter gene with the full 
length Albumin 3’UTR and deletion variant 51-100.  It is hypothesised that the differences in 
mRNA expression levels and secreted luciferase activity were due to CUG-BP1 binding to the 
Albumin 3’UTR.  Further work is needed to explore the effects of CUG-BP1 on mRNA 
translation and stability. 
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 1. Introduction 
1.1 Recombinant protein production and biotechnology 
Recombinant protein production has increasingly become a thriving industry in the past three 
decades. Since their introduction, recombinant proteins have made a huge impact on modern 
medicine by providing treatment for varying conditions ranging from cancer to infertility 
(Victibix, Follistim/Gonal-F).   For any given recombinant protein to be biologically active, it 
requires the correct folding and where possible appropriate post-translational modifications.  
If the recombinant proteins are to be used as therapeutics or for medical diagnostic purposes, 
it is crucial that they are produced to the highest degree of similarity to their naturally 
occurring equivalent.  
Table1.1 A selection of commercialised recombinant proteins produced in Chinese Hamster Ovary cell 
lines (CHO) [1] . 
 
Product                                               Therapeutic use                                 Year of approval         
Vectibix                                                     Metastatic colorectal cancer                            2006 
Myozyme                                             Pompe disease                                                 2006 
Orencia                                                Rheumatoid arthritis                                         2005 
Luveris                                                 Infertility                                                          2004    
Avastin                                                Lung and colorectal cancer                              2004    
Advate                                                 Hemophilia A                                                   2003 
 Xolair                                                 Asthema                                                            2003                                                  
Although much has changed since the early days of recombinant protein production, the 
general approach for the large scale production of recombinant proteins has been based on the 
1 
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development of genetically engineered expression systems that contain the genetic code for 
the protein of interest.  Mammalian expression systems offer advantages and are superior to 
other systems (bacteria, yeast) in that they produce proteins with post-translational 
modifications (glycosylation, phosphorylation, etc) which are essential for many proteins to 
be fully biologically active [2].  However a major obstacle for mammalian expression system 
has been the relatively low production of protein from these cells as well as being costly and 
complex to maintain [3].  To overcome this obstacle various methods have been utilised, such 
as expression vectors which contain a heterologous promoter in conjunction with 
polyadenylation signals [4].  The production efficiency of recombinant proteins in 
mammalian systems can be increased if the chosen cell line is compatible with the promoter 
[5].   In addition to this method, gene amplification to increase the gene copy number has also 
been widely used. An example of the latter is the dihydrofolate reductase (dhfr) gene that 
enables the amplification of the transfected DNA in host cells [6].  This method is one of the 
most stringent methods and frequently used processes available to select for cells that express 
the gene of interest at high level. However, a disadvantage to this system is the long selection 
process involving a steady increase of methotrexate ( an inhibitor specific to the dfhr gene) 
that is needed to amplify the gene of interest that results in the generation of cell lines with 
high productivity  [7]. 
Generally, to promote the expression of recombinant proteins a strong viral or cellular 
promoter/enhancer is used [8].  An example includes the cytomegalovirus (CMV) immediate 
early (IE) promoter-enhancer which is renowned for its strong activity in a variety of cell 
lines.  The baculovirus vectors have also been utilised in mammalian and insect systems for 
large scale expression of recombinant proteins.  The Baculovirus expression system offers 
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many advantages, such as insertion of up to 38 kb of DNA into the host genome which in turn 
allows the delivery of multiple genes from a single vector.  Furthermore, this system allows 
the production of non-toxic products and can also carry out post-translational modifications to 
the proteins [9-13].  
By optimising the coding region (codon optimisation) it is also possible to improve the level 
of gene expression in mammalian cell factories.  For example, a mammalian gene may not be 
expressed at a high level if a rare codon is used. Therefore, by replacing the rare codon for 
one that is more abundant, high level protein expression can be achieved [14].  
The transcription of recombinant genes is also heavily influenced by the site of integration  
[15].  This phenomenon is known as the “position effect”.  It is known that the integration 
into inactive heterochromatin leads to little or no levels of transgene expression, whereas the 
integration into active euchromatin allows transgene expression to occur more frequently.  A 
drawback to the latter is that this method may not be sufficient to ensure long term expression 
of the recombinant gene.  Also, it has been found that transgene expression in mammalian 
cells is rapidly inactivated or silenced in many cases.  This could be due to the influence of 
nearby condensed chromatin, as gene silencing correlates with an increase in CpG 
methylation in the promoter region of the transgene, histone hypoacetylation and methylation 
of lysine 9 of histone 3 [16, 17].  
Alternatively, prokaryotic systems can be employed to drive expression of transgenes.  
Examples of their use include that of the production of growth hormones and insulin, which 
are both produced for medicinal purposes on an industrial scale from E.coli.  However, there 
are some limitations to this system.  The lack of post-translational machinery to perform vital 
protein modification is a major caveat in this process.  The lack of appropriate chaperones in 
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bacteria may also lead to the misfolding of proteins, which could potentially lead to the 
production of proteins that are very different in terms of biological activity compared to the 
native protein [3].  The use of known prokaryotic systems is thereby restricted to the 
preparation of proteins that are not naturally glycosylated or the natively glycosylated proteins 
which are pharmacologically active without being glycosylated.  These include interleukins, 
interferons and tumor necrosis factor [18].  
A new approach is currently being employed by a small biotechnology company 
(UniTargetingResearch AS, Bergen, http://www.unitargeting.com/ ) to improve protein 
production by focusing mainly on post-transcriptional mechanisms that influence 
mRNA/protein trafficking and expression.  Rather than focusing on traditional approaches for 
increasing the level of recombinant proteins, such as optimisation of growth medium, 
increasing the transcriptional activity of the transgene by employing a strong 
promoter/enhancer or even amplification of gene copy number, this new technology tackles 
the obstacle of low yield of protein production from Chinese Hamster Ovary cells (CHO) by 
altering the signal peptide and the 3’untranslated region in the transgene.  This novel 
approach is heavily dependent on two key elements within the expression vector ( the signal 
peptide and the 3’ untranslated region (3’UTR)): because of their crucial importance in 
mRNA targeting to the endoplasmic reticulum (ER) and regulation of expression through 
mRNA stability and translation [19].  
In this chapter I will describe the biogenesis of secretory proteins focusing mainly on the 
signal peptide, signal recognition particle and the translocation of protein across the 
mammalian ER.  I also review the current knowledge on mRNA translation, localisation and 
stability with respect to untranslated regions within the RNA transcript. 
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1.2 Synthesis of secreted proteins - an overview 
Since a substantial fraction of synthesised proteins must be transported across or integrated 
into the membrane this raises the question of how the permeability barrier of the membrane is 
maintained if macromolecules cross the barrier, or how proteins could cross a barrier that 
usually prevents such movement? [20].  The process of protein transport from the cytosol into 
the ER is an extremely crucial point in the biogenesis of many proteins, comprising that of 
secretory proteins and plasma membrane proteins [21].  It has been known for decades that 
secretory proteins are synthesised with a hydrophobic N-terminal extension (signal peptide) 
that then guides proteins into the secretion pathway. Protein targeting can occur either co-
translationally or post-translationally (which will not be discussed here).  
In a co-translationally targeting manner, protein synthesis is tightly coupled to the 
translocation process. This requires a close partnership between the ribosome and components 
of the translocation machinery [22].  The advantage of this mode of targeting is the prevention 
of partial folding or the mis-folding of secretory proteins in the cytosol prior to their targeting. 
Therefore, the structures that could hamper the translocation of the protein cannot be formed 
[23]. The co-translational targeting to the ER is initiated as soon as the newly synthesised 
polypeptide emerges from the ribosome.  Once the signal peptide and growing polypeptide 
emerge from the exit subunit of ribosome, it is recognised by a universally conserved protein 
complex known as the signal recognition particle (SRP). 
Next, the complex of SRP and the newly synthesised polypeptide is targeted to the ER 
membrane via the affinities of the signal recognition particle for its receptor on the ER 
membrane.  Once the complex binds to the ER, a series of GTPase hydrolysis reactions result 
in the release of the signal recognition particle from its receptor.  This leads to the transfer of 
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the signal peptide to a protein conducting channel known as the translocon.  This alleviates 
the elongation arrest leading to the resumption of translation of the polypeptide and the 
transfer of the synthesised chain into the ER membrane [22]. 
 
1.2.1 The signal peptide  
A major breakthrough in cell biology was the discovery that secreted proteins contain N-
terminal signal peptide that mediates their translocation across the ER during synthesis [24].   
It has been discovered that the signal peptides are often interchangeable, able to tolerate a 
wide range of mutations, and can direct the secretion in evolutionary distant organisms [25-
27].  It has been estimated that ~20% of random sequences can function as signal peptides and 
promote the secretion of yeast invertase [28].  Although signal peptides vary in amino acid 
content and length, they all share similar structural features (Figure 1.1) and consist of three 
regions: the N-domain (1-5 residues in length which contains only charged amino acid 
residues), a hydrophobic core (7-9 residues in length, also known as the H-domain) and 
finally a short C-domain containing the signal peptidase recognition site [29, 30].  Other than 
that the signal peptides have no known sequence homology.      
 
 
         
 
 
 
Figure 1.1 Schematic representation of signal peptide and its three distinct domains. Signal peptides share 
common structural features: a central hydrophobic core region (green) flanked by a hydrophilic N-region 
(red) with net positive charge and a C-terminal region (blue). The arrow shows the cleavage site by the 
signal peptidase (SPase). 
     
+ + + + +  
N-domain  
Hydrophobic Polar 
H-domain C-domain  
SPase 
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The N-region of the signal peptide is positively charged and it has been reported that 
mutations that cause reduction of the net positive charge or the distance between the basic 
amino acid and the H-domain lead to an accumulation of proteins in the cytoplasm, 
accompanied with the reduction of post-translational export across the ER that can profoundly 
affect the signal peptide cleavage [31, 32].  The hydrophobic core region (H-domain), 
however, is by far the longest and most dominant of all three regions. Mutational analysis of 
signal peptides by various groups has shown that the H-domain is the most important for 
targeting of secretory/membrane bound proteins [29].  It has been reported that the 
hydrophobic core region along with the N-region play a crucial role in the translocation of 
proteins by anchoring the signal peptide firmly onto the membrane of ER [33].   
Furthermore, it has also been reported that deletion of the hydrophobic core or insertion of 
positively charged amino-acids in this region severely disrupts protein translocation and 
protein secretion [34].  The C-domain, which immediately follows the hydrophobic H-
domain, contains neutral but polar residues such as asparagine and serine, in addition to small 
non-polar and small uncharged amino acids at position -3 and -1 respectively (with respect to 
the cleavage site).  The small non-polar and uncharged amino acids crucially determine the 
site of cleavage of the signal peptide by the signal peptidase [35].  It has been claimed that 
alanine is the most commonly found amino acid residue at these two positions [36, 37].  In 
general terms, in spite of having a tripartite structure and physical similarities, the signal 
peptides differ greatly in their functional properties.  For instance, it has been claimed that 
signal peptides may differ in their entrance into the translocon [38] or their reliance on the 
translocation factors that are accessory to the process of translocation [39].  It has also been 
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reported that signal peptides can differ greatly in their overall efficiency in mediating the 
translocation process [20] or their various degree of sensitivity to translocation inhibitors [40]. 
 
1.2.2 Modification of the signal peptide and its consequences 
Altering signal peptide hydrophobicity or even basicity is one approach with potential to 
augment protein secretion levels.  However, there are some drawbacks as well as positive 
effects of these alterations.  Since the hydrophobic core and the basic N-terminus of the signal 
peptide play a critical role in the translocation of proteins, by anchoring the signal peptide 
onto the ER membrane, it has been suggested that increasing the net positive charge of the 
basic region, or increasing the hydrophobicity of the H-domain, might augment the secretion 
level of the translocated protein [41].  Furthermore it has been reported that modification to 
the basic and hydrophobic domains may potentially alter the cleavage site, presumably by 
changing the configuration of the signal peptide inside the translocon or its release into the 
lipid bilayer [41, 42].  As a result, the cleavage of the signal peptide could potentially occur at 
cryptic cleavage sites.  This could potentially decrease the biological activity of a recombinant 
therapeutic protein.  The signal peptides interact with the SRP via their ability to form α-
helical structures [43, 44].  
It has been postulated that the helical potential of the H-domain may act as a unique factor for 
recognition by SRP and other elements of the export pathway of secretory proteins.  Reducing 
the net positive charge of the N-terminus can be compensated by increasing the 
hydrophobicity of the H-domain [31, 45].   It has also been claimed that the positive charge of 
the N-terminus domain of the signal peptide may play a crucial role in associating the signal 
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peptide with the ER membrane as a result of electrostatic interaction with the negatively 
charged phospholipids [45].   
Work by Zhang et al (2005) showed that alteration to both the basic N-terminus and 
hydrophobic H-domain increases the secretion level of protein more than that of the 
modification to each domain separately.  However, further alterations (reducing the positive 
charge and increasing the hydrophobicity) to both domains did not lead to a further increase 
in the level of protein secretion.  Firstly, this pointed to a hydrophobicity limit for the signal 
peptide.  Secondly, it seems that the hydrophobic core of a signal peptide and the basic 
domain may act as a unit and share some overlapping functions. When the total 
hydrophobicity of the unit is ideal, it increases the secretion level of protein perhaps by 
having a stronger affinity for binding to SRP. On the other hand, when the total 
hydrophobicity is less than ideal, the affinity of the signal peptide for SRP may not be 
sufficient enough for proper export of the nascent chain [41]. 
 
1.2.3 Cleavage of the signal peptide and its fate 
The signal peptide is cleaved by the signal peptidase as after its insertion into the 
translocation channel or the luminal side of the membrane.  The cleavage depends on many 
aspects of the signal peptide, but the most important factor is the amino acids at positions -3 
and -1 at the N-terminus of the cleavage site.  Cleavage proceeds when charged amino acids 
are absent from -3 position and an amino acid with a short side chain is present at position -1.  
Other signal peptide features such as the length of the H-region and properties of its basic 
region may also influence the cleavage of the signal peptide [46].   
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 It has been proposed that signal peptides may regulate the timing of the cleavage as a means 
of controlling events such as glycosylation and proper folding as well as the protein exit from 
the ER [47].  For instance, the slow cleavage of the native HIV-gp 120 signal peptide results 
in the extended retention of the secretory protein in the ER. Consequently, this prolonged 
retention prevents a premature exposure of the HIV-gp 120 to the immune system or to the 
adjacent cells.  The unusually higher number of positively charged amino acids in the N-
terminus of the HIV-gp 120 has been proposed to cause this delay [47, 48]. 
 Little, however, is known about the fate of the signal peptide after cleavage, but it has been 
suggested that the cleaved fragments of the signal peptides may have functional role/s either 
in the lumen of the ER or the cytosol [46].  For instance, it has been demonstrated that the 
signal peptide of bovine preprolactin is first partly processed by the signal peptidase then 
further processed by an uncharacterised signal peptide peptidase [49].  This particular signal 
peptide is initially processed into a 20 amino acid long fragment, which contains the entire N-
region and half of its hydrophobic core region.  The fragment is later released into the cytosol 
where it binds to calmodulin in a Ca²+ dependent manner. Since this small acidic protein 
(calmodulin) regulates many cellular processes in the presence of Ca²+ signalling pathways 
[50], this indicates that the signal peptide fragments may have a regulatory function.  In 
addition, it has been suggested by others that fragments derived from signal peptide cleavage 
may play a critical role in the immunity surveillance of the cells.  For example, the signal 
peptide fragments could be presented to the natural killer cells or the cytotoxic T cells by the 
major histocompatibility complex (MHC) class 1molecules [51].  
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1.2.4 The signal recognition particle (SRP)  
The translocation of secretory proteins across the membrane of the ER is facilitated by a 
universally conserved protein complex named the signal recognition particle (SRP) [52, 53].  
This 11S ribonucleoprotein binds to the newly synthesised proteins destined for secretion or 
insertion into the membrane as soon as they emerge from the large ribosomal polypeptide exit 
tunnel (Figure 1.2) [54].  The SRP then binds to their N-terminal signal peptide and forms a 
SRP-ribosome nascent chain complex (RNC).  The association of the signal peptide with the 
SRP at this point causes elongation arrest or slow-down of translation of the newly 
synthesised protein.  Subsequently, the SRP-RNC is directed to a protein conducting channel 
(translocon) in the ER by association of SRP with its receptor (SR), which is only found on 
rough ER [55, 56].  
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Figure 1.2 Translocation of secretory/membrane bound proteins across the mammalian ER. The SRP 
recognises the emerging signal peptide, causing elongation arrest (1). The SRP-RNC complex is then 
transferred to membrane in a GTP dependent manner and binds to its receptor, SR (2).  After the docking 
of SRP on its receptor, the signal peptide is then released from SRP (3). Following GTP hydrolysis, the 
SRP disassociates from its receptor (4) [52].  Illustration taken from [52]. 
 
 
 
Interestingly, both the signal recognition particle and its receptor contain GTPase domains 
and alternate between active and inactive states that also reciprocally activate each other [57].   
The GTP hydrolysis of the SRP and its receptor leads to dissociation of SRP from its receptor 
and the release of the RNC to the translocon.  SRP is then recycled and reinitiated into 
another cycle of protein translocation [55, 56].   
The SRP protein-RNA complex in eukaryotes can be divided into two domains: the S domain 
that contains the binding site for the signal peptide [58] and provides an interface for the 
interaction with the SR via coordinated GTP binding [59], and the Alu domain that is 
involved in elongation arrest [60-62].  The S domain comprises of the proteins SRP19, 
SRP54, SRP68, SRP72 as well as nucleotides 100-250 of the 7S RNA [63].  Crucially, the 
  
13 
most conserved part of the SRP complex, namely helix 8 and SRP54 are part of the S domain 
[64].  In eukaryotes, the assembly of the SRP complex takes place in the nucleus as well as in 
the cytoplasm.  Initially, the SRP RNA molecule is transcribed in the nucleus while the 
protein subunits of SRP are synthesised in the cytoplasm.  These are then imported into the 
nucleus with the exception of SRP54.  The imported SRP proteins assemble onto the SRP 
RNA in the nucleus and then this pre-SRP is exported into the cytoplasm where SRP54 binds 
to the complex [65, 66]. 
The Alu domain of mammalian SRP however, includes the heterodimer SRP9/SRP14, which 
are bound to the extreme 5’ and 3’ ends of the 7S RNA [62].  It has been reported that the Alu 
domain is involved in peptide synthesis elongation arrest by interacting with the binding site 
of the elongation factor eEF2 that plays an essential role in protein synthesis [67, 68].  This 
leads to the antagonisation of translation as result of the interference with eEF2 binding to the 
ribosome [69].  The signal peptide recognition of the newly synthesise protein in a GTP-
dependent interaction with SR is regulated by SRP54.  The SRP54 subunit consists of 3 
domains, the amino-terminal domain (N-domain), a central GTPase domain (G-domain) and a 
C-terminal M-domain [70].  It has been reported that the N-domain associates with the G-
domain and may have a regulatory functional role [71].  Functional studies and cross-linking 
experiments have implicated the M-domain of SRP54 as primary site for the binding of the 
signal peptide to SRP [58] as well as the interaction of SRP54 to helix 8 of SRP RNA  [70].  
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1.2.5 Targeting pathways 
A variety of approaches has been employed to investigate the many aspects of protein 
translocation across the ER membrane.  There are multiple pathways by which the signal 
peptides can direct proteins to the membrane.  The translocation can be dependent on the SRP 
and the SRP receptor (SR), or can be fully independent of SRP [72].  If the targeting is 
independent of SRP, as can be found in bacteria and yeast, the translocation and targeting 
involves the SecB protein in bacteria and Sec62-Sec63 complex in yeast [73]( see Figure 1.3).  
The SRP-dependent targeting pathway (as can be found in mammals) however is regulated by 
the 54kDa subunit of the SRP and two subunits of the SRP receptor (α,β).  Interestingly, at the 
membrane the two different targeting pathways use the same targeting pore which is 
composed of the SecA and SecY-E-G complex in bacteria and Sec61 and the BiP protein in 
eukaryotic cells [74-76].  The key factor that determines the selection of SRP-dependent or 
SRP-independent targeting pathways is the signal peptide [46].  More specifically, the 
hydrophobicity of the signal peptide is the main parameter for selecting either of the 
pathways.  It has been shown that signal peptides that direct proteins to a SRP-dependent 
pathway, contain a more hydrophobic H-domain than those signal peptides which promote a 
SRP-independent pathway [77, 78].  Interestingly, a targeting pathway independent of SRP 
and the Sec complex have also been identified in the plasma membrane of bacteria and the 
thylakoid membrane of plant chloroplasts [79, 80].  The key feature of this system is the 
existence of a twin-arginine motif upstream of the H-domain of the signal peptide.  It has 
been demonstrated by several groups that most proteins targeted by the twin-arginine 
translocation system, known as Tat-system, are those which bind to redox-cofactors and fold 
or even oligomerise before targeting takes place [46]. 
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Figure 1.3 Recognition of different targeting pathways by the signal peptide. The hydrophobic region of 
the signal peptide (yellow) discriminates between an SRP-dependent (a) and SRP-independent pathway 
(b). In eukaryotic systems both pathways use the Sec61 complex. Twin-arginine translocation (Tat) so far 
has only been identified in plasmids and prokaryotes. Folded proteins with their bound co-factors (filled 
circle) use the twin-arginine translocation system (Tat-system), whereas unfolded proteins utilise the 
Sec61-dependent system.  Illustration taken from [46]. 
 
 
 
The fact that there are at least three different known targeting pathways indicates the need for 
different rates of translocation.  For instance, in rapidly growing organisms such as yeast, the 
post-translationally translocation pathway is perhaps more favorable. This is because it 
correlates with a higher rate of protein secretion than co-translational translocation.  The 
higher rate of protein translocation is achieved because it is greater than the rate of protein 
synthesis.  Therefore, it has been postulated that cells can make optimal use of the perhaps 
limited number of available Sec complexes.  Hence in bacteria and yeast, the SRP-dependent 
pathway may only be used for proteins that quickly lose their translocation capability [81, 82].   
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1.2.6 Translocation channel (translocon) 
Secretory/membrane bound proteins are translocated across the ER via an aqueous channel 
termed the translocon [72].  This multiprotein pore with a diameter of 9 to 15 Å when inactive 
and 40 to 60 Å when operational is a complex of proteins that is directly or indirectly 
involved in the translocation of proteins [83, 84].  The main component of this pore, the 
heterotrimeric Sec61, surrounds the aqueous pore that spans the lipid bilayer of the ER. Sec61 
consists of Sec61α, Sec61β and Sec61γ and its associated proteins [85].  
While the nascent chain remains in the translocon, it is kept inaccessible to either the luminal 
proteins or the cytoplasmic proteolytic proteins.  The luminal side of the translocon is sealed 
by BiP until the nascent chain grows to a threshold of ~70 amino acids long [86]. The 
growing polypeptide opens the luminal end and co-translational translocation proceeds 
through the translocon (Figure 1.4). The BiP protein is a member of Hsp70 family of luminal 
chaperones which govern the gating of the aqueous pore [87]. 
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Figure1.4 Translocation of proteins across the ER. The inactive protein pore (left) is sealed with BiP 
whereas the active pore (right) assists the translocation of the unfolded nascent chain. When a ribosomal 
subunit binds to the cytoplasmic end of the translocon, the translocon widens (40 to 60 Aº). The nascent 
chain is released into the pore where it starts folding perhaps assisted by BiP. Illustration taken from  
[87].  
 
 
1.2.7 Secretory protein trafficking: from ER to Golgi 
The secretory membrane system that modulates the delivery of lipids, carbohydrates and 
newly synthesised proteins to the cell surface is crucial for cell growth and homeostasis.  This 
system comprises of distinct organelles including the ER, Golgi complex and the plasma 
membrane [88]. The ER, a continuous membrane structure found throughout the cytoplasm of 
eukaryotes, has evolutionary acquired a wide range of functions ranging from the integration 
of proteins into membrane, the translocation of secretory proteins across the membrane, the 
synthesis of phospholipids, modification, folding and degradation of proteins, the storage of 
calcium ions and their release into the cytosol [89, 90].  This complex structure, depending on 
intracellular localisation and cell type, can have tubular morphology or a sheet like structure 
[91].  Large sections of the ER (known as rough ER), are associated with ribosomes involved 
in the synthesis of proteins that are targeted to the lumen of the ER or to the membrane.  In 
contrast, other parts (known as smooth ER) regulate ca2+ concentration, metabolise steroids 
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and carbohydrates, synthesise lipids, and are devoid from ribosomes [91].  Proteins that are 
targeted for secretion out of cells or are integrated into the plasma membrane must be 
correctly folded, assembled into oligomeric structures and glycosylated within the ER before 
being trafficked into vesicles for the Golgi complex.  While in Golgi complex prior to the 
transport of proteins to the cell surface, the proteins are further modified and processed by 
glycosyltransferases or are returned to the ER [92].  The Golgi complex provides a mechanism 
for cells to distinguish various cargoes intended for different compartments, ranging from 
endosomes and lysosomes to the basolateral and apical plasma membrane.  Most crucially the 
Golgi complex can act as a filter to separate proteins that should remain in the ER from those 
destined to be exported out of the cells [92, 93].  
 
1.2.8 Protein retrieval in the ER 
Newly synthesised proteins interact with luminal chaperones (examples include the protein 
disulfide isomerase, calnexin, calreticulin and BiP) upon their co-or post-translational 
insertion into the ER membrane.  The role of these chaperones is to facilitate folding reactions 
necessary for protein oligomerisation and maturation [88].  These chaperones exclusively 
reside in the ER and  must be separated and retained from their substrates upon cargo transport 
from the ER to Golgi complexes [94].  The retention of folding enzymes and ER-resident 
chaperones is brought about by the presence of a specific C-terminal sequence (KDEL 
tetrapeptide) that interacts with soluble receptors or the integral membrane [95].  The KDEL 
tetrapeptide is part of protein sequence that is recognised by a membrane-bound receptor for 
the KDEL tetrapeptide (Erd2) that binds to the ER-resident chaperones in the Golgi complex 
and therefore facilitate their retrieval to in the ER [96].  Incorrectly folded proteins are also 
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retained in the ER.  It has been postulated that the retention of incorrectly folded proteins 
occur as a result of extensive interactions with the ER chaperones.  This leads to the 
immobilisation and subsequent degradation of these proteins [97].  A receptor-mediated model 
of transport suggests that correctly folded proteins are recognised by the transport receptors 
which in turn target these proteins for secretion into transport vesicles. Next, proteins 
transported into Golgi and continue their transport. However, incorrectly folded protein or 
mis-folded proteins cannot be targeted by transport receptors and therefore aggregate within 
the ER [97].  
 
1.2.9 Modulation of secretory pathway: unfolded protein response 
The ER not only directly regulates the process of protein maturation, but also has a major role 
in transferring signals to the rest of the cell that may subsequently influence the rate of protein 
secretion [98].  It has been shown that within the ER there is a sensitive surveillance 
mechanism to ensure firstly that mis-folded proteins are prevented from exiting the secretory 
pathway and then secondly the mis-folded proteins are directed towards a degradation 
pathway (in the ER or cytosol) [99].   However, when homeostasis within the ER is disturbed 
(for instance, by accumulation or influx of mis-folded polypeptides that exceeds the folding 
capacity of the ER, or glucose or nutrient reduction and perturbations in ca2+ homeostasis) this 
leads to the activation of a signaling network known as unfolded protein response (UPR) 
[100].  The activation of UFR provides a check point for cells by which cell can survive and 
adapt or commit to a program of cell death under conditions of chronic stress [101].  In 
mammals, UPR is comprised of two parts: the transcriptional activation or up regulation of 
genes that increase the ER folding capacity (such as that of folding enzymes and ER 
  
20 
chaperones) and general translational attenuation of genes which overload the ER [102].  The 
activation of UPR occurs through an orchestrated action through transcription, involving ER-
membrane bound UPR sensors, IRE1 (inositol requiring-1), ATF6 (activating transcription 
factor 6) and translation, involving the protein kinase-like ER kinase (PERK) [102].   
 In unstressed cells, BiP interacts with the luminal domain of ATF6, IRE1 and PERK.  Upon 
aggregation of unfolded proteins in the ER lumen, IRE1 disassociate from BiP and dimerises 
to induce its RNase and kinase activity.  This leads to the splicing of X-box DNA-binding 
protein (XBP1) mRNA, therefore creating a strong transcriptional activator [99, 103].  Genes 
whose induction requires the IRE1/XBP1 pathway includes the ER-associated degradation 
encoding gene. Similarly, ATF6 disassociates from BiP and is transported to the Golgi 
complex, where it is cleaved by S1 and S2 proteases to produce a cytosolic fragment that is 
transported to the nucleus in order to further up regulate transcription of UPR-responsive 
genes [99, 104].  Finally, disassociation of PERK from BiP results in its dimerisation and 
autophosphorylation. The dimerisation and autophosphorylation of PERK leads to the 
phosphorylation of eukaryotic translation initiation factor 2α (eIF2α) leading to general 
attenuation of translation initiation [99].   
 
1.2.10 Modulation of secretory pathway: ER overload response 
ER overload response (EOR) however, is a stress response to deal quickly with over-
accumulation of synthesised protein in the ER membrane that leads to an increase in ca2+ 
permeability [98].  The EOR, just like the UPR requires a series of transcription factors and 
protein kinases that results in the adaptation in gene expression.  However, the EOR uses 
separate mediators in the targeting and signaling to different genes to cause reaction [98].  The 
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EOR response causes activation of the қB kinase (IKK) which in turn leads to the degradation 
of қB inhibitor (I- қB).  This induces the activation of transcription factor NF- қB (nuclear 
factor- қB) that promotes the expression of several genes encoding products involved in 
inflammatory responses or survival/death decisions [105].  
 
1.3 Eukaryotic mRNA and untranslated regions (UTRs) 
 
 
It has been estimated that in higher eukaryotic organisms a small fraction of the genetic 
material codes for proteins [106].  This suggests that most of the genomic DNA is implicated 
in the regulation of gene expression.  This regulation can be exerted at the level of 
transcription or at the post-transcriptional level, in which the translation efficiency, the 
subcellular localisation of the transcript and the stability of the mRNA are regulated [107].  
Transcriptional factors, enhancers, RNA polymerases, silencers and promoters regulate 
transcription of DNA to produce pre-mRNA molecules, which in turn undergo a series of 
stepwise processes to become mature mRNAs [106].   
Pre-mRNA transcripts in eukaryotic organisms possess a common structural feature that 
include a special modified base at the 5’ end known as the cap structure, 5’ and 3’untranslated 
regions (UTRs), introns and exons, and a stretch of adenine residues at the 3’end known as 
poly (A) region. Cis-acting regulatory elements (signals) can occur within the coding region 
as well as the untranslated regions. Processes that lead to mRNA maturation include the 
removal of introns, addition of a cap structure to the 5’end of the first exon as well as the 
inclusion of 100-250 adenine residues at the 3’end.  It is believed that most of the mRNA 
regulatory elements are found within the 5’ and 3’UTRs.  These regulatory elements mostly 
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function as binding sites for binding proteins and generate ribonucleoparticles (mRNPs) 
[108].  Whereas the primary role of the 5’UTR has been claimed to be mainly the regulation 
of mRNA translation, on the other hand the 3’UTR modulates several aspects of mRNA 
metabolism, such as subcellular localisation, translational efficiency and mRNA stability 
(Figure 1.5) [109, 110].  Interestingly, unlike DNA- mediated information (enhancers, 
promoters etc) which is essentially contained in the primary sequence, the regulatory motifs at 
the RNA level can be contained in the secondary as well as primary structure [107].  
 
 
            
 
Figure 1.5 A eukaryotic mRNA and its general tripartite structure. Some possible elements that regulate 
post-transcriptional regulation are shown.  5’ and 3’-untranslated regions mediate translation, subcellular 
localisation and mRNA stability through regulatory elements, such as cap-structure, hairpin and 
secondary structure, upstream open reading frames, internal ribosome entry sites (IRES), RNA protein 
interactions, the formation of multi-protein complexes, poly (A) tail and finally cytoplasmic 
polyadenylation elements. Illustration taken from[106].  
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1.3.1 Structural features of UTRs 
Comparative analysis of partial and completed genome sequences has shown that 5’UTRs and 
3’UTRs contain some conserved aspects.  In general, 3’UTRs are longer than 5’UTRs.  The 
average length of 3’UTRs varies, ranging from 50-800nts, whereas the average length of 
5’UTRs is relatively constant over diverse taxonomic classes (100-200nts) [106].  
Intriguingly, even the length of untranslated regions can differ within a species ranging from a 
dozen to a few thousand nucleotides [107].  It has even been claimed that a single nucleotide 
in vitro can act as a 5’UTR and initiate translation [111].  It has been reported that the intron 
content of gene regions corresponding to 5’UTRs is greater than that of 3’UTRs, implying 
that exons at 3’UTRs are perhaps much longer [112].   Furthermore, it has been found that the 
G+C content of UTRs may also vary.  It is estimated that in warm-blooded vertebrates, G+C 
content for the 5’UTR is 60% whereas the 3’UTR is 45% [112].   
 
1.3.2 UTRs and mRNA subcellular localisation 
 
mRNA subcellular localisation is an important aspect of cell development that is mostly 
achieved by active transport of transcripts to various subcellular locations or by producing 
transcripts that differ in stability [113].  The localisation of mRNA within the cytoplasm plays 
a key role in dictating the polarity of the cell in both oocytes and somatic cells in addition to 
its key role in cell fate determination and pattern formation during embryogenic development 
in species such as Drosophila.  The latter is a result of site-specific synthesis of proteins and 
the formation of a morphogen gradient, typically of a transcription factor which determines 
the overall body pattern after fertilisation [114-117].  
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Localisation of proteins through the targeting of mRNA rather than localising the protein 
itself has several advantages [118]: firstly by localising mRNA cells prevent protein 
translation elsewhere. This is highly important for cytoplasmic determinants, which are 
capable of altering the pattern of the embryo if translated in the wrong regions. For instance, 
mislocalisation of oskar and nanos in Drosophila causes the formation of a second abdomen 
in the region of the head and thorax. Secondly, it would be extremely efficient for the cells to 
localise a RNA molecule and hence perform several rounds of translation than targeting the 
synthesised protein multiple times.  Finally by localising the mRNAs, cells can set up a 
protein gradient which can maintain or establish cell diversification and polarity.  In many 
instances the key to translation of the mRNA transcript is the localisation of the transcript to 
the correct destination, which is modulated by cis-acting elements within the 3’UTR. For 
instance, translation of oskar mRNA in Drosophila is inhibited when it is mislocalised in the 
posterior pole of the embryo as a result of the interaction of trans-acting factors with three 
regions within the 3’UTR of oskar mRNA [119, 120].   Whichever way a transcript is 
localised, it must contain the targeting signal or the cis-acting localisation element. These 
elements are recognised by the trans-acting proteins that couple them to the localisation 
machinery [121-123]. The length of cis-acting elements may vary ranging from a few 
nucleotides to over 1 kb. It has been claimed that cis-acting elements are often located within 
the 3’UTR either as a combination of different elements or several copies of the same element 
[124].  It has also been reported that the cis-acting elements can also be situated in the 5’UTR 
as well as the coding region, in spite of the obvious necessity for the coding of amino acids 
[125, 126]. 
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1.3.3 UTRs and control of translation efficiency 
The structural features of the 5’UTR can have a major role in the regulation of mRNA 
translation.  For example, mRNAs encoding proteins involved in developmental processes 
(transcription factors, growth factors or proto-oncogenes) often have 5’UTRs longer than 
average and they contribute to the fine regulation of their translation [106].  These 5’UTRs 
contain upstream open reading frames (uORFs), upstream initiation codons and stable 
secondary structures that can repress translation efficiency [127].  Interestingly, the inhibitory 
effect of the secondary structures can be overcome with an increase in the level of eIF4A, an 
RNA helicase that facilitates ribosome binding and its passage along the 5’UTR towards the 
initiation codon [128].  In addition, the UTRs regulate the efficiency of translation through 
interactions between trans-acting binding proteins and the sequence elements that are targets 
for these proteins.  One of the best studied examples is the iron response element (IRE) in the 
5’UTR region of mRNA coding for proteins involved in iron metabolism [129].  These 
elements impede translation by preventing the 40S subunit from carry out its scanning 
function[107, 130].  
The actual process of mRNA translation requires events that take place at both ends of the 
mRNA transcript.  Broadly speaking it begins by the assembly of the ribosome subunit (40S) 
on the mRNA transcript [131].  The cap dependent translation in eukaryotic organisms 
initiates with the recognition of the m7G cap structure at the 5’-end of mRNA transcript with 
the initiation factor eIF4F (4F).  This heterotrimeric complex consists of 3 subunits: the cap 
binding protein eIF4E, eIF4A and eIF4G, where eIF4G associates not only with eIF4E and 
eIF4A but also with eIF3, a multi-subunit complex that associates with proteins interacting 
with the mRNA’s 5’end and with the 40S ribosomal subunit [132].  Association of the 40S 
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subunit with multiple initiation factors (eIF1, 3 and 5) and also the tRNAmet-eIF2 complex 
forms a larger complex knows as the 43S pre-initiation complex that scans the 5’end of the 
mRNA transcript for the initiation codons. Furthermore, the association of eIF4A with 
another general translation initiation factor known as eIF4B in an ATP dependent manner 
leads to the unwinding of secondary structures in the 5’UTR region [133, 134]. 
Next, eIF5 triggers the hydrolysis of the GTP bound by the ternary complex. This results in 
the release of initiation factors and joining of the large ribosomal subunit (60S) to form the 
80S ribosome that is capable of initiating elongation [135].  When the 43S pre-initiation 
complex encounters the AUG start codon, it initiates translation.  However, it has been 
claimed that a great proportion of the 5’UTRs contain upstream AUGs ranging from 15% to 
50%, the percentage dependent on the type of organism.  This implies that a scanning model 
of the ribosome for the first AUG start codon selection is ignored in mRNA transcripts with 
multiple upstream AUG start codons [106].  
Whenever the scanning subunit faces a poor initiation start codon which lacks the optimal 
context for translation initiation (Kozak sequence), it may bypass this furthest upstream codon 
and initiate translation at a more distal AUG start codon.  This mechanism (leaky scanning) 
allows for a variety of proteins to be obtained from the same mRNA transcript [136, 137].  
Furthermore, it has been discovered that there is a direct correlation between the length of the 
5’UTR and the presence of multiple AUG codons.  The longer the length of the 5’UTR, the 
greater the number of upstream AUGs found. The shorter the 5’UTR, the less number of 
AUGs present.  This suggests that upstream AUGs may be involved in keeping the basal 
translation level of an mRNA low [138, 139].    
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Furthermore, the initiation of translation can also occur in a cap-independent manner in which 
the 40S ribosomal subunit is recruited to the close proximity of the AUG start codon without 
being influenced by the cap structure.   In this mechanism the mRNA transcript of RNA and 
DNA viruses contains an element known as an internal ribosome entry site (IRES) that allows 
ribosomes to initiate effectively on highly structured 5’UTR regions.  The IRES-dependent 
translation provides cells with a crucial mechanism for protein expression to continue where 
the cap-dependent translation is prohibited, for instance by structural elements (found within 
the 5’UTR) that prevent scanning by ribosomes [140].  Although the mechanism of cap-
independent translation initiation was first discovered in the expression of 
encephalomyocarditis virus [141] and polio virus [142] since then it has been proposed that 
about 3-5% of cellular genes such as mRNAs of proteins implicated in regulating gene 
expression during  cell growth, differentiation, development, cell cycle progression, stress 
response and apoptosis may utilise the IRES-dependent translation [143, 144].  It has also 
been reported that IRES predominantly becomes activated when in a situation such as DNA 
damage and cellular stress under which cap-dependent translation is greatly decreased [145].   
Translational control can also be exerted by the 3’UTR. The 3’UTR can influence the 
translation of mRNA in several ways.  It contains short sequences (motifs) that can interact 
with the specific RNA binding proteins which in turn influence translation efficiency [146, 
147].  It is not surprising that the 3’UTRs are considered as important regions for regulation 
of translation by offering a variety of regulatory mechanisms given its proximity to the 
termination stop codon and the poly (A) tail region.  Given the position of the 3’UTR and 
from a mechanistic point of view, it is very unlikely that this region is ever scanned by the 
scanning subunit. Therefore any interaction between the 3’UTR and the RNA binding 
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proteins could potentially have long lasting influence over translation and enabling the 
modulation at any given time [148].   
It has been claimed that translation of mRNA transcripts can be influenced by the cytoplasmic 
changes in the poly (A) tail length, where an increase in length would normally correlate with 
greater efficiency of translation [149-152].  The poly (A) tail is thought to stimulate 
translation in coordination with the m7G cap by circularising the mRNA transcript.  This 
would lead to the association of the poly (A) tail binding protein (PABP) with the translation 
initiation factor eIF4G, which in turn binds to the cap binding protein eIF4E.  This association 
between PABP and eIF4G is an essential step in translation regulation since evidence from 
several groups has shown that interfering with this interaction (for instance, by over 
expression of mutant eIF4G or the truncation of eIF4G) leads to a decrease in poly (A) 
mediated translation [153, 154].  The poly (A) tail and its length are modulated by elements 
within the 3’UTR.  Polyadenylation can take place in the cytoplasm as well as in the nucleus.  
In order for cytoplasmic polyadenylation to take place, two elements within the 3’UTR are 
essential: the hexanucleotide polyadenylation signal (AAUAAA) and the nearby cytoplasmic 
polyadenylation element (CPE) where the latter is usually located within 20-30 nucleotides of 
the polyadenylation signal.  It has been reported that CPE can only mediate polyadenylation 
efficiently if it is located within 100 nucleotides from the polyadenylation signal [155, 156].  
 
1.3.4 UTRs and control of mRNA stability 
A crucial step in the post-transcriptional regulation of gene expression is the control of 
mRNA stability and turnover.  A variety of mechanisms have been suggested to define 
mRNA stability and turnover, such as the shortening of the poly (A) tail at the 3’-end or 
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equally the removal of the 5’cap structure [157].  It has been reported that in the 3’UTR of 
short-lived mRNA transcripts, such as those coding for lymphokines and cytokines, there are 
sequence elements rich in AU that have been identified. These AU-rich elements (ARE) that 
promote the shortening of the poly (A) tail, which results in degradation of the target mRNA 
[158, 159].  The ARE elements are normally found in the 3’UTRs of mRNA transcripts. The 
presence of these elements promotes instability of the mRNA transcript and functions as 
binding sites for RNA binding proteins [160, 161].  
The ARE elements are grouped into 3 classes based on their functional and structural 
properties.  Classes I and II share a common structural feature in which both classes contain 
multiple copies of the pentanucleotide AUUUA.  This pentanucleotide sequence is absent in 
class III [162, 163].  Cytoplasmic shortening and deadenylation of the poly (A) is controlled 
by the class I AREs.  Class I AREs are mainly found in mRNA transcripts encoding nuclear 
transcription factors (such as c-Myc and c-Fos) and some cytokines such as interleukin 4 and 
6 [106, 164].  Unlike class I synchronous deadenylation of mRNA, class II AREs deadenylate 
the poly (A) tail asynchronously at a different time and rate.  This produces mRNAs without 
poly (A) tails. The main characteristic of class II is the presence of the pentanucleotide 
AUUUA with a minimum of 3 in tandem.  Furthermore, an AU-rich region is found upstream 
of these nucleotides [162].  mRNA transcripts encoding class III AREs such as c-Jun lack the 
AUUUA pentamer, instead contain a U-rich segment [165].   
 
1.4 mRNA-binding proteins 
 
Post-transcriptional control of mRNA stability, translation, localisation, polyadenylation and 
splicing is commonly achieved by interaction between the non coding region of an mRNA 
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and the RNA-binding proteins (RBPs) [166].  Although all RBPs can bind to the RNA, the 
interaction is achieved with different levels of affinity and RNA-sequence specificities (RNA-
binding domains) [167].  RNA-binding proteins in general, interact with the sequences within 
the 3’UTR of target mRNA transcripts, however there is evidence of interaction between the 
RNA binding proteins and the 5’UTR or even the coding region [168].  It has been reported 
that in the C.elegans genome, there are approximately 500 genes (2%) that code for RBPs 
with one or more known RNA-binding domains such as the K Homology domain, RNA 
Recognition Motif (RRM), zinc finger domain.  While some domains only predict RNA-
binding function, others may imply a further role in the molecular function of RBPs such as 
the DEAD/DEAH box for RNA helicase activity [169].  The RNA Recognition Motif (also 
known as RNA Binding Domain) is very often found within a single protein as multiple 
repeats as seen in the poly (A) binding protein (PABP) [170].  This enables recognition of 
more complex and larger RNA targets and enhancing the specificity of binding [171].   
 
1.4.1 The diverse function of mRNA-binding proteins 
1.4.1.1 mRNA stabilisers: HU proteins 
The HU family of RNA-binding proteins, is widely becoming recognised as a regulator of 
post-transcriptional gene expression.  It has been reported that the members of this family of 
RNA-binding proteins (HU R, HU B, HU C and HU D) interact with the target mRNAs 
containing the AU and U-rich sequences through their three RNA-recognition motifs.  This 
interaction leads to modification of gene expression as a result of altering the stability of the 
target mRNA transcripts [172]. It has also been shown that the HU family of proteins can 
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increase cell division by stabilising mRNA transcripts that encode cell cycle control and 
proliferation genes such as c-fos, cyclin A and B1 [172, 173]. 
 
1.4.1.2 mRNA destablisers:  KSRP (K homology splicing regulatory protein) 
There are many RNA-binding proteins that promote mRNA degradation such as KSRP.  This 
RNA-binding protein is a member of the far upstream binding protein (FBP) family which 
contains four RNA binding K homology (KH) motifs.  It has also been shown that KSRP 
promotes degradation by associating with the ARE-containing mRNAs via an exosome 
mediated pathway [174].  
 
 
1.4.1.3 mRNA localisers: She2 and She3 
 
ASH1 mRNA (S.cerevisiae) localisation to the bud of daughter cells during cell division is an 
example where mRNA binding proteins facilitate the localisation process.  This localisation is 
achieved by association with two more proteins, She2 and She3 [175].  It has been reported 
that She2 associates as a dimer with the localisation elements in the 3’UTR and coding region 
of ASH1 mRNA [176]. 
 
 
1.4.1.4 mRNA exporters: TAP/NXF1:p15 heterodimer 
 
mRNAs are exported from the nucleus to the cytoplasm as soon as the pre-mRNA processing 
(transcription, splicing and 3’end formation) is finalized [177]. Therefore cells require a 
mechanism to ensure the export of fully processed pre-mRNA out of the nucleus. mRNA 
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binding proteins ( heterodimer TAP/NXF1: p15) are an example of where their association 
with the constitutive transport element (CTE) facilitate mRNA export [167]. 
 
1.4.1.5 mRNA translational repressors : TIAR 
It has been claimed that in the absence of environmental stress, mRNA binding protein TIAR 
acts a translational repressor for ARE-containing mRNA targets such as the tumor necrosis 
factor alpha (TNF-α).  TIAR achieves this by associating with the 40S ribosomal subunit and 
initiation factors eIF1 and 3.  This leads to formation of the preinitiation complex (containing 
the small ribosomal subunit 40S but lacking the initiation factors eIF2 and 5) that is 
translationally inactive [178, 179].  It has also been reported that under environmental stress, 
TIAR can act as a transient repressor for general mRNA pools [179].  
 
1.5 Gaussia princeps and Luciferase reporter system 
 
Gaussia princeps is a marine organism with many secretory glands capable of producing 
Luciferase in response to environmental signals.  This copepod is 10mm in length and lives in 
the Pacific Ocean. The secretory glands of this organism are made from one single cell; 
however its cytoplasm is packed with many secretory vesicles.  The secretory vesicles of this 
organism are released through a pore to the plasma membrane in response to nerve stimuli.  It 
has been reported that the secretory vesicles of Gaussia princeps contain both the Luciferase 
and its substrate, Coelentrazine.  Luciferase and its substrate react only when co-factors Ca2+ 
and O2 are present [180].  
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It has been postulated that this organism uses bioluminescence as a defence mechanism when 
approached by predators or to attract and draw the attention of a mate. Amongst other 
Luciferase reporter systems, the Gaussia Luciferase is the smallest identified Luciferase 
consisting of 185 amino acids and has a molecular weight of 19.8 kDa [181].  The naturally 
secreted Gaussia Luciferase can be readily expressed in mammalian cell lines and emits light 
at a peak of 480nm [182].  Although this system is exceedingly costly to run and requires a 
specialised luminometer to measure Luciferase activity in a short space of time, there are 
many advantages to the Gaussia Luciferase compared to that in other commercially available 
reporter systems.  For example, the Gaussia Luciferase is a secretory protein with a signal 
peptide, therefore upon synthesis it is secreted out of the cell.  This is enormously beneficial 
and time saving since the lysis of the cell is not required.  Furthermore, it has been reported 
that the bioluminescence produced by the Gaussia Luciferase is 1000-fold stronger in signal 
intensity than other reporters such as Renilla and firefly Luciferases.  In addition, it allows 
one to perform sensitive assays due to the stability of the secreted protein [181]. 
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1.6 The aims of this project 
 
The aims of this project were to study the extent to which modifications to the signal 
peptide/3’UTR sequences affect the production of recombinant reporter protein and the 
underlying mechanisms.  A series of novel constructs containing an appropriate Luciferase 
reporter and various signal peptide/3’UTR were created and expressed in an appropriate 
mammalian cell line (CHO AA8 Tet-Off).  To study whether increasing the hydrophobicity of 
signal peptide would influence activity of the reporter protein, the Chymotrypsinogen signal 
peptide hydrophobicity was increased and the reporter activity measured. In addition, 
preliminary results from the JEH laboratory suggested that the Albumin 3’UTR in 
combination with an appropriate signal peptide promotes Luciferase activity more readily 
than the native Gaussia 3’UTR; it was not known whether a particular region/motif within the 
Albumin 3’UTR is responsible for the higher reporter activity and Luciferase secretion. To 
examine this, a series of constructs with the mutated Albumin 3’UTR were created and 
subsequently the secreted Luciferase activity and mRNA expression was measured.  Finally, 
the project aimed at studying the effects of protein(s) binding to the Albumin 3’UTR and the 
extent to which the reporter activity and specific protein binding to the Albumin 3’UTR can 
be correlated. 
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2 Materials and methods 
2.1 Chemicals  
 
Name                                                                                           Supplier 
Acrylamide/bis-Acrylamide (40% stock solution) 19:1                 Sigma 
Agar                                                                                                 Sigma 
Anti Rabit IgG (whole molecule) Peroxidase Antibody                 Sigma 
Ammonium Persulphate 98%                                                         Sigma 
ATP, [α-32P]- 800Ci/mmol 10mCi/ml , 250 µCi                           PerkinElmer 
Biotin-16-UTP (250nmol)                                                               Roche 
BiotaqTM DNA Polymerase                                                             Bioline      
Blue/Orange Loading Dye,6x                                                          Promega                                                  
Bovine Serum Albumin (10mg/ml)                                                 New England BioLab 
Bradford Reagent                                                                             Sigma-Aldrich 
Bromophenol Blue                                                                           Sigma 
Chloroform                                                                                       Sigma 
Coeloentrazine                                                                                 UniTargetingResearch AS 
ColorBurstTM Electrophoresis Marker                                             Sigma 
Complete Mini,EDTA-free Protease Inhibitor                                 Roche 
CUG-BP1 (Rabbit polyclonal) Antibody                                         Abcam 
Diethyl Pyrocarbonate (DEPC)                                                        Sigma                                                  
Dimethylsulphoxide (DMSO)                                                          Sigma-Aldrich 
Dithiothreitol (DTT)                                                                         Invitrogen 
dNTP mix                                                                                          Bioline 
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DMEM Medium                                                                                 Invitrogen 
α- MEM Medium (optimum medium)                                               Invitrogen 
Ethanol                                                                                               Sigma 
Ethidium Bromide (50 µg/µl)                                                             Sigma 
Fetal Calf serum                                                                                  Sigma 
Ficoll                                                                                                   Sigma                             
Glycerol 99.5%                                                                                   Sigma-Aldrich 
Glycine                                                                                                Signam-Aldrich 
ECL solution                                                                                       GE Health care 
Isopropanol 99%                                                                                 Sigma 
Lipofectamin TM 2000                                                                         Invitrogen 
Magnesium Chloride Solution 1.M                                                     Sigma 
N,N,N’,N’-tetramethylethylene-diamine (TEMED)                           Sigma 
Nonidet P-40 (NP-40)                                                                         Sigma 
Optiphase Hisafe 2 (scintillation liquid)                                              PerkinElmer 
Phosphate buffered Saline                                                                   Invitrogen 
Phenol:Chloroform:Isoamyl Alcohol (25:24:1)                                   Sigma 
(Saturated with 10mM Tris, Ph 8.0,1mM EDTA) 
Powder Milk                                                                                        Marvel                        
RNase A (7000 u/ml)                                                                           Qiagen 
RNase T1 (1000 u/µl)                                                                          Ambion   
RNasin Ribonuclease Inhibitor (40u/ul)                                              Promega                                               
Sodium Chloride                                                                                  Fluka 
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Sodium Chloride Solution 5M                                                             Sigma          
Sodium Citrate                                                                                     Sigma                                  
Sodium Dodecyl Sulphate (SDS)                                                        Sigma 
Stealth RNAi                                                                                        Invitrogen 
Stealth RNAi (Negative Universal Control)                                         Invitrogen                                                                        
TAE: Tris-Acetae EDTA                                                                      Promega 
TBE: Tris-Borate EDTA                                                                       Sigma 
Trizol                                                                                                     Invitrogen 
Trypan Blue                                                                                           Sigma 
Trypton                                                                                                  Fluka 
Trypsin 10x solution( 0.5% Trypsin and 0.2% EDTA)                         Sigma 
Chloride                                                                                                 Sigma                                                                                 
Tween 20                                                                                               Sigma 
UltraPure™ Agarose                                                                              Invitrogen 
Yeast Extract                                                                                         Fluka 
Yeast tRNA (10mg/ml)                                                                         Ambion 
 
2.2 Antibiotics  
 
Name                   Supplier 
Ampicillin Sodium Salt                                                          Sigma-Aldrich 
Gentamycin (50 mg/ml)                                                          Invitrogen 
Hygromycin B (50 mg/ml)                                                     Invitrogen 
Penicillin-Streptomycin mix                                                   Invitrogen 
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(containing 10,000 U of Penicillin G Sodium and 10,000 µg of Streptomycin Sulphate in 
0.85% Saline /ml) 
 
2.3 Commercial kits  
 
Name                   Supplier 
Colloidal Blue Staining Kit                                                    Invitrogen 
Expand High Fidelity PCR System                                        Roche 
Light Cycler 480 SYBR Green I Master                                Roche                          
MEGAshortscript™ T7 Kit                                                    Ambion 
MinElute Gel Extraction kit                                                   Qiagen 
Miniprep kit                                                                            Eppendorf 
QIAquick PCR Purification Kit                                             Qiagen 
Primer for cDNA synthesis p (dT) 15                                    Roche 
Rapid DNA Ligation Kit                                                        Roche 
Transcriptor Reverse Transcriptase, 250 U                            Roche 
 
2.4 Buffers 
 
Binding buffer (EMSA) 
½ tablet EDTA-free complete protease inhibitor 
10 µl 1M DTT 
4.44 ml DEPC-treated water 
0.5 ml of 10x 40 mM lysis buffer 
10x 40 mM NaCl lysis buffer (EMSA)   
1.3 M NaCl                                                                 
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50 mM MgCl2                                                                                           
0.3 M Tris-HCl, pH 7.6                                                      
130 mM lysis buffer 1 (S-100 CHO cell extraction)     
130 mM NaCl 
5 mM MgCl2 
30 mM Tris-HCl, pH 7.6 
2 mM DTT 
1 minitab EDTA-free protease inhibitor  
130 mM lysis buffer 2 (S-100 CHO cell extraction)     
130 mM NaCl 
5 mM MgCl2 
30 mM Tris-HCl, pH 7.6 
0.5% [v/v] NP-40 
40 mM lysis buffer     
40 mM NaCl 
5 mM MgCl2 
30 mM Tris-HCl, pH 7.6 
1x lysis buffer (CHO S 100 cell extraction)     
0.5 ml of 10x 40 mM NaCl lysis buffer 
 4.5 ml of DEPC-treated water 
10 µl of 1M DTT 
 ½ minitab EDTA-free protease inhibitor 
 25 µl of NP-40 (0.5%) 
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Protein sample buffer (5x) 
2.25 ml of 1M Tris (pH 6.8)                                                       
5 ml of Glycerol                                                                    
0.5 g of Sodium Dodecyl Sulphate (SDS)                             
5 mg of  Bromophenol Blue                                                    
2.5 ml of 1M Dithiothreitol                                                      
5% β-Mercaptoethanol  
Protein electrophoresis running buffer (5x) 1L 
60.6 g of Tris Base                                                                   
144.1 g of Glycine                                                                      
5 g of Sodium Dodecyl Sulphate (SDS)                               
Transfer buffer 
80% (v/v) 1X protein electrophoresis running buffer 
20% (v/v) methanol 
Membrane wash solution 
0.05% (v/v) Tween-20 in 1x PBS 
Blocking solution 
5% (w/v) milk powder in membrane wash solution 
Lysis buffer (Gaussia Luciferase measurement) 
10 mM TrisHCl, pH 7.4                                                     
10 mM NaCl                                                                     
1.5 mM MgCl2                                                                                             
0.5% NP-40                                                                 
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Renilla dilution buffer  
0.5M  NaCl                                     
1M K2HPO4                                        0.1M Potassium Phosphate, pH 7.6 
1M KH2PO4                                                                                                                                                                         
1mM EDTA, pH 8.0              
  
 
0.02% BSA (w/v)                                         
Adjust the pH to 7.6 
Mili-Q H2O to final volume of 100ml 
Storage: at 4˚C after autoclaving 
Renilla dilution solution  
Required amount of Renilla buffer + 1 µl of GAR2 stabiliser (Gaussia Luciferase assay 
reagent) /50 µl of Renilla buffer 
Coelentrazine (CTZ) substrate buffer  
50 mM Tris-HCl, pH 7.6                                   
10 mM EDTA, pH 8.0                     
0.5 M NaCl     
200 µg of coelentrazine                                     
Storage: at 4˚C after autoclaving 
2x dissociation buffer 
90 mM Tris-HCl, pH 6.8 
20% [w/v] Glycerol 
2% [w/v] SDS 
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2% [w/v] β-mercaptoethanol 
0.02% [w/v] Bromophenol Blue 
 0.5x SSC Buffer (protein identification) 
4.38 mg/ml of NaCl 
2.205 mg/ml of Sodium Citrate, pH 7.0 
DEPC-treated water 
dH2O to final volume of 250 ml 
0.05% of DEPC [v/v] 
Sterilised by autoclaving                            
 
2.5 Growth medium 
Bacteria growth medium 
LB (Lysogeny Broth) Agar                                       LB (Lysogeny Broth) Medium 
Preparation of 500 ml                                                Preparation of 500 ml    
10 g of Agar (2%)                                                      5 g of Tryptone 
5 g of Tryptone                                                          5 g of NaCl                                                  
5 g of NaCl                                                                2.5 g of Yeast Extract 
2.5 g of Yeast Extract                                               dH2O to final volume of 500 ml         
dH2O to final volume of 500 ml                               Sterilised by autoclaving    
Sterilised by autoclaving                                           
Cell culture growth medium 
500 ml of DMEM Medium 
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50 ml of FCS (10%) 
5 ml of Penicillin/Streptomycin mix (1%)  
300 µl of Gentamycin 
The growth medium used for transfected cells contains 400 µg/ml Hygromycin B. 
Medium for freezing cells 
Preparation of 50 ml 
45 ml of FCS 
5 ml of Dimethylsulphoxide (DMSO) 
 
2.6 Enzymes 
Enzyme                                                                            Supplier 
Transcriptor Reverse Transcriptase, 250 U                      Roche       
Protector RNase Inhibitor 2000 U                                    Roche              
AccI (20000 U/ml)                                                            New England BioLabs 
BamHI (20000 U/ml)                                                        New England BioLabs 
PflmI (8,000 U/ml)                                                            New England BioLabs 
   
2.7 Electrophoresis and agarose gels 
 
Preparation of 1% gel 
0.250 g of Agarose 
25 ml of TAE 
1 µl of Ethidium Bromide  
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Acrylamide gel: 
Urea Stock  
18.9 g of Urea 
9 ml of 5x TBE 
Adjust to final volume of 45 ml of DEPC treated- water 
Acrylamide stock 
8.4 g of Urea 
10 ml of 40% Acrylamide/bis (19:1) 
Adjust to final volume of 20 ml with DEPC- treated-water 
To make gel: 
7.5 ml of Urea Stock 
2.5 ml of Acrylamide stock 
10 µl of TEMED 
80 µl of APS (10%) solution [w/v] 
SDS PAGE GEL  
Separating gel 
                                                                                             10%                    12.5% 
40% Acrylamide /bis - Acrylamide Stock (37.5:1)             1.75ml                2.19 ml 
2.5x Separating Gel Buffer                                                  2.8ml                 2.19 ml 
[1.875 M Tris Base pH8.9, 0.25% SDS]       
Distilled Water                                                                     2.4 ml                1.94 ml 
TEMED                                                                                6 µl                    6 µl 
APS (10%) solution [w/v]                                                    65 µl                  65 µl 
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Stacking gel 
40% Acrylamide /bis-Acrylamide Stock (37.5:1)                  0.25 ml 
5x Stacking Buffer                                                                 0.4 ml 
[0.3 M Tris, pH6.7, 0.5% SDS] 
Distilled Water                                                                       1.32 ml 
TEMED                                                                                  2.5 µl 
 APS (10%) solution [w/v]                                                     18 µl  
 
2.8 Bacterial Strain                                                                
One Shot ® TOP10 Competent Cells (Invitrogen)  
Genotype: F- mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ∆M15 ∆lacX74 recA1 araD139 
∆(araleu) 7697 galU galK rpsL (StrR) endA1 nupG                       
                                                                                                                 
2.9 Cell line                                                 
CHO AA8 Tet-Off (Clontech)                      
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2.10 Primers and oligonucleotides 
 
Table 2.1 primers used for general purpose PCRs (Chapter 3 and 4). 
 
 oligo Sequences (all in 5’ to 3’-direction) 
Gau.for  5’ TCCTAATAGAATACTGCATAACTG 
Gau.rev  5' GGATTGCATAAATTATATTTATAGGAATTAC 
G3Da.for  5’ CCAAGATGAAGAAGTTCATC CCAGG 
CDs.for   5’ GCGACCTTTGCCAGCAAGATCC 
pTRE2_rev  5’ CCATTCTAAACAACACCCTG 
Glob.rev   5’ GTATTACCGCCTTTGAGTGAGC 
Chy.rev   5’ CGTTGTTCTCGGTGGGCTTGGAATAAGCCGAGGTAA 
Chy.for  5’ GTATCTTCTGGCAGGGAAAATGAAGTGGGTAACCTT 
pTRE2.for  5’ CGCCTGGAGACGCCATC 
pTRE2a.for  5’ GGCTCCTCTTCTGCTGGGCC 
pTRE2a.rev 5’ GGCGCAGAAGAGGAGCC 
pTRE2b.for  5’ CCTCCTGGGTGCCACCTTCG 
pTRE2b.rev 5’ CGAAGGTGGCACCCAGGAGG 
Alb3.rev  5’ AGATTCTTTCCATTTTTTATTAATTGAAGC 
G3Db.rev  5’ TTAGTCACCACCGGCCCCCTTG 
BCD.rev   5’ ACCGCCTTTGAGTGAGCTGATACC 
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Table 2.2 Primers used for the Albumin 3’UTR deletion analysis work (Chapter 3 and 5). 
 
 oligo Sequences (all in 5’ to 3’- direction) 
Alb151.100For 5’ TTCTTTTTCGTTGGTGTAAAGCCTCTGTGCTTCAAT 
Alb.151.50.For 5’ CCATGAGAATAAGAGAAAGAAACTCTGTGCTTCAAT 
Alb50.151.Rev 5' CCATTTTTTATTAATTGAAGCACAGAGTTTCTTTCT 
Alb50.100.Rev 5' ATGTTTTTTAGACAGGGTGTTGTTTCTTTCTCTTAT 
Alb51.luc.For 5' CAAGGGGGCCGGTGGTGACTAAATGAAGATCAAAAG 
Alb100.151.Rev 5' CCATTTTTTATTAATTGAAGCACAGAGGCTTTACAC 
 
Table 2.3 Primers used for performing the Real-Time PCR experiment (Chapter 4, 5 and 6). 
 
Diagnostic oligo Sequences (all in 5’ to 3’- direction) 
RTluc.for  5′ GTTCTGACCTGCTCAAGAAGTGG 
G3Db.rev 5′ TTAGTCACCACCGGCCCCCTTG 
CHOGAPDH .For  5’ ATGGTGAAGGTCGGCGTGAACG 
CHOGAPDH.rev  5’ GGTCATTGATGGCAACAACTTCCTCTTTGCC 
 
Table 2.4 Primers used for performing seamless cloning procedure (Chapter 3). 
 
 oligo Sequences (all in 5’ to 3’- direction) 
5’UTR.for  5’ GGCGTGTACGGTGGGAGGCC 
5’UTR.rev  5’ TTTCCCTGCCAGAAGATAC 
CDC.for  5’ AAGCCCACCGAGAACAACGAAGACTTCAACATCG 
CDC.rev  5’ TTAGTCACCACCGGCCCCCTTGATCTTGTCC 
OliAlbSP.for  5’ ATGAAGTGGGTAACCTTTAT TTCCCTTCT 
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OliAlbSP.rev 5’ 
GGAATAAGCCGAGCTAAAGAGAAAAAGAAGAGAAAA 
AGAAGGGAAATAAAGG  
AlbSP.for   5’ GTATCTTCTGGCAGGGAAAATGAAGTGGGTAACCTTTTTCC 
AlbSP.rev   5’ GGAATAAGCCGAGCTAAAGAGCGTTGTTCTCGGTGGGCTT 
Gausig.for  5’ GGAGTCAAAGTTCTGTTTGCC 
Alb3’UTR.for 5’ CATCTACATTTAAAAGCATCTCAGC 
 
 
 
 
 
Table 2.5 Primers used for the protein binding work. Regions in blue refer to T7 minimum promoter 
sequence (Chapter 6). 
 
 oligo Sequences (all in 5’ to 3’- direction) 
Full3UTR.for    5’ TAATACGACTCACTATAGGCATCTACATTTAAAAGC 
Full3UTR.rev   5’ AGATTCTTTCCATTTTTTATTAATTGAAGC 
Del(1-50).for    5’ TAATACGACTCACTATAGGATGAAGATCAAAAGC 
Del(1-100).for  5’ TAATACGACTCACTATAGGCAACACCCTGTCTAAAAAAC 
Del(1-150).for  5’ TAATACGACTCACTATAGGCTCTGTGCTTCAATTAATA 
Del(1-50&101-
150).for            5’ 
TAATACGACTCACTATAGGATGAAGATCAAAAGCTTATTC 
GloFor141_T7 5’ TAATACGACTCACTATAGGGCAGGCTGCTGGTTGTCTAC 
GloRev368      5 CCTGAAGTTCTCAGGATCC 
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2.11 Plasmids 
 
Names                                                                                           Source                 
PTRE2hygGG*G*G                                          UniTargetingResearch AS, Bergen 
PTRE2hygGXG*G                  UniTargetingResearch AS, Bergen 
PTRE2hygGX1G*G                             UniTargetingResearch AS, Bergen 
PTRE2hygGX2G*G                                           UniTargetingResearch AS, Bergen                      
PTRE2hygGG*G*Alb 3∆β                                UniTargetingResearch AS, Bergen 
PTRE2hygGXG*A5 3∆β                                   UniTargetingResearch AS, Bergen 
PTRE2hygGX1G*A5 3∆β                                 UniTargetingResearch AS, Bergen 
PTRE2hygGX2G*A5 3∆β                                 UniTargetingResearch AS, Bergen 
PTRE2hygGG*G*Alb 3∆β (∆1-50)                                          JEH Laboratory 
PTRE2hygGG*G*Alb 3∆β (∆1-100)                                        JEH Laboratory 
PTRE2hygGG*G*Alb 3∆β (∆1-150)                                        JEH Laboratory 
PTRE2hygGG*G*Alb 3∆β (∆51-100)                                      JEH Laboratory 
PTRE2hygGG*G*Alb 3∆β (∆101-150)                                    JEH Laboratory 
PTRE2hyg                                                                                  Clontech 
 
2.12 Storage of materials 
 
Bacteria strain (Top10cells)                                                        -80˚C 
Buffers and solutions                                                                   Room temperature 
  
50 
Cell lines                                                                                      Liquid Nitrogen 
Enzymes                                                                                      -20˚C 
Enzyme buffers                                                                            -20˚C 
Growth media                                                                               +4˚C 
Luciferase medium and cell extract samples                               -80˚C 
Oligonucleotides                                                                          -20˚C 
Plasmids                                                                                       -80˚C 
 
 
 
2.13 DNA techniques                                 
2.13.1 Ligation 
 
The Rapid DNA ligation kit (Roche) was used in this study to ligate the DNA fragments to be 
inserted with double digested vector.  To maximise the chance of ligation, various ratios of 
insert to vector (3:1, 5:1 and 6:1) were used. The calculation to obtain the ratio was as 
follows:   
 
    Ratio of insert =  ng of vector x kb of insert x 3    
                                           kb of vector   
Where ng is nanogram and kb is kilobase.  To set up a ligation reaction the following steps 
were carried out: 
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1. 1x DNA dilution buffer was added to digested vector and insert (according to the ratio) 
to a final volume of 10 µl. 
2. 10 µl of T4 DNA ligation buffer was mixed immediately before use and added to the 
reaction. 
3. After thorough mixing, 1 µl of T4 DNA ligase was added to the reaction vial and mixed. 
4. The reaction mix was incubated for 5 min at RT. 
The ligation reaction products were used directly for transformation of competent cells (One 
Shot ® TOP10 E.coli).     
 
2.13.2 Electrophoresis of DNA 
 
Agarose gel electrophoresis was used to separate digestion products and to purify PCR 
products.  To make the gel and achieve the desired percentage, the appropriate amount of 
agarose powder was mixed with 1x TAE electrophoresis buffer and heated in a microwave 
oven until it was completely melted.  The melted agarose was allowed to cool down for 5-10 
min.  At this point, 1 µl of ethidium bromide (10 µg/µl) was added to the melted agarose to 
facilitate visualisation.  The solution was poured into an appropriate gel casting tray 
containing comb/s and it was allowed to cool down for a further 15-20 min and solidify at RT.  
After the gel was solidified, the comb/s was removed and 1x TAE electrophoresis buffer was 
poured in to fill up the gel tank.  Then 4 µl of samples and 1 µl loading buffer were loaded 
into wells of the gel.  The electrophoresis was performed with an appropriate voltage (60 V) 
for 30-35 min. Finally, the gel was photographed under UV-light. 
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2.13.3 Restriction digestion  
 
Restriction sites for BamHI and AccI were located in the vector sequences by using the web-
based program NEB cutter 2.0 (http://tool.neb.com/NEBcutter2/index/php).  The vector and 
seamless cloning product were digested with the same restriction enzymes.  
General reaction mix for a typical digestion is shown below 
10x   Buffer (according to the enzyme)                         = 5 µl 
BSA (100x)                                                                    = 0.5 µl 
Restriction digestion enzyme (s)                                   = 1 µl (of each) 
DNA (miniprep product)                                               =10 µl 
dH2O (final volume of 50µl)                                         = 32.5 µl 
 
The reaction mix was incubated at 37ºC for 105 to 120 min. 
 
2.13.4 Gel extraction  
 
After separation of DNA fragments by gel electrophoresis, extraction of DNA fragment was 
carried out by using a MinElute Gel Extraction kit (Qiagen) to obtain the desired fragments of 
restriction enzyme digestion products. The digestion products were separated on 0.8% 
agarose gels.  The visualisation of DNA took place under UV-light and gel extraction was 
carried out as according to the manufacturer’s instruction. 
• The desired band was cut out of the gel and the fragment weighed. 
• 3 volumes of binding buffer were added for every volume of excised gel fragment. 
• The gel slice was placed in the binding buffer and incubated at 50ºC for 5-10 min. 
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• One volume of isopropanol was added and 800 µl of mixture added to a spin column       
in a 2 ml collection tube and centrifuged for 1 min at 10000 g, the filtrate was discarded and 
750 µl of wash buffer was added to the spin column. 
• The spin column was centrifuged for 1 min at 10000 g, the filtrate was discarded and the 
spin column centrifuged again for an additional 1 min. 
• The spin column was placed in a fresh collection tube, 30 µl of elution buffer added to 
the centre of the column and the column centrifuged for 1 min at 10000 g. 
• Finally the spin column was discarded and the purified product was collected from the 
bottom of the collection tube. 
 
2.13.5 Polymerase Chain Reaction (PCR) 
 
PCR was performed to amplify the DNA fragments in vectors to either verify the presence of 
specific sequences or as an integral part of the seamless cloning procedure.  The Eppendorf 
Mastercycler Gradient PCR machine was used throughout. 
                           
   General reaction mix for a typical PCR reaction (Expand High Fidelity PCR Kit) 
                          10x buffer                                                                 =5µl 
                          dNTP mix (2.5 mM)                                                 =2µl 
                          Forward primer (10 pM)                                           =5µl 
                          Reverse primer  (10 pM)                                           =5µl 
                          DNA template                                                           =1µl 
                          DNA polymerase                                                       =1µl                                                                                                                
                          dH2O                                                                          =31µl                     
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                          General thermocycling program for a Typical PCR  
                          Step              TM               Time (m/s)                 cycle 
                             1                 95 ºC                 2m                          1  
                             2                 95 ºC                 30s                         30 
                             2                 58 ºC                 30s          30           30                                                                            
                             2                 72 ºC                 1m                          30 
                             3                 72 ºC                 5m                           1 
                             Finally hold at 4ºC 
The optimal annealing temperature was obtained by performing gradient PCR.  
 
2.13.6 PCR purification 
 
Throughout this study PCR products were purified using QIAquick PCR purification kit and 
this was used according to the manufacturer’s instructions.  To purify PCR products, 5 
volumes of buffer BP was added to one volume of PCR sample.  A QIAquick spin column 
was placed into a 2ml collection tube and the sample mix transferred to the spin column.  The 
column mix was centrifuged at 13000 rpm for 30-60 s. Next, the flow-through was discarded 
and the spin column placed back into the collection tube.  To wash, 750 µl of buffer PE was 
added to the spin column and the column centrifuged at 13000 rpm for 30-60 s.  The flow-
through was discarded, the spin column placed back into the collection tube and centrifuged 
for additional 1 min.  The spin column was placed into a microcentrifuge tube and 50µl of 
elution buffer EB transferred to the centre of spin column. After 1 minute of incubation, the 
microcentrifuge tube was centrifuged at 13000 rpm for 30-60 s.  The purified PCR product 
was collected from the bottom of the tube.  
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2.13.7 Quantification of DNA 
DNA was diluted in dH2O water (1:50) and the absorption was measured 
spectrophotometrically using a Biophotometer™ (Eppendorf®). The calculation of 
concentration was based on the knowledge that an OD=1.0 at 260nm corresponds to 50 µg/ml 
DNA (double stranded) or 37 µg/ml DNA (single stranded).  Concentrations of DNA were 
expressed as µg/ml and a good quality sample was judged to be characterised by a 260/280 
ratio of 1.7-1.9. 
 
2.13.8 DNA sequencing 
Sequencing of all the constructs was carried out by MWG bio-tech (Germany).  Prior to the 
sequencing, ~1 µg of DNA samples were placed in microcentrifuge tubes and dried for 30-45 
min in a desiccator.  Finally, 10 µl of forward and 10 µl of reverse primers per reaction were 
sent to MWG along with the samples.  
 
2.14 Bacterial techniques 
2.14.1 Transformation of E. coli cells (One Shot® TOP 10)  
 
 TOP10 competent cells were thawed on ice prior to transformation. For each reaction, 20-30 
µl of competent cells were used.  0.5 µl of plasmid (irrespective of concentration) was used 
for a single transformation experiment.  To each aliquot of TOP10 cells, 0.5 µl of chosen 
plasmid was added.  As a negative control, one aliquot of cells was left without plasmid to 
check that the selection procedure is accurate and that there is no background resistance.  The 
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cells were tapped gently to mix and immediately kept on ice for a minimum of 30 min.  The 
mixture was heat shocked for 30 s at 42ºC and then immediately placed back on ice.  80 µl of 
pre-warmed SOC medium was added to the reaction mix.  Tube(s) were taped together and 
placed on their side in a shaker at 37ºC for 60 min.  50 µl of reaction mix was then spread on 
pre-made LB agar containing Ampicillin with a final concentration of 100 µg/ml.  This was 
carried out with a continuous flame nearby to prevent contamination.  Using a glass spreader, 
cells were spread evenly across the agar plates to cover the whole surface with a glass 
spreader.  The spreader was flamed for 30 s prior to use, then placed on agar to cool it down. 
Plates were incubated overnight at 37ºC. 
 
2.14.2 Miniprep, small scale plasmid purification  
Eppendorf miniprep kits were used for small scale plasmid preparations following the 
manufacturer’s instructions.  A single colony from the overnight plates was selected and 
placed in a tube containing 10 ml of LB medium and of 10 µl of Ampicillin with a final 
concentration of 100 µg/ml.  The tube was incubated overnight at 37ºC with shaking at 200 
rpm. 1.5 ml of overnight culture was centrifuged at 13000 rpm for 5 min.  The supernatant 
fluid was discarded. 0.2 ml of buffer P1 containing RNase was then added and the pellet and 
the buffer mixed a few times with a pipette. In order to lyse the bacteria 0.250 ml of buffer P2 
was added.  Tubes were mixed gently by inversion until the colour changed to blue. 0.35 ml 
of buffer P3 was added next, mixed by inversion and centrifuged for 10 min at 13000 rpm.  
The supernatant fluid was transferred to the columns (ideally 850 µl is taken up and poured 
into the column).  The supernatant fluid was then centrifuged for 1min at 13000 rpm. Next, 
0.5 ml of buffer PB was added and centrifuged for 1 min at 13000 rpm.  The liquid at the 
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bottom of columns was discarded and 0.75 ml of buffer PE was added next.  The columns 
were centrifuged for 1 min and the liquid discarded.  This step was repeated.  The columns 
were then placed in 1.5 ml microcentrifuge tubes and 50 µl of elution buffer was added.  The 
elution buffer was added to the centre of column and left for 1 min and then centrifuged for 1 
min at 13000 rpm.  Finally, the purified plasmid was collected from the bottom of 
microcentrifuge tube.  The column was discarded. 
 
2.15 Cell culture techniques 
 
2.15.1 General cultivation of cells 
 
CHO AA8 Tet-Off cells (Clontech) were grown at 37ºC in an atmosphere containing 5% CO2. 
Cells were cultivated in T-25 or 75 flasks in a monolayer and fed with DMEM medium 
(Dulbecco’s Modified Eagle Medium + GlutaMax) supplemented with 10% [v/v] FCS, 1% 
[v/v] penicillin-streptomycin mix and 300 µl of Gentamycin.  Cells were grown until they 
reached ~90% confluency then subcultured (this normally takes 2-3 days for non-transfected 
CHO cells).  They were washed twice with 1x PBS and then treated with 1 ml of 1x trypsin 
for T-25 flask and 2-3 ml of trypsin for T-75 flask in order to detach the cells.  Cells were 
incubated with trypsin for 2-4 min and then observed under the microscope.  When cells were 
fully detached, fresh growth medium was added to a final volume of 10 ml and the 
resuspended cells were taken up and poured into universal tubes and centrifuged for 5 min at 
1500 rpm.  The cell pellet was resuspended in 10ml of fresh DMEM.  Next, depending on the 
required dilution, 2 or 3 ml of resuspended cells were dispensed into new flasks.  8 or 12 ml 
of fresh medium was added depending on the flask size. 
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2.15.2 Stable transfection of CHO cells 
Stable transfection was performed over a 4 day period.  Day one of the transfection procedure 
began by plating out the cells in 6-well plates. 6x105 cells were seeded into each well so as to 
reach ~90 confluency by the next day.  Three wells of each plate were used for transfecting 
the CHO cells with one construct.  On day two of transfection, using a 96 well (microtiter) 
plate a complex of lipofectamineTM 2000 and DNA was made.  To form the complex, 100 µl 
of optiMEM medium was added to two wells of the microtiter plate in two rows.  Then the 
required amount of DNA (up to 4 µg) was added to the wells of the first row of the plate.  
Next 10 µl of lipofectamineTM 2000 was added to the wells of second row.  Then the contents 
of the wells in the first row were transferred to the well of the second row to form the DNA-
lipofectamine complex.  To achieve this, the contents of the wells in the first row were 
pipetted out and transferred to the corresponding wells of second row then pipetted up once 
more and finally pipetted back gently into the well of the second row.  This procedure was 
repeated only once.  Once the DNA-lipofectamine complex was formed, the cells were 
incubated for 30 min at room temperature. Next, 100 µl of optiMEM was added to give a final 
volume of volume 0.320 ml.  
The medium from the 6-well plates was removed and CHO cells were washed with1 ml of 1x 
PBS.  Then the 320 µl volume of DNA-lipofectamine complex was transferred gently to each 
well of the 6-well plate and a further 0.5 ml of optiMEM was added to each well.  The cells 
were then incubated with the DNA-lipofectamine complex for 5-6 hours.  After this period, 2 
ml of DMEM growth medium was added to each well.  
On day 3, the transfected cells were washed and trypsinised with 1x PBS and 1x trypsin 
respectively.  Cells were transferred to T-25 flasks. On day 4 the transfected cells were 
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washed and trypsinised again, re-seeded into a T-75 flask and cells were then grown in a new 
growth medium containing 400 µg/ml Hygromycin B to maintain selection pressure.  Cells 
were selected against Hygromycin, since the vector contained the gene that confers resistance 
against hygromycin.  The effective concentration of hygromycin had been previously 
determined by the industrial partner (UniTargetingResearch AS, Bergen).  After this step cells 
were cultivated for ~ 4 weeks in medium containing hygromycin.  Finally, the transfected 
cells were harvested for the measurement of Luciferase activity and RNA extraction. 
 
2.15.3 Transient co-transfection 
In transient co-transfection experiments equal volumes (2 µg of each) of a vector containing 
firefly Luciferase sequence and an appropriate plasmid expressing Gaussia Luciferase were 
used.  The procedure was the same as described above in 2.15.2 for stable transfection, except 
that transfected cells were kept in 6 well plates post-transfection and no selection media was 
applied. 
 
2.15.4 siRNA transfection 
CHO cells (500,000) were seeded in a 6 well plate 24 hours before transfection in order to 
reach 30-50% confluency.  On the day of transfection, the growth medium was replaced with 
fresh medium containing only 5% Fetal Calf Serum. 80 pmol of siRNA (4 µl) was added to 
246 µl of OptiMEM medium for each well and incubated for 10 min at room temperature. 
Equally, for each well 5 µl of LipofectamineTM 2000 and 245 µl of OptiMEM were mixed and 
incubated for 10 min at room temperature.  Next, the two solutions were mixed and incubated 
for further 25 min and then added gently to the cells in the 6 well plate.  The medium was 
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replenished the next day and cells were collected on day 1-4 after siRNA transfection to 
maximise the chance for observing the siRNA knock down.  The same procedure was applied 
for the transfection of non-specific siRNA as a control. 
 
2.15.5 Sample collection and cell harvesting (stable transfection) 
2.15.5.1 Medium samples for Luciferase activity measurement 
From each well, 0.9 ml of medium was collected and divided into 2 aliquot of 
microcentrifuge tubes.  Samples were then centrifuged at 10000 g for 10 min at 4ºC (this was 
carried out to remove dead cells or debris) and 0.4 ml of the supernatant fluid was transferred 
to 2 new microcentrifuge tubes.  Samples were stored at -80˚C until to be assayed. 
2.15.5.2 Cell samples for Luciferase activity measurement 
To harvest cells for the preparation of cell extracts, after collecting the culture medium cells 
were washed once with 2.5 ml of cold 1x PBS.  The wash buffer was removed completely and 
250µl of lysis buffer added to the cells.  Cells were incubated for 5 min at room temperature 
and then 250 µl of suspension transferred to a microcentrifuge tube on ice.  To collect the 
remaining cell material, 250 µl of 1xPBS was added to each well of the 6 well plate and wells 
were rinsed carefully by pipetting up and down the 1xPBS.  The solution was transferred to 
the original microcentrifuge tube on ice (now with a final volume of 500 µl) and centrifuged 
at 10000 g for 10 min at 4˚C to pellet the cell debris.  Finally, 450 µl of cell extract was 
transferred into a new microcentrifuge tube. The samples were stored at -80˚C. 
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2.15.6 Cryogenic storage 
 
To store cell stocks cells were grown to ~90% confluency or higher, trypsinised and pelleted 
by centrifugation at 1500 g for 5 min.  The pellet was resuspended in 3 ml of freezing 
medium (90% [v/v] FCS +10% [v/v] DMSO) and 1ml of suspension transferred to Cryo-vials.  
Tubes were kept in the freezer (-20ºC) for two hours, then placed at -80ºC.  Next day tubes 
were transferred to a liquid nitrogen storage tank. 
 
2.15.7 Thawing of cryogenic storage cells 
 
Frozen cells were thawed by placing the Cryo-vials in a water bath (37˚C), and then 
transferred to a universal tube and 5 ml of complete growth medium was added.  The cell 
resuspension was centrifuged at 1500 rpm for 5 min to remove the DMSO from the cells.  The 
cell pellet was resuspended in 5ml of complete growth medium and transferred to a T-25 
flask.  Once the cells reached ~90% confluency, the cells were split and re-seeded in T-75 
flask.  The cells were split every second day thereafter. 
 
2.15.8 Luciferase assay  
 
Samples from culture medium and cell extracts were measured for Gaussia Luciferase 
activity.  First an optimum dilution with minimal inhibitory effect from other components of 
the samples was found by performing a series of dilutions from 1:10 through to 1:21870 in 
Renilla dilution buffer in a 96- well plate.  The optimum dilution was important as the plate 
reader (plate ChameleonTM multilabel counter, Hidex) cannot measure accurately a 
luminescence signal which is too weak or too intense.  Once an appropriate dilution was 
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found, culture medium and cell extract samples were diluted in Renilla dilution buffer 
accordingly.  Next, 25 µl of each sample dilution was dispensed to 2 wells of a white 
microtiter plate (Nunc, Roskilde, Denmark).  The white microtiter plate was used to avoid 
signal interference between wells.  The plate was covered with aluminium foil and kept at 
room temperature for 10-15 min prior to measurement.  The plate reader was programmed to 
dispense 150 µl of coelentrazine substrate buffer to each well. The results of measurement 
were given in RLU in which 1 RLU is equal to 1 photon hitting the detector.  The RLU was 
then converted to percentage of Gaussia Luciferase activity observed from the standard 
construct (cell population) GG*G*G. 
 
2.15.9 Cell count 
 
The confluent CHO AA8 Tet-Off cells were washed once with 1x PBS and trypsinised with 2 
ml of 1x trypsin.  To remove the trypsin, 8 ml of growth medium was added and cells were 
centrifuged at 1500 rpm for 5 min. The cells were then resuspended in 2 ml of growth 
medium.  To count the number of live cells, Trypan Blue exclusion method was used.  Equal 
volume of Trypan Blue solution (Sigma) and cell suspension were mixed together, and the 
number of cells excluding Trypan Blue were counted using a haemocytometer. The 
subsequent cell concentration and total number of cells per ml was determined by using the 
following calculation:  
Cells per ml: the average count per square x the dilution factor x 104 
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2.16 RNA techniques 
 
Throughout this study while working with RNA, great care was taken to keep the samples 
RNase free.   For this reason all the solutions were made with DEPC treated water. 
 
2.16.1 RNA extraction 
 
Cells were grown in 6-well plates to ~90% confluency and total RNA extracted by using 
Trizol (Invitrogen).  After removal of culture medium, cells were washed with 1x PBS and 
1ml of Trizol added and incubated for 5 min at room temperature.  Next, 0.2 ml of chloroform 
was added, the tubes were mixed vigorously for 15 s and then incubated for 2-3 min at room 
temperature.  The samples were then centrifuged at 12000 g for 15 min at 4ºC. This leads to a 
formation of a red phenol-chloroform phase at the bottom of the tube and a colourless 
aqueous phase on top.  The top layer containing the RNA was carefully removed to a new 
microcentrifuge tube and 0.5 ml of isopropanol added to it.  After mixing by inversion 
samples were incubated for 10 min and centrifuged at 12000 g for 15 min at 4ºC to pellet the 
RNA at the bottom of the tube.  The supernatant fluid was then carefully removed and the 
pellet washed with 1ml of 75% ethanol.  Tubes were vortexed and centrifuged at 7500 g for 5 
min at 4ºC.  The supernatant fluid was removed and the pellet was then air-dried. Finally, the 
air-dried pellet was resuspended in 50-100 µl of DEPC-treated water and incubated at 55-
60ºC until the pellet was completely dissolved. 
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2.16.2 Measuring RNA concentration by spectrophotometry 
 
RNA samples were diluted in DEPC water (1:50) and absorbance was measured 
spectrophotometrically using a Biophotometer™ (Eppendorf®). The calculation of 
concentration was based on knowledge that an OD=1.0 at 260nm corresponds to 40 µg/ml 
RNA. Concentrations of the measured RNA were therefore expressed as µg/ml and good 
quality of sample was attributed by a 260/280 ratio of 1.7-1.9. 
 
2.16.3 RT-PCR 
 
Throughout this study, reverse transcription was carried out using a Transcriptor Reverse 
Transcriptase kit (Roche).  To set up a 20 µl reaction, the following components were pipetted 
into a small thin-walled Rnase and Dnase free reaction tube on ice according to the 
manufacturer’s instruction: 
 
Reaction mix for a typical RT-PCR 
Template RNA                                      1µg of total RNA 
Oligo (dT)15 primer                               1µl 
Water, PCR grade                                  up to 13µl     
Transcriptor RT buffer                          4µl 
RNase inhibitor                                     0.5µl 
dNTP mix (1mM each)                         2µl 
Transcriptor Reverse Transcriptase      0.5µl  
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The reaction was mixed by vortexing. Tubes were briefly centrifuged and the samples 
incubated for 30 min at 55˚C.  The reaction tubes were stored at -15-25˚C. 
 
2.16.4 Real-Time PCR 
2.16.4.1 Background 
Real-Time PCR is a technique that uses a fluorescent dye (e.g. Light Cycler 480 SYBR Green 
1 Master, Roche) to measure in real time the amount of double stranded DNA products that 
are produced over 45 cycles.  Real-time PCR uses cDNA as starting material with a typical 
amplicon being between 100–200 base pairs.  For this study primers were designed to 
produce 100 base-pair amplicons for both the target gene (Gaussia Luciferase) and reference 
gene (Glyceraldehyde 3 phosphate dehydrogenase also known as GAPDH). The Real-Time 
PCR measurements in this study were carried out by using a LightCycler® 480 (Roche).  
 Since the fluorescent dye has the capability of binding to any double helix structure, it will 
fluoresce at 483-533nm upon binding to DNA at the major groove. This light can be 
calculated while the actual experiment is running.  Furthermore, the SYBR Green 1 Master 
has the capability to produce small amount of fluorescence in its unbound state and this 
crucially allows the measurement of the point at which the log-linear part of amplification 
curve crosses the background noise or crossover points [183].  The crossover point or Cp 
value is proportional to the initial cDNA concentration of samples [184]. 
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2.16.4.2 Standard curves 
PCR was used to amplify a double stranded 100bp region from all the Gaussia Luciferase and 
GAPDH samples. The amplified products were purified by using QIAquick PCR purification 
kit (Qiagen) and then diluted in a series of 1:10 serial dilutions (15 times) to create a standard 
curve for Gaussia Luciferase and GAPDH samples. In addition, 1:10 dilution of those 
samples to be quantified were made and analysed alongside the standard curve in order to be 
sure that the crossover points of the samples fell within the curve.  Furthermore, a calibrator 
sample could be found from this data if a standard sample showed a crossover point (Cp 
value) similar to those obtained for the selection of unknown samples.  The calibrator was 
used by the LightCycler® 480 to correct for PCR efficiency.  
 
2.16.4.3 Sample measurement 
Once it was established that 1:10 dilution for all the unknown samples was appropriate, the 
samples were diluted accordingly.  The primers that were utilised for the Real-Time PCRs 
were produced by Eurofins (MWG, Germany) by using MWG-HYPER gel purification 
system to obtain primers with the highest purity. To carry out a Real-Time experiment, a 
master mix was made which consisted of   10 µl of SYBR Green 1Master mix (Roche), 1 µl 
of forward and reverse primers and 3 µl of PCR grade water for each reaction.  The mix was 
loaded into a LightCycler® 480 96-well plate (Roche).  Next, 5 µl of diluted samples to be 
quantified was added to each well.  As negative control 5 µl of water was added to one well 
along with 15 µl of reaction mix.  The plates were sealed by using a LightCycler® 480 sealing 
foil and then centrifuged for 2 min at 1500 g before carrying out the measurements. 
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2.17 Protein binding techniques 
2.17.1 S-100 cell extraction of CHO cells 
 
CHO cells were grown in T-175 flasks until cells reached ~90% confluency. Then 5ml of 1x 
trypsin was added and cells incubated for 5-10 min at 37° C.  5 ml of growth medium was 
added and cells pelleted by centrifugation at 210 g for 5 min and resuspended in 20 ml of 
PBS.  Cells were centrifuged at 210 g for 5 min and the resulting pellet was washed and re-
suspended with 2ml of 130 mM NaCl lysis buffer 1 (see 2.4). 1ml of cell re-suspension was 
transferred to a 1.5ml microcentrifuge tube, centrifuged (pulse spin at 4500 g) and the 
supernatant fluid removed.  The remaining half of re-suspended cells was added and another 
round of pulse spin centrifugation (4500 g) performed.  The pellet was resuspended in 400 µl 
of 130 mM lysis buffer 2 (see 2.4).  Cells were lysed by passing them through a 21-gauge 
needle several times, collected and centrifuged at 5000 g at 4°C for 5 min.  The supernatant 
fluid was diluted with 3 volumes of 40 mM lysis buffer (see 2.4). The diluted fluid was 
divided equally into two ultra centrifuge tubes and ultracentrifugation was carried out at 
53000 g at 4°C for 60 min.  The supernatant fluid was collected and stored in -80°C. 
 
2.17.2 In-vitro transcription to synthesise non-labelled and radiolabelled 
RNA probe 
 
To perform in-vitro transcription and obtain template of the Albumin 3’UTR RNA transcript, 
initially a typical PCR was carried out where the minimal T7-polymerase promoter sequence 
was incorporated at the 5’ position of the forward primer (see Table 2.5). Purified PCR 
products (QIAquick PCR purification kit, Qiagen) were then used as template to synthesise 
non-labelled and radiolabelled RNA transcripts of interest.  Following purification of PCR 
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products, 0.8 µg of DNA was used in in-vitro transcription using MEGAshortscriptTM Kit 
(Ambion).  Reaction mixtures were prepared in an RNase free microcentrifuge tube at room 
temperature in the order shown below according to the manufacturer’s instruction:      
Reaction mix for a typical in-vitro transcription for production of non-labelled RNA   
Water (Nuclease free)                                                                    to 25 µl of final volume 
10x T7reaction buffer                                                                    2.5 µl 
CTP solution (75mM)                                                                    2 µ 
GTP solution (75mM)                                                                    2 µl 
UTP solution (75mM)                                                                    2 µl 
ATP solution (75mM)                                                                    2.5 µl 
Template DNA                                                                               0.8 µg 
T7 enzyme mix                                                                               2 µl 
Reaction mix for a typical in-vitro transcription for production of radiolabelled RNA   
 
Water (Nuclease free)                                                                       to 25 µl of final volume 
10x T7reaction buffer                                                                      2.5 µl 
CTP solution (75mM)                                                                       2 µl 
GTP solution (75mM)                                                                      2 µl 
 UTP solution (75mM)                                                                     2 µl 
 [α-32P] ATP (PerkinElmer) 800 ci/mmol                                        2.5 µl 
Template DNA                                                                                 0.8 µg 
 T7 enzyme mix                                                                                2 µl 
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The reaction was mixed by gently flicking the tube and then it was centrifuged briefly to 
collect the reaction mixture at the bottom of the tube.  The reaction was incubated for 3 hr. To 
remove the template, 1 µl of turbo DNase was added and mixed well. The reaction was 
incubated at 37°C for 15 min at room temperature. Finally 70 µl of DEPC-water was added to 
the reaction mixture. 
 
2.17.3 Phenol-Chloroform extraction 
 
Phenol-Chloroform extraction was performed following the in-vitro transcription procedure to 
remove possible free nucleotides and enzymes present in the reaction mix.   Initially 70 µl of 
Phenol: Chloroform: Isoamyl Alcohol 25:24:1 (Sigma) was added to the reaction and mixed 
by inverting the tube.  The reaction was centrifuged at 13000 rpm for 10 min at 4°C. The 
aqueous phase was removed and mixed with 70 µl of chloroform. The mixture was 
centrifuged at 13000 rpm for 10 min at 4°C.  The aqueous phase was added to 500 µl of 
chilled ethanol containing 15 µl ammonium acetate (5M) to precipitate the transcript.  The 
mixture was stored overnight at -80°C to precipitate the RNA and the following day it was 
centrifuged at 15000 g for 60 min at 4°C.  The supernatant fluid was removed carefully and 
RNA precipitated at the bottom of the tube as pellet.  The resulted pellet was air dried and 20 
µl of nuclease–free water added to dissolve the precipitated RNA transcript.  Finally the 
concentration of the transcript was measured by spectrophotometry. 
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2.17.4 Measuring concentration and activity of radiolabelled RNA 
transcript 
 
The incorporation of 32P-ATP into the RNA transcript was determined by scintillation 
counting. A 1/10 dilution of RNA transcript to be measured was spotted (0.1 µl) in duplicate 
onto Whatman filter paper and then was placed into scintillation vials with approximately 5-
10 ml of Optiphase HisafeTM scintillation cocktail (Perkin-Elmer®).  In addition a blank 
sample without any RNA was also set up. The 32P radioactivity of RNA transcripts was 
measured in counts per min (cpm), in a TRI-CARBTM 2007 TR (Perkin Elmer® liquid 
scintillation counter.  The output by the scintillation counter machine was averaged and used 
to calculate the total activity and concentration in fmols/µl of RNA transcript. 
Activity of sample in MBq 
A = (readout 1+ readout 2)/2 = cpm average of two duplicates (see 2.17.4) 
B = A x 200(dilution factor) = total cpm of radiolabelled RNA transcript  
Test by JEH laboratory showed that 77360300cpm = 0.74 MBq  
=> (B / 77360300) x 0.74 = activity of whole sample (MBq) 
Theoretical maximum yield = 2.22 x 106  
=> Isotope stock used = 10 mCi/ml or 10 µCi/µl 
Assuming 100% integration of isotope in RNA transcript→ 2.5 µl (amount of radio active 
ATP used per reaction) x 10 = 25 µCi 
=> 2.22 x 106  x  25 = 55500000 dpm (disintegrations per min) 
Since 32P has a half life of 14 days, a decay factor (Y) must be included in the calculation 
based on time from reference date. 
Decay factor (Y) = activity at present time/ activity at reference date 
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Calculating percentage of isotope incorporation in RNA transcript => C 
C = [total sample activity/ (total dpm x decay factor)] x 100 
C = [B / (55500000 x Y)] x 100  
Calculating maximum possible yield of RNA Transcript (µg) => D 
Amount of ATP used per in-vitro transcription reaction = nmoles 
Proportion of A bases = number of A bases in RNA transcript / total number of all four bases 
in RNA transcript  
Molecular weight of each nucleotide = 330 (Dalton) 
=> D = C/100 x ((total amount of ATP (nmoles)/ proportion of A bases in RNA transcript) x 
330  
Calculating total yield (ng) => E 
E = D/20 x 1000 where 20 = the actual volume of transcript 
Calculating concentration of fmol/µl of transcript => F 
First calculating the concentration in pmol = E/(186/330) x 1000000 where 186 = total 
number of nucleotides in the transcript 
Then concentration in pmole/100 x 1000 => concentration of fmol/µl of transcript 
2.17.5 Assessing the integrity of radiolabelled RNA transcript 
 
Prior to protein binding assays, integrity of RNA transcript was checked by subjecting a 
sample of radiolabelled RNA transcript to electrophoresis in a denaturing urea 
polyacrylamide gel and then visualised by autoradiography.   
General reaction mix for a  denaturing urea polyacrylamide gel 
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7.5 ml of urea stock (18.9 g of Urea +9 ml of 5x TBE to final volume of 45 ml with DEPC-
treated water) 
2.5 ml urea acrylamide stock (8.4 g of urea + 10 ml of 40% acrylamide/bisacrylamide (29:1) 
to the final volume of 20 ml with DEPC-treated water)) 
10 µl of TEMED 
80 µl APS (10%) solution [w/v] 
 
After solidification of the gel (15-20 min), samples of RNA transcript were loaded in 2x gel 
loading buffer and the gel was run for 90-120 min at 120 V.  Next, the gel was wrapped and 
exposed to a Kodak Biomax XAR X-ray film for up to an hour.  The film was developed in a 
Konia®SRX-101TM film processor. 
 
2.17.6 Electrophoretic mobility shift assay (EMSA) and competition assay 
 
EMSA assays were carried out in which binding of radiolabelled RNA to cell protein extracts 
was assessed by electrophoresis through a non-denaturing polyacrylamide gel.  The required 
amount of radioactively labelled transcript (12 fmol per reaction) and non-labelled transcript 
if applicable (as competitor) were heated at 70°C then allowed to cool down to ~40°C.  This 
allows the RNA transcripts to be denatured and theoretically refold into their native form. 
Prior to assembling the binding reaction, the native polyacrylamide gel was pre-run in 0.5x 
TBE buffer at 120 V. 
The reaction mix was incubated for 15 min at room temperature. 40 U of RNase T1 (1/25 
dilution of RNase T1 in binding buffer) was added to each reaction and samples incubated for 
  
73 
further 5 min at room temperature.  2 µl of 20% Ficoll was added before loading samples on 
to the gel.  As a marker, bromophenol blue was loaded in one lane.  Electrophoresis was 
carried out in 0.5x TBE buffer for 2 hr until the bromophenol blue dye had run completely off 
the bottom of the gel. Finally, the gel was loaded between 2 sheets of GelAir Cellophane 
Support and placed in a gel air dryer (115 V, 60 Hz,Bio-Rad) until it was completely dried 
out. The gel was exposed to Kodak Biomax XAR film and developed in Konia®SRX-101TM 
film processor. 
 
General reaction mix for a native polyacrylamide gel 
1.25 ml of 40% acrylamide/bisacrylamide stock (79:1) 
[3.75 ml of 40% (29:1) acrylamide/bisacrylamide + 6.25 ml of 40% acrylamide] 
1 ml of 5x TBE buffer  
7.65 ml of DEPC- treated water 
10 µl of TEMED 
90 µl of ammonium persulphate 
General reaction mix for a typical EMSA 
Protein extracts                           2-2.5 µg 
Labelled RNA transcript            12 fmol 
Competitor RNA Transcript      ?µl excess fold of competitor (only applicable for competition 
assay) 
40 mM lysis buffer (see 2.4)       to a final volume of 8 µl 
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2.17.7 UV Cross-linking assay 
The required amount of labelled RNA probe (50 fmol per reaction) and non-labelled RNA 
transcript (required excess fold based on experiment) were heated at 70°C and allowed to cool 
down to ~40°C.  This allows RNA transcripts to be denatured and theoretically refold into 
their native form.  The denatured and refolded RNA transcripts (non-labelled and labelled) 
were added to a mixture of protein extracts and 40 mM lysis buffer to make the reaction mix.  
The reaction mix was incubated at room temperature for 15 min.  40 U of RNase T1 (1/25 
dilution of RNase T1 in binding buffer) was added and the reaction mix incubated for a 
further 5 min at room temperature.  The reaction mix was then cross-linked for 12 min in 
SpectroLinker XL 1000 V Cross-Linker at 4,500 µW/cm2 on ice.  Samples were incubated 
with 10 µg of RNase A (1 µl) at 37°C for 1 hr. 3 µl of 5X Laemmli protein sample buffer was 
added to each reaction and boiled for 5 min. Samples were loaded onto a 10% SDS-PAGE 
(29:1) gel and run initially at 120 V for 30 min and then 150 V for 2.5 hr in 1x protein 
electrophoresis running buffer (see 2.4).  5 µl of colorBurstTM Electrophoresis Marker (8000-
22000 kDa) was loaded into one lane as marker.  The gel was removed and placed in between 
2 sheets of GelAir Cellophane Support and inserted in a gel air dryer (115 V, 60 Hz,Bio-Rad) 
until it was completely dried out.  The gel was exposed to Kodak Biomax XAR film and 
developed in the Konica SRX-101A developer. 
 
General reaction mix for a typical UV Cross-linking 
Protein extracts                                          2.5-3 µg 
Competitor (non-labelled transcript)        1-2µl (depending on the excess fold of competitors) 
50 fmol of radiolabelled RNA transcript  2-4 µl  
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40 mM lysis buffer (see 2.4)                     up to final volume of 13 µl 
 
General reaction mix for 10% SDS-PAGE gel 
Separating gel (75-80% of whole gel) 
40% Acrylamide/Bis Acrylamide Stock (29:1)                                      1.75 ml 
Separating buffer (1.875M Tris Base pH 8.9, 0.25%SDS)                     2.8 ml 
Distilled water                                                                                         2.4 ml 
TEMED                                                                                                   6 µl 
APS (10%) solution [w/v]                                                                       65 µl 
Stacking gel(20-25% of whole gel) 
40% Acrylamide/Bis Acrylamide Stock (29:1)                                       0.25 ml 
5x stacking buffer stock (0.3M Tris Base pH 6.7, 0.5%SDS)                0.4 ml 
Distilled water                                                                                         1.32 ml 
TEMED                                                                                                    2.5 µl 
APS (10%) solution [w/v]                                                                        18 µl 
 
The separating gel mixture was immediately poured into the gel cassettes using a 5 ml pipette 
and filled up to ~80% of gel cassettes.  2 ml of distilled water was added and the gel was 
allowed to polymerise for 20-30 min at room temperature. 
Once the separating gel was set, the top layer of distilled water was poured out and the gel 
was rinsed with 2 ml of fresh distilled water.  The inner side of the cassettes was dried with 
clean paper towel and the stacking mixture was immediately poured into the cassettes onto the 
top of the separating gel. 
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2.17.8 Isolation of RNA-binding proteins 
 
To synthesise the biotinylated probe, the same procedure in 2.17.2 was followed with the 
exception of adding 2 µl of Biotin-UTP-16.  The synthesised biotinylated transcripts were 
subjected to phenol/chloroform extraction (see 2.17.3) and quantified by spectrophotometry. 
20 µg of biotinylated transcript were heated at 70°C for 5 min, then at 40°C for 20 min and 
then allowed to cool down at room temperature. The MagneSphere Streptavidin-Coated 
Paramagnetic Particles (SA-PMP) (0.6 ml with a final concentration of 1 mg/ml) were 
incubated with 100 µl of 0.5x SSC buffer, 10 µg of BSA and 10 µg of yeast tRNA for 60 min 
at room temperature with shaking.   
The SA-PMPs (beads) were washed twice with 300 µl of 0.5x SSC buffer.  Next, the SA-
PMPs were incubated with 20 µg of biotinylated transcript in 300 µl of 0.5x SSC buffer for 
10 min at room temperature.  For a negative control no biotinylated transcript was added. To 
remove the unbound transcript, beads were washed with 0.3 ml of 0.5x SSC buffer.  Then the 
beads were incubated with 1 mg of CHO cell extract in 500 µl of 40 mM lysis buffer (see 2.4) 
with an additional 25 µg of yeast tRNA, 10 µg of BSA and 800 U/ml of RNasin at 4°C for 60 
min with shaking.  In order to separate beads from non-bound material, beads were pelleted 
magnetically by placing them onto MagnaRackTM (Invitrogen).  The supernatant fluid was 
removed and SA-PMPs washed 5 times with 1ml of 40 mM lysis buffer.  Beads were then re-
suspended in 25 µl of 40 mM lysis buffer. 10 µl of re-suspension was mixed with 2x 
dissociation buffer (see 2.4) in order to release bound protein/s. Protein/s were denatured for 5 
min at 95°C and loaded into a 10% SDS-PAGE gel. The gel was visualised by Novex 
Colloidal Blue (Invitrogen).  
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General reaction mix for a typical in-vitro transcription of biotinylated RNA probe 
Water (Nuclease free)                                                            to 25 µl final volume 
10x T7 reaction buffer                                                            2.5 µl 
ATP solution (75mM)                                                            2 µl 
CTP solution (75mM)                                                            2 µl 
GTP solution (75mM)                                                            2 µl 
UTP solution (75mM)                                                            2 µl 
Biotin-UTP-16                                                                       2 µl 
Template DNA                                                                       0.8 µg 
T7 enzyme mix                                                                       2 µl 
 
2.17.9 Staining the 10% SDS-PAGE gel 
Colloidal blue staining solution was prepared according to the manufacturer’s instructions 
(Invitrogen), as follows: 55 ml of de-ionised water was added to 20 ml of ethanol, 5 ml of 
stainer B and 20 ml of stainer A.  The gel was placed in a clean container with staining 
solution and shaken for 3-12 hr.  The staining solution was decanted and replaced with 200ml 
of de-ionised water and shaken for a minimum of 7 hr to de-stain the gel. 
 
2.18 Protein techniques 
 
2.18.1Bradford assay 
 
The protein content of cell extract samples was measured by Bradford assay in which Bovine 
Serum Albumin (BSA, New England BioLab) was used as a standard over a range from 0.02, 
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0.04, 0.06, 0.08 and 0.1 mg/ml.  Samples were diluted in a range of 1:20 to 1:120 and an 
appropriate dilution selected by colour comparison to the chosen dilution of the standard 
curve. 50 µl of samples and standards were transferred into a 96-well microtiter plate.  200 µl 
of Bradford reagent (Sigma) was added to each well and the plate incubated at room 
temperature for 10 min before the absorbance was measured by Multiskan Ascent microplate 
reader at 595nm. 
 
2.18.2 Western blotting and analysis 
Western Blotting was carried out to identify proteins following SDS-PAGE. After 
electrophoresis, the proteins were transferred to a PVDF membrane (Roche) by a semi dry 
transfer method.  Initially, the membrane was placed in a clean container containing 100% 
methanol for 30 seconds. The membrane was then placed in a clean container containing 
distilled water at room temperature for 2 min while being shaken.  Next the membrane was 
transferred to a clean container containing transfer buffer at room temperature for 10-15 min. 
Three layers of Whatman chromatography paper (grade 3MM) were soaked in transfer buffer 
and placed on the transfer apparatus (atta AE6675 semi-dry transfer blotter).  The air bubbles 
were removed by using a clean glass tube before the membrane was laid on top of them. Next, 
the separating part of the gel was placed on top of the membrane before placing three more 
layers of soaked Whatman paper in transfer buffer. Transfer was carried out at 15 V for 50 
min. The PVDF was then removed and placed overnight in blocking solution at 4°C with 
shaking to prevent non-specific binding of the antibodies to the membrane. 
The membrane was blocked with 5% (w/v) of dried milk powder (Marvel) in PBS containing 
0.05% (v/v) Tween 20 (Sigma).  The CUG-BP1 primary antibody was then diluted (1/1000) 
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in blocking solution.  Then the membrane was incubated with the primary antibody for 1 hr at 
room temperature with shaking. The membrane was washed 4 times for 10 min and then 
incubated with the secondary antibody (anti Rabit IgG (whole molecule) peroxide antibody) 
diluted 1:5000 in blocking solution for 1 hr with shaking. The membrane was then washed 5 
times for 10 min each to remove any non-specific binding.  An Amersham™ ECL+ western 
blotting detection system (GE Healthcare) was applied to visualise the secondary antibody. 
The ECL solutions were let to warm up for 5 min at room temperature prior to mixing.  2ml 
of solution A and 50 µl of solution B were mixed gently in a universal tube wrapped with foil. 
The membrane was placed onto a plastic film gently blot dried with Whatman paper.  The 
mixed solution was poured onto the membrane and was spread evenly by placing a second 
plastic film on top of the membrane.  The membrane incubated at room temperature for 5 
min. The plastic films were removed and the membrane was gently blot dried with Whatman 
paper. A fresh dry plastic film was placed on top of the membrane.  The membrane was 
exposed to Kodak Biomax XAR film (Sigma) in a Hypercassette (GE Healthcare) in the dark 
for 5 to 15 min (depending on the intensity of the signal).  The films were developed by 
Konica SRX-101A developer. 
 
2.18.3 Protein identification by mass spectrometry analysis (courtesy of 
NEPAF) 
Bands were excised from the gel using a razorblade in a clean air cabinet.  Proteins in the 
bands were digested in the gel using a GenomicSolutions ProGest robot and the following 
standardised procedure was followed. The gel pieces were cut into smaller pieces using a 
pointed forceps and transferred into a pierced PCR plate.  Gel pieces were incubated for 10 
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min at room temperature with 25 mM NH4HCO3 (ammonium bicarbonate) and for 10 min 
with 100% MeCN (acetonitrile).  This washing cycle was repeated once.  Then, gel pieces 
were treated with DTT (10 mM, 1 hr, 40 °C), the reaction was allowed to cool down for 20 
min and cysteines were alkylated using ICH2CONH2 (10 mM, 30 min, 20 °C).  Gel pieces 
were washed and dehydrated using MeCN and incubated with 1.5µg of trypsin (Promega, 3 
hr, 37°C).  Proteolytic peptides were extracted using water and MeCN and the extracts were 
concentrated under vacuum to 10µl and finally 3 µl of this mixture was used for LCMS 
analysis (Liquid Chromatography Mass Spectrometry).  To perform the LCMS analysis an 
aliquot of the digests was transferred into an autosampler vial and analysed using an Ultimate 
3000 Nano-HPLC system (Dionex, UK) coupled online to an LTQ XL orbitrap mass 
spectrometer. The following parameters were used for the analysis: 
Column:    Dionex Pepmap C18 column, 3um ID 25cm 
Mobile Phase A 0.05% Formic Acid in LCMS H2O 
Mobile PhaseB 0.05% Formic Acid in 80% Acetonitrile 
Flow rate  300ul/min 
Gradient: 4% to 50% B in 102 min 
 
Segment runtime:   120 min 
MS Resolution:  30,000 
FTMS ACG Targets:  5x 105 
Top 3 FT MS/MS at 35% normalized collision energy 
MS/MS Resolution:  30,000, 1 microscan 
FT MS/MS AGC Target:   3x 105 
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Dynamic Exclusion:  Repeat Count=2,  
Exclusion duration : 180 seconds 
MS/MS Threshold:  10,000 
Max IT FTMS:  50.000 ms 
Full MS mass range:   400- 1600 m/z 
MS/MS mass range:             Full 
 
To perform data analysis thermo raw binary data files were converted into MSMS peak lists 
(Mascot Generic Format, *.mgf) using Thermo ProteomeExplorer 1.0.  Next Data were 
searched using an in house installed version of X!Tandem (x! tandem TORNADO 
(2009.04.01.1). All processing of gel slices and protein identification was carried out by 
NEPAF, Newcastle University. 
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3 Creation of gene constructs to investigate effects of 
signal peptides/3’UTR on reporter activity 
 
3.1 Introduction 
 
To examine elements that influence post-translational regulation such as signal peptide and 
3’UTR, the Gaussia princeps Luciferase was used as reporter system in a series of novel gene 
constructs that were created by utilising a seamless cloning method.  The names and codes 
that have been used to identify constructs in this study are based on the different elements that 
make up any given construct.  The expression vector PTRE2hyg (Clontech) was used 
throughout to make all the gene constructs (Figure 3.1) and all the constructs names begin 
with the name of the expression vector
 PTRE2hyg.  This is followed by the 5’ untranslated 
region (5’UTR), the signal peptide coding region, the Gaussia Luciferase coding region and 
the 3’ untranslated region (3’UTR).  
In all constructs the 5’UTR region is from the Gaussia princeps Luciferase gene. Immediately 
after the 5’UTR region is the signal peptide coding region. In this thesis the Human 
Chymotrypsinogen signal peptide, the Human Albumin signal peptide and finally the native 
Gaussia Luciferase signal peptides were utilised as the signal peptide of a given gene 
construct.  The coding region of the signal peptide is then followed by the Gaussia princeps 
Luciferase coding region/sequence in all of the constructs.  The asterisk “*” on the letter G 
indicates that this region has been codon optimised with respect to mammalian codon usage 
without changing the amino acid composition.  This is termed the humanisation of the coding 
region.  The region following the Gaussia Luciferase coding region is the 3’UTR. In this 
thesis the Albumin and Gaussia Luciferase 3’UTRs were utilised to make the constructs. 
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Finally, sequences at the end of the 5’and 3’-untranslated regions were upstream and 
downstream sequences respectively derived from the pTRE2hyg vector.  The codes used 
throughout were:  
G: Gaussia 
 X: Chymotrypsinogen signal peptide 
X1: Chymotrypsinogen signal peptide with 1 mutation 
X2: Chymotrypsinogen signal peptide with 2 mutations 
A: Albumin signal peptide 
A5: Albumin 3’UTR (with 5 point mutations) 
Alb: Albumin 3’UTR (wild type): 
3∆β: without β-globin vector-derived sequences 
US: Upstream sequences from vector 
DS: Downstream sequences from vector 
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Figure 3.1 Schematic representation of the terminology used in this study to identify constructs.  In all the 
constructs, the 5’UTR and the coding region were obtained from the Gaussia princeps Luciferase.  The 
signal peptides of Chymotrypsinogen, Human Albumin and Gaussia Luciferase were used in this study. 
Finally, either the endogenous Gaussia Luciferase or Albumin 3’UTR were included in the constructs. 
 
 
3.2 Seamless cloning 
Seamless cloning is a PCR based cloning method in which a series of PCRs (5 separate PCRs 
in the present study) are performed to amplify a region in order to insert it into a vector 
without using linker sequences or incorporating new restriction sites [185].  The strategy by 
which this method was applied in the present work is shown schematically in Figure 3.2.  To 
begin this procedure 3 separate PCRs were performed to amplify the Gaussia 5’UTR, a signal 
peptide coding region of interest and finally the Gaussia Luciferase coding region (sequence) 
separately.  To amplify the actual signal peptide without using a template, the forward and 
reverse primers are designed in such a way that the primers share a region of homology 
between them (see Table 2.4, OliAlbSP.for 5’, OliAlbSP.rev 5’).  This region of homology is 
used by the polymerase to amplify the signal peptide without using template. 
  Reporter protein CDS          5’UTR        SP    3’UTR 
 Gaussia 
Chymotrypsinogen 
or 
Albumin 
or 
Gaussia 
Gaussia Luciferase coding sequence 
Gaussia/Albumin  
G        X/A/G*                     G*                G/Alb 3∆β /A5 3∆β 
   PTRE2hyg G      X/A/G*     G *     G/Alb 3∆β /A5 3∆β 
    DS   US 
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Once these 3 regions were amplified, then the signal peptide coding region was linked to the 
Gaussia coding sequence and the Gaussia 5’UTR region by carrying out further PCRs with 
specific forward and reverse primers for the signal peptide (see Table 2.4, AlbSP.for 
5’,AlbSP.rev5’) which contain regions of homology with the 3’-end of the 5’UTR (Figure 
3.2, highlighted in red) and with the 5’-end of Gaussia coding region (Figure 3.2, highlighted 
in green).  These overlapping regions theoretically allow the polymerase to use these regions 
as a template so that PCR leads to a product in which the coding region of the signal peptide 
is attached to the Gaussia 5’UTR (PCR number 4 in Figure 3.2).  The forward primer for the 
Gaussia 5’UTR was designed specifically in such a way that the amplicon contains BamHI 
unique restriction site up stream of the 5’UTR.  A further PCR reaction (PCR 5) was carried 
out in which subsequently the Gaussia Luciferase coding region was linked to the Gaussia 
5’UTR and signal peptide (the product of PCR 4).  The reverse primer for the Gaussia coding 
region was designed in such a way that it contained the AccI unique restriction site.  Since any 
given gene construct in this thesis and the product of PCR 5 contained the BamHI and AccI 
unique restriction site at the same positions, their double digestion and subsequent ligation led 
to complete replacement of the gene construct signal peptide (Figure 3.2).  
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            PCR1                                        PCR2                                 PCR3                                                                                                                                                                                             
                                                                                                                                       
  BamHI 
                                                                                         
  BamHI                                                                                               AccI 
                                                                                                                                         
 
 
 
                     BamHI                                                 AccI 
SP CDS         3’UTR DSUS         5’UTR
 
 
                                                 
SP
 
US 5’UTR CDS 3’UTR DS
 
 
SP CDS         3’UTR DSUS         5’UTR
 
Figure 3.2 Schematic representation of the seamless cloning procedure.  The vector and product of PCR5 
are digested with the restriction enzymes BamHI and AccI that can then be ligated together.  As a 
consequence the signal peptide of the construct will be replaced. 
 
 
 
 
 
 
           5’UTR   Signal peptide       
 
                  5’UTR +  Signal peptide (PCR 4)
        Double digestions of both the final product of the PCR5 and any given gene construct with the BamHI and AccI 
    Coding Sequence 
                                         5’UTR+ Signal peptide +Coding Sequence (PCR 5)     
Double digested vector ↑ Double digested vector ↑ 
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3.3 Results 
 
3.3.1 Construction of pTRE2hyg GXG*Alb 3∆β 
To correct the Albumin 3’UTR for the 5 point mutations in construct GXG*A5 3∆β, it was 
logical to replace the A5 3’UTR of the previously made construct GXG*A5 3∆β with the 
Albumin 3’UTR but without the 5 point mutations in construct GG*G*Alb 3∆β.  The strategy 
used to make the constructs was to find two unique restriction sites at either end of the 3’UTR 
region and replace the A5 3’UTR (containing the 5 point mutations) with the Alb 3’UTR 
(corrected Albumin 3’UTR for the 5 point mutations). Constructs GXG*A5 3∆β and 
GG*G*Alb 3∆β were treated with restriction enzymes AccI and PflMI (Figure 3.3). The AccI 
restriction site is in the middle of the Gaussia Luciferase coding region and the PflMI 
restriction site is in the downstream sequences. Therefore, by digesting the plasmid, the 
3’UTR from both constructs was removed.  Next, ligation was performed between the vector 
(lane 2) and insert (lane7). The product of the ligation was used directly for transformation.  
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Figure 3.3 Double digestion of construct GXG*A5 3∆β (lane 2) and construct GG*G*Alb 3∆β (lane 7) 
using restriction enzymes AccI and PflmI.  Lanes 3 and 5 represent the double digestion of construct 
GX1G*G and construct GX2G*G (containing the additional vector-derived sequences).  Lane 4 and 6 
represent empty wells. Lane 1 represents the DNA Hyper Ladder I.  
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From each transformation plate 5 colonies were selected for transformation of TOP10 
competent cells and colony PCR was performed using several single colonies as template 
(Figure 3.4).  Samples together with forward and reverse primers (pTRE2hyg.for and 
BCD.rev respectively, 10 µl each with a concentration of 10 pmol) were sent to MWG for 
sequencing.  The results of pair-wise alignment confirmed the successful construction of 
GXG*Alb 3∆β.                 
                                                                                              
1 4 5 63 8 109 11 12 13 14 15 16 1772
700bp
                                                
           
Figure 3.4 Agarose gel electrophoresis showing the screening single colonies for the presence of construct 
GXG*Alb 3∆β by colony PCR.  Primers CDC.for and Alb.3 rev were used. The expected product of these 
PCRs was ~700 bp long. Lane 1 is DNA HyperLadder I and Lanes 2-6, 7-11 and 12-16 show the expected 
band.  Lane 17 represents a negative control.  
 
 
 
3.3.2 Construction of pTRE2hyg GAG*Alb 3∆β 
The strategy to make this construct was to use the seamless cloning procedure as discussed 
previously in this chapter.  This required removing the Chymotrypsinogen signal peptide 
coding region from the construct GXG*Alb3∆β and replacing it with the Albumin signal 
peptide.  The sequence of the Human Albumin Signal peptide was obtained from the gene 
bank database (Accession Number NM_000477).  Initially, oligonucleotides were designed as 
primers for PCR so that the forward and reverse primers (OliAlbSP.for and OliAlbSP.rev) 
share 14 base pairs in homology.  The aim of this initial PCR was to obtain the complete 
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sequence of the Albumin signal peptide as the template for carrying out the seamless cloning.  
To initiate making of construct GAG*Alb3∆β and performing the seamless cloning procedure 
(see 3.2), further primers were designed for the Albumin signal peptide so that the forward 
primers (AlbSP.for) shared sequence homology with the Gaussia 5’UTR and the reverse 
primers (AlbSP.rev) shared sequence homology with the Gaussia Luciferase coding region.  
To achieve this, 5 separate PCRs were performed.  First, PCR1 was performed to amplify a 
region upstream of Gaussia 5’UTR to the end of this region using appropriate primers 
(5’UTR.for and 5’UTR.rev) in order to accommodate the restriction site BamHI (Figure 3.5 
lane 2).Figure Next, PCR2 was performed using the Albumin signal peptide forward and 
reverse primers (OliAlbSP.for and OliAlbSP.rev) (Figure 3.5 lane 3). Then PCR3 was carried 
out using Gaussia Luciferase coding region’s forward and reverse primers (CDS.for and 
CDS.rev) to amplify the Gaussia Luciferase coding region (Figure 3.5 lane4).  
 
1 765432
1 0 0 b p
5 0 0 b p
 
Figure 3.5 Agarose gel electrophoresis showing products of 3 PCRs carried out to amplify the Gaussia 
Luciferase 5’UTR (PCR1), the Albumin signal peptide (PCR2) and the Gaussia Luciferase coding region 
(PCR3, see Figure 3.2 for details). Lane 1 represents DNA HyperLadder IV.  Lane 2 shows the product of 
PCR1.  The expected product for this PCR was 210bp long.  Lane 3 shows the product of PCR 2 (the 
signal peptide). The expected product for this PCR was 54 bp long.  The Gaussia Luciferase coding region 
was obtained by performing PCR3 (lane5).  The expected product for this PCR was 507bp long.  Lanes 5, 
6 and 7 represent the negative controls for PCRs1-3 respectively. 
 
 
The next step was to amplify in tandem the Gaussia 5’UTR and Albumin signal peptide 
regions by performing a separate PCR (PCR4) using the 5’UTR.for and AlbSP.rev primers. 
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As shown in Figure 3.6 (left panel), this PCR produced a product of approximately 300 base 
pairs.  To perform the PCR 4, product of PCR1 and 2 were used as template after performing 
the PCR purification with Qiagen PCR purification Kit.  Once this region was amplified it 
was linked with the Gaussia Luciferase coding sequence.  For this purpose, 5’UTR.for and 
CDS.rev primers were used (Figure 3.6, right panel). 
 
1 32 1 2 3
3 00 bp 
80 0b p
 
 
Figure 3.6 Agarose gel electrophoresis showing the product of PCR 4 and 5. PCR4 (left panel) was 
performed to amplify a region upstream of the Gaussia 5’UTR to the end of the Albumin signal peptide 
(see Figure 3.2 for details).  The expected product of this PCR was 296bp long (left panel, lane 2).  PCR5 
(right panel) was performed to amplify in tandem the product of PCR 3 (see Figure 3.5) and 4 (right 
panel, lane 2). The expected product for this PCR was 771bp long. Lane 1 in both gels represents DNA 
HyperLadder IV.  The lane 2 in both gels represents the expected products and the lane 3 represents (in 
both gels) the negative control for the two PCRs. 
 
 
 
The next step was to digest both construct GXG*Alb3∆β (Figure 3.7) and the amplified 
region of PCR5 (Figure 3.8) with two restriction enzymes (BamHI and AccI).  The double 
digestion of the product of PCR 5 produced 2 bands (Figure 3.8).  The lower band of ~400bp 
was ligated with the linearised vector.  The transformation, colony PCR and sequencing to 
confirm the identity of construct GAG*Alb 3∆β was carried out in similar way to that for 
GXG*Alb 3∆β. 
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Figure 3.7 Agarose gel electrophoresis showing the result of the double digestion of construct 
GXG*Alb3∆β.  Digestion using BamHI and AccI produced two fragments that included a ~400bp insert.  
Lane 1 represents the DNA ladder I and lane 2 shows the digested plasmid with its two fragments. 
                                   
 
                                               1                                                 2   
 
 
                        400bp 
                   
 
Figure 3.8 Agarose gel electrophoresis showing the double digestion of the product of PCR5 (see figure 3.6 
for details).  The cleavage site for BamHI is located upstream of Gaussia 5’UTR and the cleavage site for 
AccI is in the middle of Gaussia Luciferase coding region.  Double digestion of the final amplified region 
produced two fragments. Lane 1 represents the double digestion products of PCR5. Lane 2 shows DNA 
HyperLadder IV. 
 
 
 
 
                                                                          
3.3.3 Construction of pTRE2hyg GAG*G 3∆β  
The strategy to make constructs GAG*G 3∆β was to double digest the construct GG*G*G 
3∆β and replace its signal peptide with the Albumin signal peptide.  This required the double 
digestion of previously made construct GAG*Alb3∆β in order to obtain the Albumin signal 
peptide for the ligation process.  Constructs were double digested with restriction enzymes 
BamHI and AccI.  The product of digestion (insert) was used for ligation with the double 
digested GG*G*G 3∆β vector (Figure 3.9). 
                                                  
400bp 
1000bp 
1 2 
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Figure 3.9 Agarose gel electrophoresis showing the double digestion of constructs GG*G*G 3∆β (lane 2) 
and GAG*Alb 3∆β (lane 4).  Double digestion of both constructs using BamHI and AccI linearised the 
vectors and produced for both a ~400bp band that represented the insert.  Lane 1 is DNA ladder I and 
lanes 2, 4 show the digested vectors.  Lane 3 is an empty well. 
 
The transformation, colony PCR and sequencing to confirm the identity of construct 
GAG*G* 3∆β was carried out in similar way to that for GXG*Alb 3∆β. 
                
 
3.4 Albumin 3’UTR deletion constructs 
 
3.4.1 Construction of pTRE2hyg GG*G*Alb 3∆β (∆51-150)  
Two novel deletion constructs were made using the construct GG*G*Alb 3∆β with deletion 
of 100 nucleotides within their 3’UTR (Figure 3.10).  The strategy was to use primers that 
amplify specific regions of the Albumin 3’UTR region but exclude the amplification of 
region/s base 51-150 for construct GG*G*Alb 3∆β (∆51-150) or regions 1-50 &101-150 for 
construct GG*G*Alb 3∆β (∆1-50&101-150).  Crucially, the amplified region/s must cover 
the restriction sites for AccI and PflmI.  
 
 
insert 
vector 
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Figure 3.10 Schematic representation of the full length Albumin 3’UTR (red) and its deletion constructs 
(blue). The broken lines represent the deleted regions. The hexamer AAUAAA represent the 
polyadenylation signal.  
 
 
 
To make the construct GG*G*Alb 3∆β (∆51-150), hereafter referred to as ∆51-150, initially 2 
PCRs were carried out in order to amplify a product that covered the restriction sites for AccI 
and BamHI (Figure 3.11).  The reverse primer for the PCR1 (Alb50.151.Rev) was designed so 
that its 3’- tail would bind to base 50-42 and its 5’-portion would bind to bases 177-151 in the 
Albumin 3’UTR.  The forward primer for this PCR (G3Da.for) was designed so that it would 
bind to a region in the Luciferase coding sequence in order to accommodate the AccI 
restriction recognition site. This PCR produced a product that was approximately 400bp long 
(Figure 3.12 lane 2, left panel).  For the second PCR, the forward primer (Alb.151.50.For) 
was designed so that its 5’-portion would bind to bases 151-164 and its tail shared sequence 
homology with bases 29-50.  
The reverse primer (BCD. rev) for this PCR was designed so that it would bind to a region in 
downstream sequences to accommodate the restriction site PflmI.  This PCR produced a 
530bp product (Figure 3.12 lane 3, left).  Finally to anneal the product of PCR 1 and PCR 2, 
the third PCR was carried out with the forward primer of PCR 1 and the reverse primer of 
PCR 2 following PCR purification of both products (Qiagen PCR purification Kit).  This PCR 
produced a ~900bp product (Figure 3.13 left panel).  Next the product of PCR 3 was purified 
1 50 100 150 
AAUAAA Full length Albumin 3’ UTR (186 bps) 
AAUAAA Deletion ∆ 51-150 (86 bps) 
AAUAAA Deletion ∆1-50&101-150 (86 bps) 
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with the Qiagen PCR Purification Kit and double digested with AccI and PflmI restriction 
enzymes (Figure 3.13, right panel lane 2).  
 
 
 
 
 
 
 
 
 
                                                               
                                                                        PCR 3 
 
 
Figure 3.11 Schematic representation of the strategy used to make the deletion construct ∆ 51-150. The 
broken line in blue represents the deleted region within the Albumin 3’UTR.  The vertical red lines 
represent the beginning and end of the Albumin 3’UTR.  The double vertical green lines represent the 
Luciferase coding sequence/region and downstream sequences (CDS and DS) respectively.  The two 
arrows indicate the restriction site for AccI and PflmI.  
 
 
 
1 2 3 4 5 61 62 3 4 5
100bp
300bp
400bp
600bp
 
 
Figure 3.12 Agarose gel electrophoresis showing the results of 5 PCRs (left panel) and their negative 
controls (right panel) to create the Albumin deletion constructs.  To make deletion construct ∆51-150, 2 
separate PCRs were performed (lane 2 and 3, left panel).  These products were then subjected to PCR 
purification and linked together to obtain the final product (PCR3) using the forward primer used for 
PCR 1 and the reverse primer used for PCR 2.  Lane 1 (in both gels) represents DNA HyperLadder IV.  
Lanes 2&3 in the right panel show the negative controls for PCR1&2. Lane 4, 5 and 6 from left panel 
represent the products of 3 PCRs that were used for the construction of ∆1-50&101-150. Lane 4, 5 and 6 
(right panel) represent the respective negative controls for the 3 PCRs. 
 
  
 
                            
 
 
AccI 
50  151  186  
Albumin 3’UTR (151-186) 
 
Albumin 3’UTR (1-50) 
PCR 1  PCR 2  
PflmI 
Luciferase coding region    
   DS CDS 
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vector900bp
 
Figure 3.13 Agarose gel electrophoresis showing the final product of PCR3 (see Figure 3.11 for details) for 
deletion construct ∆51-150 (left panel).  Lane 1 (left panel) represents the DNA HyperLadder1V.  Lane 2 
(left panel) represents the final product.  The gel on right shows the double digestion (lane 2) of PCR3 and 
construct GG*G*Alb 3∆β (lane 3) to obtain the insert and the linearised vector for the ligation.  Lane 1 
(right panel) represents the DNA HyperLadder I. 
 
 
 
 
The transformation, colony PCR and sequencing to confirm the identity of construct 
GG*G*Alb 3∆β (∆51-150) was carried out in similar way to that for GXG*Alb 3∆β. 
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3.4.2 Construction of pTRE2hyg GG*G*Alb 3∆β (∆1-50&101-150) 
 
To make the deletion construct GG*G*Alb 3∆β (∆1-50&101-150), hereafter referred to as 
∆1-50&101-150, 5 PCRs were performed (Figure 3.14).  
 
 
                                    PCR 4 
 
                                                                      PCR 5 
 
Figure 3.14 Schematic representation of the strategy for making the double deleted construct ∆1-50&101-
150.  5 PCRs were performed to amplify multiple regions.  Regions in broken blue represent the deleted 
regions.   Regions in vertical red lines represent the beginning and end of the Albumin 3’UTR. Two 
vertical green lines at either ends represent the Luciferase coding sequence/region and downstream 
sequences (CDS and DS).  The two vertical arrows indicate the restriction sites for AccI and PflmI. 
 
 
 
PCR1 was performed with primers (G3Da.for and G3Db.rev) that amplify a region within the 
Gaussia Luciferase coding region toward its very end.  This was carried out to accommodate 
the AccI restriction site.  The amplified product of this PCR was approximately 300bp long 
(figure 3.12 lane 4).  Next to perform PCR 2, the forward primer (Alb51.for) for this PCR was 
designed in such a way so that its 3’-end would share sequence homology with a region 
within the Gaussia coding region to the very end of this region (nucleotides 486-507) and its 
5’-portion would bind to nucleotides 51-64 of the Albumin 3’UTR. The reverse primer 
(Alb100.151.Rev) for this PCR was designed so that its 3’-end would bind to positions 101-
92 and its 5’-portion shared sequence homology with bases 177-153 of the Albumin 3’UTR. 
AccI 51 - 100         150 - DS                      PflmI 
PCR 1 PCR 2 PCR 3 
5 1 100 151 186 CDS CDS DS 
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The amplified product of this PCR was ~ 100bp long (Figure 3.12 lane 5, left panel).  PCR 3 
was performed to amplify base 151 to a region within the downstream sequences in order to 
accommodate the PflmI restriction site.  The forward primer (Alb151.100For ) for this PCR 
was designed so that its 5’-portion would bind to bases 151-164 of the Albumin 3’UTR and 
its 3’-end shared sequence homology with bases 79-100 of the Albumin 3’UTR.  The 
expected product of this PCR was ~ 550bp long (Figure 3.12 lane6, left panel).  The next task 
was to carry out PCR 4 and link the products of PCR 1 and 2 following PCR purification of 
both products with the Qiagen PCR purification kit.  To perform this PCR, the forward primer 
of PCR1 and reverse primer of PCR 2 were used.  The expected product of this PCR was ~ 
400bp long (Figure 3.15, left panel).  Finally, PCR 5 was performed with the forward primer 
of PCR 1 and the reverse primer of the PCR 3 (Figure 3.15, right panel).  This PCR was 
carried out to link products of PCR 1-3.  The amplified region was ~ 950bp long.  The 
product of PCR 5 was purified with Qiagen PCR purification kit and then treated with 
restriction enzymes AccI and PflmI (Figure 3.16) along with the construct GG*G*Alb 3∆β, 
and then the product ligated into the vector.  
 
 
1 2 3 1 2 3
400bp 1000bp
 
 
Figure 3.15 Agarose gel electrophoresis showing the product of PCR 4 (lane 2, left panel, see Figure 3.14 
for details) and the product of PCR 5 (lane 2, right panel, see Figure 3.14 for details).  The final product 
PCR 5 was purified with PCR Purification Kit (Qiagen) and then treated with the restriction enzymes 
AccI and PflmI to obtain the insert.  Lane 1 of both gels represents the DNA ladder (HyperLadder IV in 
left panel, HyperLadder I in right panel).  Lane 3 in either picture represents the negative control. 
 
 
  
98 
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Figure 3.16 Agarose gel electrophoresis showing double digestion of the product of PCR 5 (see Figure 3.14 
for details) with the restriction enzymes AccI and PflmI.  Lane 1 represents the DNA HyperLadder I.  
Lane 2 represents the digested product of PCR 5. 
 
 
The transformation, colony PCR and sequencing to confirm the identity of construct 
GG*G*Alb 3∆β (∆1-50&101-150) was carried out in similar way to that for GXG*Alb 3∆β. 
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3.5 Summary 
 
To study the elements that influence post-transcriptional regulations, such as signal peptide 
and 3’UTR, a series of gene constructs were created.  The gene constructs were made by 
using a seamless cloning method that allows two or more DNA fragments precisely to be 
linked together, therefore avoiding the inclusion of unwanted sequences [186].  To identify 
the presence of the sequence of interest, colony PCR was performed by using individual 
colony that were obtained after ligation of vector and inserts. Finally, pair wise alignment was 
carried out to verify the creation of constructs.   
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4 Manipulation of signal peptide/ 3’UTR and its effect on 
protein expression and mRNA abundance 
4.1 Introduction 
 
Reporter systems have turned into priceless tools to study gene expression.  They have rapidly 
become an integral part of scientific work in various fields, from molecular biology to 
biomedical and pharmaceutical research.  Luciferases, as some of the most common and 
widely used reporter systems are being frequently used to examine the regulation of gene 
expression.  Recently Gaussia Luciferase has been used to assess effects of modification of 
expression vectors on recombinant protein synthesis/secretion so as to develop vectors and 
mammalian cell expression technology [187].  In this study Gaussia princeps Luciferase was 
chosen as reporter system to assess elements such as signal peptide and 3’UTR that influence 
post-translation regulatory mechanisms and subsequently affect the expression/secretion of a 
reporter protein.  
Novel gene constructs were made by utilising seamless cloning procedure which contained 
the Gaussia Luciferase 5’UTR, a signal peptide coding region, Gaussia coding region and 
various 3’UTR of interest (see chapter 3).  These novel gene constructs were then stably or 
transiently transfected into CHO cells.  Following transfection, culture medium and cell 
extract samples were obtained to assess activity of the reporter protein.  To study the effect of 
signal peptide hydrophobicity on Luciferase activity and mRNA abundance level, cells were 
transfected with constructs that contained the Chymotrypsinogen or Albumin signal peptide 
or the native Gaussia Luciferase signal peptide.  Chymotrypsinogen is a precursor of the 
digestive enzyme, Chymotrypsin that is involved in the breaking down proteins into amino 
acids.  This inactive enzyme is produced by pancreatic acinar cells.  Human serum albumin, 
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in contrast, is the most abundant protein in blood plasma and is produced in the liver.  The 
serum albumin is involved in maintaining the osmotic pressure and the transport of fatty 
acids, thyroid hormones, unconjugated bilirubin and drugs. 
The selection of the Chymotrypsinogen and the Albumin signal peptides was based mainly on 
their pattern of expression.  Chymotrypsinogen is produced in response to stimuli, which 
mimics the bulk secretion of the Gaussia princeps Luciferase in nature.  This is in direct 
contrast to the constitutive production of albumin directly into blood from hepatic cells [187].  
To determine Luciferase activity by cells transfected with the gene constructs of interest, 
detectable light energy (Relative Light Unit) was measured by a Luminometer using both 
culture medium and cell extracts. In many experiments but not all, the construct containing 
the native Gaussia signal peptide and Gaussia 3’UTR was chosen as standard reference 
construct (GG*G*G) and Luciferase activity in these cells was set as 100%.  The Luciferase 
activity in culture medium and cell extract for other constructs was expressed as a percentage 
of Luciferase activity for the standard reference construct GG*G*G in culture medium. 
Furthermore, total RNA extraction was performed to assess whether manipulation of 3’UTR 
correlates with protein expression.  To achieve this Real-Time PCR was performed to 
quantify mRNA abundance relative to the level of housekeeping gene, glyceroldehyde-3-
phosphate dehydrogenase (GAPDH).  
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4.2 Results 
 
4.2.1 Increasing signal peptide hydrophobicity and its effects 
 
Prior to this study a series of constructs had been created (JEH laboratory) in which mutations 
(see table 4.1) were made in the H-domain of the Chymotrypsinogen signal peptide 
(PTRE2hyg GXG*A5 3∆β, GX1G*A5 3∆β, GX2G*A5 3∆β, GXG*G, GX1G*G and 
GX2G*G).  First, a mutation was made so that the amino acid serine was replaced with the 
highly hydrophobic amino acid phenylalanine as a single mutation (X1).  To increase further 
the hydrophobicity of the Chymotrypsinogen signal peptide, the first threonine residue in the 
H-domain of Chymotrypsinogen was also substituted with the amino acid alanine as well as 
the substitution of serine to phenylalanine as double mutation (X2).  However during cloning, 
5 point mutations were randomly introduced within the Albumin 3’UTR (A5) and mutations 
were detected by sequencing the constructs. 
Table 4.1 Amino acid sequences of the wild type human Chymotrypsinogen signal peptide (X) and its two mutant 
variants that were investigated in this study.  To make X1 Chymotrypsinogen signal peptide, the residue serine was 
substituted with phenylalanine.  To make X2 Chymotrypsinogen signal peptide, the first threonine residue was 
replaced with alanine as well as the substitution of serine to phenylalanine. The substitute residues are underlined 
and highlighted.  
 
 
   Signal peptide Amino acid sequence 
   X= wild type 
M  A    F    L  W    L   L    S   C   W   A  L     L  G    T   T    F   G 
MetAlaPheLeuTrpLeuLeuSerCysTrpAlaLeuLeuGlyThrThrPheGly 
X1= with 1 mutation 
M  A    F    L  W    L   L    F   C   W   A  L     L  G    T   T    F   G 
MetAlaPheLeuTrpLeuLeuPheCysTrpAlaLeuLeuGlyThrThrPheGly 
X2= with 2 mutations 
M  A    F    L  W    L   L    F   C   W   A  L     L  G    A   T    F   G 
MetAlaPheLeuTrpLeuLeuPheCysTrpAlaLeuLeuGlyAlaThrPheGly 
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To examine the effect of signal peptide hydrophobicity on Luciferase activity and mRNA 
abundance level, CHO AA8 Tet off cells were stably transfected with constructs PTRE2hyg 
GXG*A5 3∆β, GX1G*A5 3∆β and GX2G*A5 3∆β.  These constructs contained the Human 
Albumin 3’UTR into which 5 point mutations had been randomly introduced during cloning. 
Furthermore these constructs did not contain the Rabbit β-globin vector-derived sequences. 
The β-globin vector-derived sequences labelled as β-globin poly (A) by Clontech, were made 
of 2 exons and one intron from the β-globin gene as well as the 3’UTR from the same gene. 
After transfecting the cell line with these constructs, cells were grown for approximately 4 
weeks as a mixed population with growth medium containing Hygromycin to maintain 
selection pressure on the transfected cells.  Transfection was carried out on two batches of 
CHO cells 4 days apart. Culture medium was harvested and cell extracts were prepared. 
Luciferase activity was measured (see chapter 2) in all samples.  For every transfected cell 
line, 3 parallel cell populations were obtained separately and therefore the results presented 
here are the average of 6 parallel measurements from a single construct unless otherwise 
stated. These procedures were followed for all the transfections throughout this study unless 
otherwise stated. 
It would appear from Figure 4.1 that increasing hydrophobicity of the signal peptide 
(Chymotrypsinogen) had no significant effect on the expression of Gaussia Luciferase.  One 
plausible explanation for the observed finding here is that perhaps the native 
Chymotrypsinogen signal peptide was already sufficiently hydrophobic that converting the 
amino acid serine to amino acid phenylalanine or amino acid threonine to amino acid alanine 
had no significant effect on overall hydrophobicity and thus did not influence the reporter 
activity.  
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Figure 4.1 Gaussia Luciferase activity in the culture medium samples from cells transfected with 
constructs containing the Albumin 3’UTR (with 5 point mutations) and Chymotrypsinogen signal peptide 
(with or without mutations).  Data are shown as percentage of Luciferase activity for construct GXG*A5 
3∆β.  The results showed that increasing signal peptide hydrophobicity had no detectable effect on the 
activity of the Luciferase reporter. The error bars represent the standard error of the mean. 
 
  
 
The data obtained from the Gaussia Luciferase activity in the cell extract (Figure 4.2) did not 
show any statistically significant difference between constructs GXG*A5 3∆β, GX1G*A5 
3∆β and GX2G*A5 3∆β. 
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Figure 4.2 Gaussia Luciferase activity in the cell extract samples from cells transfected with constructs 
containing the Albumin 3’UTR and Chymotrypsinogen signal peptide.  Data are shown as percentage of 
Luciferase activity for construct GXG*A5 3∆β in the culture medium.  The error bars represent the 
standard error of the mean. 
                  
 
 
In addition CHO AA8 Tet off cells were also stably transfected with constructs GXG*G, 
GX1G*G and GX2G*G (Figure 4.3).  The signal peptide in these constructs was the 
Chymotrypsinogen signal peptide without mutation in construct GXG*G, with one mutation 
(substitution of serine with phenylalanine) in construct GX1G*G and two mutations 
(substitution serine with phenylalanine and first Threonine residue with alanine) in construct 
GX2G*G.  However these construct contained the β-globin vector-derived sequences with 
Gaussia 3’UTR. 
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Figure 4.3 Gaussia Luciferase activity in the culture medium samples from cells transfected with 
constructs containing the Gaussia 3’UTR and Chymotrypsinogen signal peptide.  Data are shown as 
percentage of Luciferase activity for construct GXG*G.  The data presented here suggests that increasing 
the hydrophobicity of signal peptide significantly reduced the activity of the Luciferase reporter in the 
culture medium.  Statistical significance relative to the construct GXG*G was calculated by using the 
Mann-Whitney U test where *=p≤0.05 where n=6. The error bars represent the standard error of the 
mean. 
 
 
 
 
The result in Figure 4.3 suggests that increasing total hydrophobicity of the signal peptide in 
constructs containing the Gaussia 3’UTR significantly reduced the Luciferase activity in the 
culture medium.  This was in contrast to constructs containing the Albumin 3’UTR where 
increasing the hydrophobicity of signal peptide had no detectable effect on the activity of the 
reporter protein.  In contrast, no statistical difference was observed for the activity of 
Luciferase reporter in cell extract samples (Figure 4.4).  
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Figure 4.4 Gaussia Luciferase activity in the cell extract samples from cells transfected with constructs 
containing the Gaussia 3’UTR and Chymotrypsinogen signal peptide.  Data are shown as percentage of 
Luciferase activity for construct GXG*G in the culture medium.  The error bars represent the standard 
error of the mean. 
 
 
 
Overall the data obtained from the cell lines expressing constructs with the Albumin and 
Gaussia 3’UTRs showed that Luciferase activity was significantly higher in constructs 
containing the Albumin 3’UTR.  It must be noted that the Albumin 3’UTR containing 
constructs did not contain vector-derived sequences.  This is in contrast to constructs 
containing the Gaussia 3’UTR that also contained vector-derived sequences (Figure 4.5).  
Therefore, higher Luciferase activity could be attributed to the deletion of vector-derived 
sequences, as well as the choice of 3’UTR. 
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Figure 4.5 Luciferase activity in culture medium samples from cells transfected with constructs containing 
the Albumin and Gaussia 3’UTRs.  Statistical significance relative to the construct GXG*A53∆β was 
calculated by using the Mann-Whitney U test where **=p≤0.01 and where n=6.  The error bars represent 
the standard error of the mean. 
 
 
 
Interestingly, the results of Luciferase activity in cell extract for both groups of construct 
(Figure 4.6) mimicked the Luciferase activity in the culture medium.  
 
 
 
 
 
 
 
 
                     
  
109 
                      
Gaussia Luciferase Activity-Cell Extract
0
0.5
1
1.5
2
2.5
3
3.5
4
GXG*A5
3∆β
GXG*G GX1G*A5
3∆β
GX1G*G GX2G*A5
3∆β
GX2G*G
pe
rc
en
ta
ge
 
o
f l
u
ci
fe
ra
se
 
ac
tiv
ity
 
re
la
tiv
e 
to
 
G
XG
*
A
5 
3∆
β
 
ac
tiv
ity
 
in
 
m
ed
iu
m
****
 *
 
Figure 4.6 Luciferase activity in cell extract samples from cells transfected with constructs containing the 
Albumin and Gaussia 3’UTRs. Luciferase activity is shown as percentage of the Luciferase activity 
relative to GXG*A5 3∆β activity in culture medium.  Statistical significance relative to the construct 
GXG*A5 3∆β was calculated by using the Mann-Whitney U test where **=p≤0.01 and where n=6.  The 
error bars represent the standard error of the mean.  
 
 
                  
However, it should be noted that downstream vector-derived sequences had been removed 
from constructs containing the Albumin 3’UTR but not from those with the Gaussia 
Luciferase 3’UTR and therefore significantly higher Luciferase activity could be attributed 
either to removal of vector-derived sequences or the difference in 3’UTR.  The significantly 
higher Luciferase activity observed for constructs containing the Albumin 3’UTR compared 
to Gaussia 3’UTR  could not have been due to utilisation of the Chymotrypsinogen signal 
peptide since both groups of constructs had Chymotrypsinogen as the signal peptide.  It is 
however possible that β-globin vector-derived sequences could alter the secondary structure 
of the mRNA and as a result de-stabilise the mRNA transcripts, therefore potentially leading 
to lower Luciferase activity.  
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4.2.2 Removal of vector-derived sequences and its effect on the 
secretion of Luciferase 
 
Overall it would appear from Figures 4.5 that constructs containing the Albumin 3’UTR 
showed significantly higher Luciferase activity than constructs containing Gaussia 3’UTR. 
The data also suggested that increasing the signal peptide hydrophobicity had little or no 
significant effect on the reporter activity in constructs containing the Albumin 3’UTR.  The 
higher Luciferase activity in constructs containing the Albumin 3’UTR could have been due 
to the choice of 3’UTR or the removal of β-globin vector-derived sequences since the two 
groups of constructs differed only in absence or presence of vector-derived sequences and the 
choice of 3’UTR.   
To investigate the positive/negative effect of β-globin vector-derived sequences on the 
Luciferase secretion and reporter activity, CHO AA8 Tet-Off cells were stably transfected 
with construct GG*G*G (containing the vector-derived sequences) and construct GG*G*G 
3∆β (without vector-derived sequences).  The results showed that reporter activity and 
Luciferase secretion improved significantly by removing the β-globin vector-derived 
sequences in GG*G*G 3∆β (Figure 4.7).  This was in agreement with the findings by 
UniTargetingResearch AS, Bergen [188]. 
The significantly higher Luciferase activity in cells expressing the construct GG*G*G 3∆β 
compared to construct GG*G*G could be directly attributed to the deletion of vector-derived 
sequences since both constructs utilised the endogenous Gaussia Luciferase signal peptide 
and 3’UTR and were identical except for loss of vector-derived sequences. 
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Figure 4.7 Gaussia Luciferase activity in the culture medium samples shown as percentage of construct 
GG*G*G Luciferase activity.  The results showed that the removal of vector-derived sequences 
significantly improved the Luciferase activity in construct GG*G*G 3∆β.  Statistical significance relative 
to the construct GG*G*G was calculated by using the Mann-Whitney U test where *=p≤0.05 and where 
n=3.  The error bars represent the standard error of the mean. 
 
 
 
4.2.3 Effect of Albumin signal peptide on Luciferase activity 
It would appear from the results in this chapter that when a hydrophobic signal peptide 
(Chymotrypsinogen signal peptide) was used in combination with the Albumin 3’UTR, 
significantly higher Luciferase secretion and reporter activity was observed.  However, little 
was known about the Albumin signal peptide and its effect on Luciferase activity.  Work by 
others [187] had shown that using the Human Albumin signal peptide, in conjunction with the 
native Gaussia 3’UTR, had negative effect on reporter activity and Luciferase secretion.  
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Figure 4.8 Luciferase activity in the culture medium samples shown as percentage of the standard 
reference construct GG*G*G Luciferase activity.  The results show that replacing the hydrophobic 
Gaussia signal peptide with the Albumin signal peptide reduces the reporter activity.  Statistical 
significance relative to the construct GG*G*G was calculated by using the Mann-Whitney U test where 
*=p≤0.05, **=p≤0.01 and where n=6.  The error bars represent the standard error of the mean. 
 
 
 
The significantly lower Luciferase activity in constructs GAG*Alb 3∆β and GAG*G 3∆β 
could have been due to the lower Albumin signal peptide hydrophobicity compared to the 
native Gaussia Luciferase signal peptide, as demonstrated in Figure 4.9, and deletion of 
vector-derived sequences.  Furthermore, it is conceivable to consider the possibility of mis-
targeting of the mRNA transcripts by an insufficiently hydrophobic Albumin signal peptide.  
Since the reporter activity of the Albumin signal peptide has been estimated by 
UniTargetingResearch AS, Bergen, at 2% of the native Gaussia signal peptide, it remains to 
be seen whether replacing less hydrophobic amino acids within the Albumin 3’UTR with 
more hydrophobic amino acids such as alanine would positively influence reporter activity. 
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Figure 4.9 Human Albumin and the native Gaussia Luciferases hydrophobicity plot based on 
hydrophathy scale for amino acid residues adopted from Eisenberg et al 1982 [189] (courtesy of 
UniTargetingResearch AS, Bergen).  Human Albumin signal peptide activity is shown as percentage of the 
native Gaussia Luciferase signal peptide.  The arrows in the Albumin signal peptide indicate possible 
targets for making amino acid substitutions.  
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4.2.4 Effect of signal peptide hydrophobicity/3’UTR on the mRNA 
expression level 
 
To investigate the effect of signal peptide hydrophobicity/3’UTR on mRNA expression level, 
RNA was prepared (see chapter 2) from cells expressing all constructs that were previously 
used in transfection experiments.  For every transfected cell line, 3 parallel cell populations 
were obtained separately.  Then RT-PCR was carried out to obtain the cDNA. Finally Real-
Time PCR was performed on the cDNA to obtain a normalised relative ratio of Gaussia 
Luciferase over the housekeeping gene GAPDH. Next the mean of normalised relative ratio 
for each set of samples was introduced as percentage of the mean of construct GG*G*G 
samples.   
The data obtained from the mRNA quantification (Figure 4.10) showed a similar pattern to 
the results of Gaussia Luciferase activity in the culture medium in that mRNA abundance 
level was significantly higher in constructs containing the Albumin 3’UTR (without vector-
derived sequences) than construct with the Gaussia 3’UTR (with vector-derived sequences).  
The data also suggested that deletion of β-globin vector-derived sequences in construct 
GG*G*G 3∆β also significantly improved the expression level of mRNA. Interestingly, as  
previously seen with the Luciferase activity, increasing the hydrophobicity of 
Chymotrypsinogen signal peptide had little or no detectable effect on the mRNA expression 
level in both the constructs containing the Albumin 3’UTR/ Gaussia 3’UTR with the 
Chymotrypsinogen signal peptide.  Finally no significant difference was observed in the level 
of mRNA expression between construct GG*G*G and the constructs with the 
Chymotrypsinogen signal peptide (with or without mutations) and Gaussia 3’UTR.  
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Figure 4.10 Relative quantification of mRNA abundance compared to standard reference construct 
GG*G*G.  The quantification of mRNA is relative to the house keeping gene GAPDH. The data showed 
that mRNA expression was significantly higher in constructs containing the Albumin 3’UTR.  The results 
also showed that deletion of β-globin vector-derived sequences significantly improved the expression of 
mRNA in constructs GG*G*G 3∆β.  Statistical significance relative to the construct GG*G*G was 
calculated by using the Mann-Whitney U test where *=p≤0.05 and where n=3.  The error bars represent 
the standard error of the mean. 
 
 
          4.2.5 Effect of Albumin signal peptide on mRNA expression 
 
Interestingly, there were no significant differences in mRNA expression levels between cells 
expressing construct GG*G*G and constructs GAG*G 3∆β or GAG*Alb 3∆β (Figure 4.11). 
The fact that mRNA expression levels for constructs GAG*G 3∆β and GAG*Alb 3∆β did not 
differ significantly from construct GG*G*G, perhaps highlighted once again the importance 
of signal peptide hydrophobicity in its targeting role.  The data presented in Figures 4.8 and 
4.11 indicated huge discrepancies between the mRNA expression level and protein synthesis. 
Furthermore, normalisation of Gaussia Luciferase activity to the mRNA abundance (see 
Figure 4.12) for cells expressing constructs GAG*G 3∆β and GAG*Alb 3∆β relative to 
construct GG*G*G clearly showed that Luciferase activity did not correlate with the mRNA 
abundance.  A plausible explanation for this could have been the effects of the Albumin signal 
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peptide.  It is postulated that the Albumin signal peptide causes mis-targeting or inefficient 
targeting of the mRNA transcript during translocation across the ER (see introduction).  This 
could be due to the low hydrophobicity level and therefore potentially poor activity of the 
Albumin signal peptide.  It would be interesting to know whether replacing the less 
hydrophobic amino acids within the H-domain of Albumin signal peptide (3 serine residues 
and 1 threonine) with more hydrophobic amino acids such as phenylalanine improves its 
targeting function. 
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Figure 4.11 Relative quantification of mRNA abundance compared to standard reference construct 
GG*G*G.  The quantification of mRNA is relative to the house keeping gene GAPDH.  The data show 
that no significant difference was observed in mRNA expression between standard reference construct 
GG*G*G and constructs GAG*G 3∆β and GAG*Alb 3∆β.  The error bars represent the standard error of 
the mean. 
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Figure 4.12 Normalisation of Gaussia Luciferase activity over mRNA abundance. The figure shows that 
the luciferase activity for cells expressing constructs GAG*G 3∆β and GAG*Alb 3∆β did not correlate 
with the mRNA abundance.  
 
4.3 Transient co-transfection 
 
 
To exclude the site of integration of the transgene as a contributing factor for the observed 
differences in secreted Luciferase activity in cells expressing the various constructs, transient 
co-transfection of the constructs of interest and firefly Luciferase was performed.  Samples of 
medium and cell extracts were collected and a ratio of Gaussia Luciferase activity to firefly 
Luciferase was established.  CHO AA8 Tet-Off cells were co-transiently transfected with 
construct GG*G*G and constructs containing the Gaussia 3’UTR but without vector-derived 
sequences (GG*G*G 3∆β, GAGG* 3∆β) and constructs containing the corrected Albumin 
3’UTR for 5 point mutations (GAG*Alb 3∆β, GXG*Alb 3∆β).  
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As it was previously observed in this study, the data presented in Figure 4.13 showed that 
deletion of β-globin vector-derived sequence improved the secreted Luciferase activity in 
construct GG*G*G 3∆β.  The data also indicated that highest ratio of Gaussia Luciferase 
activity to firefly Luciferase was observed in construct containing the Albumin 3’UTR and 
Chymotrypsinogen signal peptide.  Furthermore, as it was seen previously in this chapter, 
replacing the hydrophobic signal peptides Gaussia or Chymotrypsinogen with the Albumin 
signal peptide reduced the ratio of the secreted Luciferase activity over firefly Luciferase.  
The data obtained from the cell extract samples also showed a similar pattern to those of 
culture medium samples.   
Since the pattern of Luciferase activity observed in various constructs in the transient co-
transfection was essentially the same as found with the stable transfections, the results would 
indicate that the positional effect of the plasmid in the genome could not have been a 
determining factor for the pattern of secreted Luciferase activity for the stable transfections.  
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Figure 4.13 Transient co-transfection. Ratio of Relative Light Unit (RLU) values of Gaussia Luciferase 
activity in the culture medium samples to the firefly Luciferase activity in the cell extract (A) and the 
Gaussia Luciferase activity in the cell extract against the firefly Luciferase activity in the cell extract (B). 
The data presented here suggest that the pattern of Gaussia Luciferase activity in transient co-transfection 
is similar to that observed for stable transfections.  The error bars represent the standard error of the 
mean. 
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4.4 Summary 
 
It was shown in this chapter that increasing the hydrophobicity of the Chymotrypsinogen 
signal peptide had little or no detectable influence on reporter protein expression.  One 
plausible explanation for this could be the hydrophobicity limits of the signal peptide in 
general, that beyond which is not effective as shown by others [41].  Overall the data 
presented in this chapter suggested that the secreted Gaussia Luciferase activity and mRNA 
expression were significantly higher in construct containing the Albumin 3’UTR.  The results 
also strongly suggested that the deletion of vector-derived sequences significantly improved 
the Luciferase activity and mRNA abundance.  This could have been due to alteration or 
conformation changes in the secondary structure of the mRNA transcript, therefore leading to 
higher stability of transcript.  The data also showed that the highest level of reporter activity 
and mRNA abundance is achieved where the Chymotrypsinogen signal peptide (with or 
without mutations) is used in combination with the Albumin 3’UTR.  The results in this 
chapter also suggested that replacing a hydrophobic signal peptide (native Gaussia or 
Chymotrypsinogen) with a less hydrophobic signal peptide (Albumin signal peptide), 
significantly reduces the protein expression.  This not only once more highlighted the 
importance of hydrophobic signal peptide but interestingly its combination with the 3’UTR. 
The data presented in this chapter also suggested that differences in secreted Luciferase 
activity and mRNA expression were not due to differences in the site of integration.  
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5 Albumin 3’UTR: a deletion analysis 
 
5.1 Introduction 
 
It has widely become recogonised that the 3’UTR is a crucial post-transcriptional regulatory 
element and regulates mRNA transcripts[190].  3’UTR sequences regulates gene activity 
through the interaction of RNA binding proteins and small non-coding RNAs such as 
miRNAs [190, 191].  These interactions could potentially influence mRNA stability or alter 
translation and localisation. In the past recent years mRNA stability has emerged as a key 
mechanism for the rapid regulation of gene expression [192].  
It was seen in the previous chapter that constructs containing the Albumin 3’UTR (without 
vector-derived sequences) consistently promoted high levels of mRNA and reporter activity 
compared to constructs containing the Gaussia Luciferase 3’UTR (with vector-derived 
sequences) when it was used with an appropriate signal peptide (either the Chymotrypsinogen 
or native Gaussia Luciferase signal peptides).  The data presented in chapter 4 showed that 
the greater level of Gaussia Luciferase activity in constructs containing the Albumin 3’UTR 
compared to control cell populations (construct GG*G*G) was not attributable to differences 
in the site of integration of plasmids within the genome.   However, the question remains - is a 
particular region of the Albumin 3’UTR responsible for promoting the high level of secreted 
Luciferase that was observed? 
In order to understand how the Albumin 3’UTR or a particular region/s promote Luciferase 
secretion and reporter activity, a series of deletions were made within the Albumin 3’UTR. 
The regions deleted were 50,100 and 150 nucleotides long (Figure 5.1). No deletions were 
made in the last 36 nucleotides of the Albumin 3’UTR. 
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Figure 5.1 Schematic representation of the full Albumin 3’UTR construct (in red) and its mutant variants 
(in blue).  All the deletions were made within the first 150 bps. Regions in broken lines represent the 
deleted nucleotides.  The hexamer AAUAAA represent the polyadenylation signal.  Only Deletion 
construct 51-150 and deletion construct 1-50 & 101-150 were made in this study (see chapter 3). Other 
deletion constructs were obtained from JEH laboratory.  
 
 
 
5.2 Results 
 
5.2.1 Albumin 3’UTR deletion analysis: Luciferase activity 
CHO AA8 Tet-Off cells were stably transfected with constructs containing the full length 
Albumin 3’UTR and its deletion mutants and grown for approximately 4 weeks as a mixed 
population using growth medium containing Hygromycin to maintain selection pressure on 
the transfected cells.  Transfection was carried out on two batches of CHO cells 4 days apart. 
1 50 100 150 
AAUAAA 
AAUAAA Deletion ∆ 1-50 
AAUAAA Deletion ∆ 1-100 
AAUAAA Deletion ∆ 1-150 
AAUAAA Deletion ∆ 51-100 
AAUAAA Deletion ∆ 101-150 
AAUAAA Deletion ∆ 51-150 
AAUAAA Deletion ∆ 1-50&101-150 
Full Albumin 3’UTR (186 bps) 
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Culture medium was harvested and cell extract samples prepared, and Luciferase activity was 
measured.  For every transfected cell line, 3 parallel cell populations were obtained separately 
and therefore the results were the average of 6 parallel measurements from a single construct 
unless stated otherwise. 
It would appear from Figure 5.2 that Gaussia Luciferase activity is significantly reduced in all 
the deletion constructs with the exception of ∆51-100 and ∆51-150.  The reduction of 
Luciferase activity in cells expressing the deletion construct 1-50 &101-150 was found to be 
close to significance (p value = 0.055).  The data presented in Figure 5.2 suggest that by 
deleting the region 51-100, Luciferase production is maintained and deleting other regions 
leads to either a not significant reduction (∆51-150), significant reduction (or close to 
significant reduction) of the reporter activity and Luciferase secretion.  
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Figure 5.2 Gaussia Luciferase activity in the culture medium samples from cells transfected with construct 
containing the full length Albumin 3’UTR and its deletion variants shown as percentage of Luciferase 
activity for construct GG*G*Alb 3∆β.  The data presented here show that high levels of Luciferase 
activity were maintained in deletion constructs 51-100 and 51-150.  Statistical significance relative to the 
construct GG*G*Alb 3∆β was calculated by using the Mann-Whitney U test where *=p≤0.05, **=p≤0.01, 
ť=0.055 and where n=6.  The error bars represent the standard error of the mean. 
 
 
 
The data presented in Figure 5.2 showed that deletion of nucleotides 1-150 leads to highest 
reduction in Luciferase activity.  This suggests that elements that regulate mRNA translation, 
are located within the first 150 nucleotides of the Albumin 3’UTR.  The data also showed that 
the greatest reduction in secreted Luciferase activity amongst the constructs with a single 
region deletion was observed with deletion construct ∆1-50 and ∆ 101-150, indicating that 
these regions are required to maintain reporter activity.  
Interestingly, the data presented in Figure 5.3 indicated that Luciferase activity in cell extract 
samples showed a similar pattern to that observed with the culture medium samples.  Activity 
in extracts from cells expressing the deletion constructs ∆1-50 (p value = 0.016), ∆1-150, 
∆101-150 and ∆1-50 & 101-150 was significantly reduced.  The results presented in Figure 
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5.3 also showed that the greatest reduction of Luciferase activity was observed in cells 
expressing the deletion construct ∆1-150.  This too was in agreement with the activity pattern 
to that observed for the culture medium samples for these cells.  The data also showed that the 
reduction of luciferase activity in cells expressing the deletion constructs ∆1-100, ∆51-100 
and ∆51-150 relative to the cells expressing the full length Albumin 3’UTR was found not to 
be significant.  
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Figure 5.3 Gaussia Luciferase activity in cell extract samples prepared from cells transfected with 
constructs containing the full Albumin 3’UTR and its mutant variants shown as percentage of Luciferase 
activity for construct GG*G*Alb 3∆β in the culture medium. Statistical significance relative to the 
construct GG*G*Alb 3∆β was calculated by using the Mann-Whitney U test where *=p≤0.05, **=p≤0.01 
and where n=6.  The error bars represent the standard error of the mean. 
 
 
 
Overall, the observations from the Luciferase activity in the culture medium and cell extract 
indicate that deletion of nucleotides 1-50 or 101-150 has a significantly negative effect on the 
reporter activity.  This could mean that deleting these regions negatively influences the 
stability or indeed the translation of transcripts.  On the other hand it appears that deleting the 
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region that contains nucleotide 51-100 has little or no negative effect on the stability or 
translation of transcript.  
 
5.2.2 Albumin 3’UTR deletion analysis: mRNA quantification 
To study the effect of Albumin 3’UTR deletions at the mRNA expression level, CHO AA8 
Tet-Off cells were stably transfected as described previously with construct containing the full 
length Albumin 3’UTR and its deletion variants , cells harvested and mRNA extracted. 
Relative quantification of the mRNA expression for all the Albumin 3’UTR deletion 
constructs was compared to the  Gaussia Luciferase mRNA expression of construct 
GG*G*Alb 3∆β.   
In agreement with the data presented in Figure 5.3, the mRNA expression level was 
significantly lower in deletion constructs ∆1-50, ∆1-150 and ∆1-50 & 101-150.  The data 
presented in Figure 5.4 showed that reduction of mRNA abundance in cells expressing the 
deletion constructs ∆1-100, ∆51-100, ∆101-150 and ∆51-150 relative to cells expressing the 
full length Albumin 3’UTR was found not to be significant.  
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Figure 5.4 Relative quantification of mRNA abundance compared to construct GG*G*Alb 3∆β.  The 
quantification of mRNA is relative to the house keeping gene GAPDH.  The data presented here showed 
that the level of mRNA expression was significantly lower in deletion constructs ∆1-50, ∆ 1-150 and ∆1-50 
& 101-150.  This mirrored the Gaussia Luciferase activity level for these deletion variants.  Statistical 
significance relative to the construct GG*G*Alb 3∆β was calculated by using the Mann-Whitney U test 
where *=p≤0.05, **=p≤0.01 and where n=6 for Alb, Del 1-50, Del 1-00, Del 1-150 Del 51-150 and n=5 for 
Del 51-100, Del 101-150 and Del 1-50&101-150.  The error bars represent the standard error of the mean. 
 
 
 
The normalisation of Gaussia Luciferase activity to the mRNA level (see Figure 5.5) also 
showed that Luciferase activity for cells expressing constructs ∆1-50, ∆ 1-100 and ∆1-50 
correlated with the mRNA level, whereas for cells expressing constructs ∆ 51-100, ∆101-150, 
∆51-150 and ∆1-50&101-150 did not. 
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Figure 5.5 The normalisation of Gaussia Luciferase activity to mRNA abundance.  The figure shows that 
Luciferase activity for deletion constructs ∆1-50, ∆1-100 and ∆1-150 correlated with the mRNA 
abundance for those constructs.  The figure also shows that reporter activity in the deletion constructs 
∆51-100, ∆51-150 and ∆1-50&101-150 was greater than the mRNA abundance whereas this was lower in 
the deletion construct ∆101-150. 
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5.3 Summary 
Overall it can be observed from the data presented in this chapter that the Gaussia Luciferase 
activity in the culture medium is only maintained where the region containing nucleotide 51-
100 is deleted.  The data also suggested that deletion of nucleotides 1-50 and 1-100, 1-150 
and 101-150 leads to a statistically significant reduction in Gaussia Luciferase activity.  The 
reduction of reporter activity in cells expressing the deletion construct ∆1-50 & 101-150 was 
found not to be statistically significant (p value = 0.055).  The data also showed that deletion 
of nucleotides 1-50, 1-150 and 1-50&101-150 leads to significant reduction in mRNA level. 
The greatest reduction in mRNA expression and Luciferase activity was observed by deletion 
of nucleotides 1-150.  One plausible explanation for the significantly lower mRNA expression 
level and the reporter activity in the culture medium and cell extract for cells expressing the 
deletion construct ∆1-150 could be due to destabilisation of the mRNA transcripts, which is a 
result of the deletion of most of the Albumin 3’UTR.  It has long been known that for any 
given RNA molecule, functionality depends on primary sequence as well as the secondary 
folding[193] (see 8.2.3).  
On the other hand, it is speculated that as a result of alteration to the secondary structure of 
the RNA transcript (see 8.2.2), inhibitory protein/s could bind to a deletion variant such as 
∆1-50 more readily than other Albumin 3’UTR deletion variants.  This could be plausibly a 
valid explanation for the significantly lower Gaussia Luciferase activity and mRNA 
abundance in cells expressing the deletion construct ∆1-50.  
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6. The Albumin 3’UTR and protein binding 
 
6.1 Introduction 
It is becoming increasingly apparent that RNA binding proteins play an important role in the 
regulation of mRNA stability, translation and localisation by associating with the regulatory 
sequences that are present in mRNA transcripts such as AU-rich sequences, stem loop 
structures and the poly (A) tail [194].  These trans-acting factors influence the regulation of 
gene expression by modulating events such as nuclear degradation of pre-mRNA, alternative 
splicing, RNA editing, RNA stability and ultimately the translation of mRNA transcripts.  
This influence is achieved by association of the trans-acting factors with specific 
sequences/motifs which are present typically in the 5’UTR or the 3’UTR [107].   
In chapter 4 and 5 results revealed that using constructs containing the Albumin 3’UTR 
(without vector-derived sequences) led to a higher level of Luciferase mRNA and secreted 
protein compared to constructs containing the Gaussia Luciferase 3’UTR (with vector-
derived sequences).  It was postulated that differences in mRNA and protein levels were due 
to specific binding of protein/s to possible regulatory element/s within the Albumin 3’UTR.  
In this chapter experiments are described where techniques such as Electrophoresis Mobility 
Gel Shift Assay (EMSA) and UV Cross-linking were applied to investigate evidence of 
protein/s binding to the Albumin 3’UTR.  Subsequently mass spectrometry analysis was 
carried out to identify protein/s which bound to the Albumin 3’UTR.  This result was then 
confirmed by utilisation of several experimental techniques such as siRNA knock down and 
western blotting.  In addition, this chapter discusses evidence of siRNA knock down on the 
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candidate protein/s and its effects on the promotion of Luciferase activity and mRNA 
abundance is investigated.  
 
6.2 Results 
 
6.2.1 Optimisation of EMSA reaction 
To characterise the interaction of proteins in CHO cell extracts with the Albumin 3’UTR, 
EMSA were performed.  The principle for EMSA is that protein/RNA complexes migrate 
more slowly than the free RNA fragments through a non-denaturing polyacrylamide gel.  To 
allow the protein-RNA interaction, S-100 CHO cell extracts were incubated with the Albumin 
3’UTR radiolabelled RNA transcript and the protein and RNA complexes were subjected to 
electrophoresis in a non denaturing polyacrylamide gel.  To optimise the EMSA protocol, 
different relative ratios of radiolabelled RNA transcript (fmols) to S-100 CHO cell extract 
(µg); 12 fmols of RNA transcript was incubated with 1, 1.5 and 2µg of protein extracts (see 
Materials and Methods).  As shown in Figure 6.1, complex formation was seen as a distinct 
shift in migration as the amount of protein extract increased.  Complex formation was 
achieved with 1.5 and 2 µg of protein.  In this study hereafter 12 fmols of RNA transcript and 
2 µg of S-100 CHO cell extracts were used for an EMSA reaction to ensure complex 
formation. 
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Figure 6.1 Optimisation of EMSA reaction to investigate protein binding to the full Albumin 3’UTR. 
Complex formation is seen as distinct shift in molecular weight after increasing the amount of S-100 CHO 
cell extract.  Lane 1 shows the radio-labeled RNA transcript alone (control reaction).  Lanes 2-4 represent 
RNA-protein binding complex formation with 1, 1.5 and 2 µg of protein, respectively.  The arrow 
indicates a distinct shift in migration of complex formation in comparison to control reaction. 
  
 
6.2.2 Determining the specificity of protein binding to the Albumin 3’UTR-
EMSA 
 
To determine the specificity of the RNA-protein interaction and complex formation in EMSA, 
competition reactions were carried out using  non-labelled full Albumin 3’UTR and β-globin 
3’UTR as specific and non-specific competitors respectively.  Both specific and non specific 
competitors were synthesised with the MEGAshortscriptTM Kit (Ambion) by performing in-
vitro transcription (see 2.17.2) and subsequently quantified by spectrophotometry.  Both 
specific and non-specific competitors were added to the EMSA reaction in 20, 40 and 80 
molar excess.  As show in Figure 6.2, less complex formed as the amount of specific Albumin 
3’UTR competitor was increased. 
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Figure 6.2 Specificity of protein binding to the Albumin 3’UTR.  The intensity of protein binding and 
complex formation decreases as the molar ratio of specific competitor (non-labelled full length Albumin 
3’UTR RNA transcript) increases (lane 3-5) whereas increasing the non-specific competitor (non-labelled 
β-globin RNA transcript) had no effect on the complex formation (lane 6-8).  The arrow indicates complex 
formation decreases as the molar ratio of specific competitor increases. 
 
This indicates that there was greater competition between the radiolabelled Albumin 3’UTR 
and its self-competitor for binding to the protein/s as the molar ratio of self competitor (non-
labelled full length Albumin 3’UTR) was increased.  As shown in Figure 6.2, competition for 
binding to the protein/s reaches its highest when an 80 molar excess of the specific competitor 
was applied.  In contrast, increasing amounts of a non-specific competitor had less effect on 
complex formation.  The data presented in Figure 6.2 strongly indicate that binding of CHO 
cell proteins to the radiolabelled Albumin 3’UTR RNA transcript is specific. 
 
Lane 1: probe (radiolabelled Albumin 3’UTR RNA transcript only) 
 
Lane 2: probe + S-100 CHO cell extract 
 
Lane 3:+ 20X specific competitor 
 
Lane 4:+ 40X specific competitor 
 
Lane 5:+ 80x specific competitor 
 
Lane6:+ 20x non-specific competitor 
 
Lane7:+ 40x non-specific competitor 
 
Lane8:+ 80x non-specific competitor 
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6.2.3 Competition analysis with the Albumin 3’UTR deletion regions: 
EMSA 
Having established CHO cell protein binding to the Albumin 3’UTR and its specificity, a 
competition experiment was performed with unlabelled truncated transcripts of the Albumin 
3’UTR in which specific regions were deleted.  The aim was to identify region/s within the 
Albumin 3’UTR that were responsible for protein binding.  The Albumin 3’UTR of deletion 
constructs (see chapter 5) were used as competitors in this experiment.  In addition the full 
length Albumin 3’UTR RNA transcript was used as control.  Based on the previous results 
(Figure 6.2) a 20 fold molar excess ratio of all competitors was used.   
 
 
Figure 6.3 Competition assay with the Albumin 3’UTR deletion constructs as competitors.  The Albumin 
3’UTR deletion constructs were used in an EMSA experiment to identity deletion construct/s which 
compete for binding to protein extract with the radiolabelled full length Albumin 3’UTR RNA transcript.  
The strongest competition appeared to be with the deletion regions 1-50 and 101-150 (lanes 3 and 7).  The 
arrow indicates the protein-RNA complex formation. 
 
 
1 2 3 4 5 6 7 8 9  10 
Lane 1: Probe (radiolabelled full length Albumin 3’UTR 
RNA transcript) 
 
Lane 2: Probe + S-100 CHO cell extract   
 
Lane 3:+ Deletion transcript 1-50 
 
Lane 4: + Deletion transcript 1-100 
 
Lane 5: + Deletion transcript 1-150 
 
Lane 6: + Deletion transcript 51-100 
 
Lane 7: + Deletion transcript 101-150 
 
Lane 8: + Deletion transcript 51-150 
 
Lane 9: + Deletion transcript 1-50&101-150 
 
Lane 10: Self competitor (radiolabelled full length 
Albumin 3’UTR RNA transcript + unlabelled full length 
Albumin 3’UTR RNA transcript) 
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As shown in Figure 6.3 little or no competition was observed by deletion region 1-150.  This 
indicates that all the possible binding motifs for the candidate protein/s were located within 
the first 150 nucleotides.  It would also appear from Figure 6.3 that the strongest competition 
was provided by the deletion regions 1-50 and 101-150.  This indicates firstly that protein 
binding to the Albumin 3’UTR occurs primarily outside the first 50 nucleotides. Then 
secondly, any candidate protein/s potentially bind to nucleotides 51-100 within the Albumin 
3’UTR.  The data also showed a lesser degree of competition with deletion regions 1-100, 51-
100, 51-150 and 1-50 & 101-150.  This could suggest that candidate protein/s may bind to 
other region/s within the Albumin 3’UTR.   
To quantify the intensity of complex formation in Figure 6.3, densitometry analysis of 
autoradiograph image of an EMSA competition assay was carried out.  Autoradiography 
image of EMSA competition experiment was analysed by software (UV MW band).  The 
intensity of distinct bands was used to assess competition for binding to candidate protein/s 
between the Albumin 3’UTR and the deleted regions.  The intensity of the bands was 
expressed as a percentage of the band intensity for the control (radiolabelled full length 
Albumin 3’UTR RNA transcript).  
The procedure was performed independently for complex observed in the EMSA competition 
assay (Figure 6.3).  The data obtained from the quantification of the complex formation in the 
EMSA assay was in agreement with the visual inspection of the autoradiography image.  As 
shown in Figure 6.3, the strongest competition for binding to protein/s was seen with the 
deletion regions 1-50 and 101-150 competitors.  Interestingly, densitometry analysis showed 
yet again that there is a varying degree of competition for the binding to candidate protein/s 
amongst other competitors (deletion regions 1-100, 51-100, 51-150 and 1-50&101-150) 
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indicating that possibly there are multiple binding site/s within the Albumin 3’UTR for 
candidate protein/s.  
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Figure 6.4 Quantification of the complex formation in the EMSA competition assay via densitometry.  The 
intensity of bands was quantified and expressed as a percentage of control (radiolabelled full length 
Albumin 3’UTR RNA transcript) band intensity.  The error bars represent the standard error of the 
mean. 
 
 
  
In agreement with the visual inspection of the EMSA competition assay, the data presented in 
Figure 6.4 also showed that little or no competition was observed with the deletion region 1-
150.  This potentially indicates that the major binding sites for the protein/s are placed within 
the first 150 nucleotides of the Albumin 3’UTR. The quantification of complex formation was 
in overall agreement with the visual inspection of the data. 
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6.2.4 Protein binding to the Albumin 3’UTR: UV Cross-linking 
6.2.4.1 Optimisation of UV Cross-linking reaction 
To further investigate the interaction between protein and the Albumin 3’UTR transcripts, UV 
Cross-linking experiments were performed.  In a typical UV Cross-linking experiment, an 
RNA transcript is cross-linked to proteins and then separated as distinct bands and visualised 
on a denaturing SDS-PAGE gel.  The experiments are carried out by cross linking the RNA 
transcript and proteins (see 2.17.7) prior to RNaseA treatment and then separating materials 
on SDS-PAGE gel.  The UV Cross-linking analysis separated independent protein 
components present in the cross-linking of RNA transcript and proteins and by using a 
molecular marker, the approximate molecular weight of the cross linked proteins and nucleic 
acid was determined. 
                                   
1 2
45 KDa
60 KDa
100 KDa
  
 
Figure 6.5 UV Cross-linking experiment to reveal protein binding to the Albumin 3’UTR.  The RNA-
protein interaction is shown as distinct bands (lane 1 and 2) which are separated based on molecular 
weight.  Lanes 1 and 2 show the cross-linking of radiolabelled full length Albumin 3’UTR RNA transcript 
with 2.5 µg and 2 µg of S-100 CHO cell extract, respectively.  
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As shown in Figure 6.5, UV Cross-linking followed by SDS-PAGE analysis showed presence 
of several distinct bands (5) ranging from ~45 kDa to 100 kDa. It appeared from the data that 
when 2.5 µg of S-100 CHO cell extract was used with the radiolabelled full length Albumin 
3’UTR RNA transcript, stronger bands were observed.  In this study hereafter 2.5 µg of S-100 
CHO cell extract was used for UV Cross-linking experiment. 
 
 
6.2.4.2 Specificity of protein binding to the Albumin 3’UTR: UV Cross-linking 
To confirm the results of EMSA for specificity of protein binding to the Albumin 3’UTR,  
UV Cross-linking experiments were performed where non-labelled full Albumin 3’UTR and 
β-globin 3’UTR were used as specific and non-specific competitors at 20, 40 and 80 fold 
molar excess.                                                                                                                                    
           
45 KDa
60  KDa
100 KDa
1 72 3 4 5 6
 
Figure 6.6 Examining the specificity of protein binding to the Albumin 3’UTR.  The intensity of distinct 
bands representing the interaction between the CHO cell extract and the Albumin 3’UTR decreases as the 
molar ratio of specific competitor (non-labelled full length Albumin 3’UTR RNA transcript) increases 
(lanes 2-4) whereas increasing the molar ratio of non-specific competitor (non-labelled β-globin RNA 
transcript) had little or no significant effect on the intensity of complex formation and bands (lanes 5-7).  
The arrow indicates approximate molecular weight of complexes between the protein and labelled RNA 
transcript. 
Lane 1: Probe (radiolabelled full length Albumin 3’UTR 
transcript) +2.5µg of S-100 CHO cell extract+ RNase 
T1&RNase A 
 
Lane 2:  + 20X Specific competitor 
 
Lane 3:  + 40X Specific competitor  
 
Lane 4:  + 80 X Specific competitor  
 
Lane 5: +20X Non-specific competitor 
 
Lane 5: + 40X Non-specific competitor  
 
Lane 5: + 80X Non-specific competitor  
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As shown in Figure 6.6, 5 prominent bands were seen cross-linked to the radiolabelled RNA 
transcript.  The data presented in Figure 6.6 also showed that protein binding to the Albumin 
3’UTR was specific as it had been seen previously in this chapter with EMSA.  The data also 
showed that by increasing the molar ratio of specific competitor (non-labelled full length 
Albumin 3’UTR RNA transcript) from 20 to 80 fold excess, the intensity of  bands with 
approximate molecular weights ranging from 45 to 100 kDa was reduced and at 80 molar 
excess all but disappeared.  This result mirrored the result of EMSA for specificity of protein 
binding (Figure 6.2), confirming that interaction between the proteins and RNA transcript 
appeared specific. 
 
6.2.4.3 Competition analysis with the Albumin 3’UTR deletion regions: UV Cross-
linking 
In order to further investigate protein binding to the various regions of the Albumin 3’UTR, 
UV Cross-linking competition experiments were carried out using unlabelled full length 
Albumin 3’UTR RNA transcripts with deletion transcripts as competitors. In addition an 
unlabelled full length Albumin 3’UTR was used as a positive control.  
 
 
 
 
  
140 
                                                                  
1 2 3 4 5 6 7 8 9
45kDa
60kDa
100kDa
 
 
 
Figure 6.7 UV Cross-linking competition assay with the Albumin 3’UTR deletion constructs as specific 
competitors.  The Albumin 3’UTR deletion constructs were used in a UV Cross-linking experiment to 
identity deletion construct/s which competes for binding to protein extract with the radiolabelled full 
length Albumin 3’UTR RNA transcript (probe).   
 
 
 As shown in Figure 6.7, the lowest competition amongst all the competitors was observed 
with the deletion region 1-150 as it was seen with the EMSA competition assay (see Figure 
6.3).  This suggests that binding motif/s for candidate protein with a molecular weight of ~50, 
are probably located within the first 150 nucleotides of the Albumin 3’UTR.  The data 
presented in Figure 6.7 also showed that the strongest competition for binding to the protein 
with a molecular weight of ~50 kDa was provided by the deletion construct 1-50.  This was in 
agreement with the previous finding in this chapter (see 6.2.3) although the EMSA 
competition experiment gave no information on the precise proteins involved in the 
interaction with the RNA transcripts.  This yet again could suggest that the region which 
contains nucleotides 1-50 is not required for binding to any candidate protein/s.  
The data presented in Figure 6.7 also showed that deletion region 101-150 provided the 
second strongest competition for binding to protein with a molecular weight of ~50 kDa.  This 
could imply that binding motif/s for this candidate protein is probably located in region which 
contains nucleotides 51-100.  This was based on observation that firstly, the deletion region 1-
Lane 1: Probe (radiolabelled full length Albumin 3’UTR RNA transcript) 
+ protein extract+RNaseT1& RNase A 
Lane 2:+ Deletion transcript 1-50 
 
Lane 3: + Deletion transcript 1-100 
 
Lane 4: + Deletion transcript 1-150 
 
Lane 5: + Deletion transcript 51-100 
 
Lane 6: + Deletion transcript 101-150 
 
Lane 7: + Deletion transcript 51-150 
 
Lane 8: + Deletion transcript 1-50 & 101-150 
 
Lane 9: Self competitor (radiolabelled full length Albumin 3’UTR RNA 
transcript + unlabelled Albumin full length 3’UTR transcript  
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150 showed little or no competition for binding to candidate protein/s.  Secondly, the deletion 
region 1-50 showed the strongest competition.  Figure 6.7 also showed that deletion regions 
101-150 and 51-150 provided the strongest competition for binding to protein with the 
molecular weight of ~70 kDa.  This could also indicate the existence of more than one 
possible binding site (motif) for the candidate protein/s within the Albumin 3’UTR.   
The results of the EMSA and UV Cross-linking competition experiments suggested a varying 
degree of competition for binding to protein/s by various competitors with respect to the 
positive control (unlabelled full Albumin 3’UTR).  This would suggest a preference of 
protein/s to bind to certain region/s of the Albumin 3’UTR.  To gather a more precise measure 
of competition, densitometry analysis of autoradiograph image of two independent UV Cross-
linking assays was carried out.  The intensity of signal for distinct bands over two 
experiments was used to assess competition for binding to protein/s amongst the Albumin 
3’UTR RNA transcripts.  Autoradiography image of EMSA competition experiments were 
analysed by software (UV MW band) to quantify the intensity of bands.  The intensity of the 
bands was expressed as a percentage of the appropriate band for the control (radiolabelled full 
length Albumin 3’UTR RNA transcript).  To perform densitometry analysis, signals for the 
bands with molecular weight of ~50 kDa in Figure 6.7 were quantified and then averaged and 
expressed as a percentage of the control’s band intensity (radiolabelled full length Albumin 
3’UTR RNA transcript).  
Interestingly, densitometry analysis data for UV Cross-linking experiments (Figure 6.8) 
showed a similar pattern to the densitometry analysis of the EMSA competition assay. As 
shown in Figure 6.8 the strongest competition for binding to protein/s was observed with the 
deletion region 1-50 unlabelled RNA transcripts and the competition was statistically 
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significant.  The data also showed that the second strongest competition was observed with 
the deletion region 101-150.  This competition of deletion region 101-150 was also found to 
be significant.  The data also showed that competition of deletion regions 51-100 and 1-50& 
101-150 for binding to protein/s was also significant.  Interestingly, deletion regions 1-100, 1-
150 and 51-100 showed no competition for binding to protein/s.   
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Figure 6.8 Quantification of band intensity by densitometry analysis.  The intensity of bands obtained 
from two independent UV Cross-linking competition experiments for binding to protein/s with a 
molecular weight of ~50 kDa was quantified and expressed as percentage of the control (radiolabelled full 
length Albumin 3’UTR RNA transcript) band intensity.  Statistical significance relative to the control was 
calculated by using the Mann-Whitney U test where **=p≤0.01 and where n=6.  The error bars represent 
the standard error of the mean. 
 
 
 
In addition, densitometry analysis was performed for bands immediately above the 60 kDa 
molecular weight observed in Figure 6.7.  To perform densitometry analysis, signals obtained 
from a single experiment were quantified and then averaged and expressed as a percentage of 
the control’s band intensity (the full length Albumin 3’UTR radiolabelled transcript).  In 
agreement with previous findings in this chapter, unlabelled 1-150 transcript showed no 
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competition (Figure 6.9).  This could suggest that the majority of the binding sites for 
candidate proteins are located within the first 150 nucleotides of the Albumin 3’UTR.  In a 
contrast to a previous finding in this chapter, the strongest competition was observed with the 
unlabelled 101-150 RNA transcript not the unlabelled 1-50 RNA transcript.  Unlabelled 51-
100 and 51-150 RNA transcripts also showed strong competition indicating that various 
regions of the Albumin 3’UTR show varying degrees of competition for binding to perhaps a 
variety of protein/s.  Interestingly, unlabelled 1-100 and 1-50&101-150 showed the lowest 
competition for binding to protein/s with molecular weight of ~70 kDa. 
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Figure 6.9 Quantification of band intensity by densitometry analysis.  The intensity of bands for a 
protein/s with molecular weight of ~70 kDa was obtained from a typical UV Cross-linking competition 
experiment.  The intensity of signals was then quantified and expressed as a percentage of the control’s 
band intensity (radiolabelled full length Albumin 3’UTR RNA transcript).  The error bars represent the 
standard error of the mean. 
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6.2.5 Streptavidin MagneSphere Paramagnetic Particles (SA-PMPs) and 
protein separation 
 
RNA affinity techniques followed by mass spectrometry have been widely used to isolate and 
identify RNA-binding proteins. Streptavidin MagneSphere Paramagnetic Particles (SA-
PMPs) were used in this study to isolate bound proteins utilising the strong binding affinity 
between biotin and Streptavidin which has long been known to be a very strong and stable 
interaction [195]. 
 EMSA, UV Cross-linking competition assays showed that unlabelled 1-50 deletion 
transcripts gave the strongest competition for binding to protein/s when they were used as a 
specific competitor against radiolabelled full length Albumin 3’UTR RNA transcript. 
Therefore, it was decided to select deletion construct 1-50  for the “bait” with which to isolate 
and identify protein/s that can bind to the Albumin 3’UTR RNA.  The unlabelled 1-50 and 
globin 3’UTR (as a negative control) transcripts were labelled with biotin (see 2.17.8) and 
then immobilised on Streptavidin MagneSphere Paramagnetic Particles (SA-PMPs).  The 
biotinylated control transcript was used in order to distinguish the specificity of protein 
binding to the Albumin 3’UTR RNA transcript.  
The magnetic beads were then incubated with S-100 CHO cell extract, washed to remove 
unbound particles and after separation by 10% SDS-PAGE, bound protein/s were then 
visualised by staining the gel with Colloidal Coomassie. Staining of the SDS-PAGE gel 
revealed three distinct bands each of a molecular weight of under ~60 kDa.  They were only 
present in the unlabelled 1-50 biotinylated transcript (Figure 6.10).  The focus of protein 
identification in this study was only on specific protein/s that bind to the Albumin 3’UTR, 
therefore only the region with the triplet bands in unlabelled 1-50 transcript and its immediate 
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corresponding region in control transcript were subjected to mass spectrometry analysis.  The 
actual process of protein identification and excision of bands was performed by a private 
company (NEPAF, Newcastle University). 
 
 
 
 
                                                       
 
Figure 6.10 Isolation of protein/s attached to biotinylated 1-50 RNA transcript.  Attached protein/s to the 
biotinylated 1-50 and control (biotinylated globin 3’UTR) transcript were subjected to 10% SDS-PAGE 
gel separation.  The regions selected in small rectangular boxes were subjected to mass spectrometry 
analysis. 
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Following mass spectrometry analysis, three proteins were identified that were only present in 
the sample containing the deletion region 1-50 biotinylated RNA transcript.  The identified 
proteins were absent in sample containing the negative control.  The identified proteins were 
as follows: 
1) Far upstream element (FUSE) binding protein 3 
2) Regulator of differentiation 1 (Rod 1) 
3)  CUG-BP1 
 
1) Far upstream element (FUSE) binding protein 3: This protein is a member of an 
ancient family of single stranded DNA binding proteins which are required for proper 
regulation of c-myc proto-oncogene and may activate gene expression.  It has been 
shown that this family of proteins bind to a variety of RNAs and therefore is likely to 
be multifunctional [196]. 
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Protein id                                 Mass     log (e)     pI       rI    log (I)   
ENSRNOP00000021871         61.9       -17.1        8.4      3     6.10  
 protein sequence: 
Matched peptides are highlighted and underlined: 
1          MAELVQGQSAPVGLKAEDFVDALHRVRQIAAKIDSIPHLNNSTPLVDPSVYGYGVQKRPL          60 
61        DDGVGNQLGALVHQRAVITEEFKVPDKMVGFIIGRGGEQISRIQAESGCKIQIASESSGI              120 
121      PERPCVLTGTPESIEQAKRLLGQIVDRCRNGPGFHNDIDGNSTIQELLIPASKVGLVIGK                180 
181      GGETIKQLQERTGVKMVMIQDGPLPTGADKPLRITGDPFKVQQAREMVLEIIREKDQADF        240 
241      RGVRSDFTSRAGGGSIEVSVPRFVVGIVIGRNGEMIKKIQNDAGVRIQFKPDDGISPERA             300 
301      AQVMGPPDRCQHAARIINELILTAQEREILGGLTGTRGRGRGRGDWSVGTPGGIQEITYT            360  
361      VPADKCGLVIGKGGENIKSINQQSGAHVELQRNPPPNTDPNLRIFTIRGAPQQIEVARHL              420 
421      IDEKVGGASLGAPTAFGQSPFSQPPAAPHQNTFPPRAFPNIAAKVNGNPHSTPVSGPPAF              480    
481      LTQGWGSTYQAWQQPTQQVPSQQSQPQNSQPDYSKAWEDYYKKQGHTTSAAPQASSPPDY    540   
541      TMAWAEYYRQQAAFYGQTLGQAQAHSQEQ                                                                                      569 
Figure 6.11 Mass Spectrometry analysis result for far upstream element (FUSE) protein 3.  The data 
shows the identified protein’s specification and sequence.  Log (e) represents the expectation of finding 
protein stochastically, pI represents the isoelectric value for the intact gene product, rI represents the 
number of found peptides after digestion with trypsin and log (I) represents the sum of raw spectrum 
intensities.  Mass Spectrometry analysis carried out by comparing the sequence of peptide fragments with 
the following 5 protein sequence databases : cavPOR 3 ENSEMBLE 53, cRAP with Sigma-Aldrich 
Universal Protein Standard Sequences, monDom 5 ENSEMBLE 50.5e,  RGSC 3,4 ENSEMBLE 52, 
NCBIM37 ENSEMBLE 52. 
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2) Regulator of differentiation 1 (Rod 1): an RNA binding protein which suppresses 
differentiation and binds to RNA preferentially to both poly (U) and Poly (G) sequences[197].  
 
NCBI id                                      Mass     log (e)     pI       rI    log (I)   
NP_005147.3                              55.7       -16.0      9.2      12    7.20 
Partial protein sequence: 
Matched peptides are highlighted and underlined: 
  1        ANGNDSKKFKGDRPPCSPSRVLHLRKIPCDVTEAEVISLGLPFGKVTNLLMLKGKSQAFL          60 
  61      EMASEEAAVTMVNYYTPVTPHLRSQPVYIQYSNHRELKTDNLPNQARAQAALQAVSAIQS       120 
121     GNLTLHGAPSNEVTILPGQSPVLRIIIENLFYPVTLEVLHQIFSKFGTVLKIITFTKNNQ                    180  
181     FQALLQYADPVNAHYAKMALDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDFTRLDLP        240 
241     SGDGQPSLEPPMAAAFGAPGIISSPYAGAAGFAPAIGFPQATGLSVPAVPGALGPLALTS               300 
301     SAITGRMAIPGASGIPGNSVLLVTNLNPDLITPHGLFILFGVYGDVHRVKIMFNKKENAL               360 
361     VQMADANQAQLAMNHLSGQRLYGKVLRATLSKHQTVQLPREGQEDQGLTKDFSNSPLHRF   420 
421     KKPGSKNFQNIFPPSATLHLSNIPPSVTMDDLKNLFTEAGCSVKAFKFFQKDRKMALIQL              480 
481     GSVEEAIQALIELHNHDLGENHHLRVSFSKSTI                                                                                      513 
Figure 6.12 Mass Spectrometry analysis result for regulator of differentiation 1 (Rod 1).  The data shows 
the identified protein’s specification and sequence.  Log (e) represents the expectation of finding protein 
stochastically, pI represents the isoelectric value for the intact gene product, rI represents the number of 
found peptides after digestion with trypsin and log(I) represents the sum of raw spectrum intensities. 
Mass Spectrometry analysis carried out by comparing the sequence of peptide fragments with the 
following 5 protein sequence databases : cavPOR 3 ENSEMBLE 53, cRAP with Sigma-Aldrich Universal 
Protein Standard Sequences, monDom 5 ENSEMBLE 50.5e,  RGSC 3,4 ENSEMBLE 52, NCBIM37 
ENSEMBLE 52. 
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3) CUG-BP1: CUG-BP1, is the founder member of CELF/Bruno-like family of RNA binding 
proteins that has been reported to be involved in myotonic dystrophy type 1 (DM1) [198].  
The known members of CELF/Bruno-like family of RNA binding proteins are extremely 
comparable in their structural organization. They contain 3 RNA recognition motifs (RRM), 
one in the C-terminal region and two in the N-terminal region with high degrees of 
conservation. Interestingly for all the members, the sequence content of the linker region 
between the RRM 2 and 3 has been less conserved [199].  It has also been reported that the 
primary transcripts of several members of the CELF family are subject to alternative splicing 
with 4 known protein isoforms for human CUG-BP1 and 7 protein isoforms for CUG-BP2 
[200, 201].  Following a computational analysis in the 3’UTRs of many short-lived 
transcripts, it was found that these transcripts share an 11-mer nucleotide region 
(UGUUUGUUUGU) termed the GU-rich element (GRE).  It was also found that CUG-BP1 
binds specifically to the GRE [202].   
Due to the similarity of this 11-mer nucleotide sequence with a region within the Albumin 
3’UTR (UGUUUUCUUUU), which was removed in deletion constructs 51-100 and 51-150 
(nucleotides 75-85) and also the considerable evidence for the binding of CUB-BP1 to CUG 
and UG dinucleotide repeats that function as a regulator of translation and stability of mRNA 
transcripts, it became of interest to further study the CUG-BP1 protein and its possible 
binding to the Albumin 3’UTR.   
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NCBI id                                      Mass     log (e)     pI       rI      log (I)   
NP_941989.1                              55.1      -8.10        8.6       4      6.47 
Partial protein sequence: 
Matched peptides are highlighted and underlined: 
 1     MAAFKLDFLPEMMVEHCSLNSSPVSKKMNGTLDHPDQPDLDAIKMFVGQVPRTWSEKDLR           60 
61      ELFEQYGAVYEINVLRDRSQNPPQSKGCCFVTFYTRKAALEAQNALHNMKVLPGMHHPIQ              120 
121    MKPADSEKNNAVEDRKLFIGMISKKCTENDIRVMFSSFGQIEECRILRGPDGLSRGCAFV                 180 
181    TFTTRAMAQTAIKAMHQAQTMEGCSSPMVVKFADTQKDKEQKRMAQQLQQQMQQISAASV         240 
241    WGNLAGLNTLGPQYLALYLQLLQQTASSGNLNTLSSLHPMGGLNAMQLQNLAALAAAASA           300 
301    AQNTPSGTNALTTSSSPLSVLTSSGSSPSSSSSNSVNPIASLGALQTLAGATAGLNVSSL                        360 
420    AGMAALNGGLGSSGLSNGTGSTMEALTQAYSGIQQYAAAALPTLYNQNLLTQQSIGAAGS              480 
481    QKEGPEGANLFIYHLPQEFGDQDLLQMFMPFGNVVSAKVFIDKQTNLSKCFGFVSYDNPV                540 
541    SAQAAIQSMNGFQIGMKRLKVQLKRSKNDSKPY                                                                                      513 
Figure 6.13 Mass Spectrometry analysis result for CUG-BP1.  The data shows the identified protein’s 
specification and sequence. Log (e) represents the expectation of finding protein stochastically, pI 
represents the isoelectric value for the intact gene product, rI represents the number of found peptides 
after digestion with trypsin and log (I) represents the sum of raw spectrum intensities.  Mass 
Spectrometry analysis carried out by comparing the sequence of peptide fragments with the following 5 
protein sequence databases : cavPOR 3 ENSEMBLE 53, cRAP with Sigma-Aldrich Universal Protein 
Standard Sequences, monDom 5 ENSEMBLE 50.5e,  RGSC 3,4 ENSEMBLE 52, NCBIM37 ENSEMBLE 
52. 
 
6.2.6 Confirmation of the Albumin 3’UTR and CUG-BP1 interaction 
In attempts to confirm the results of mass spectrometry analysis and the presence of CUG-
BP1 in EMSA RNA-protein complexes, 2 experiments were carried out; a supershift and 
EMSA assay with extracts after knock down of CUG-BP1 by siRNA.  The supershift 
experiment was carried out where Rabbit Polyclonal CUG-BP1 antibody (Abcam) was used 
in a typical EMSA reaction.  Theoretically the binding of specific antibody to the complex 
would further increase the molecular weight of the complex so resulting in a greater shift.  
The supershift assay was performed as described in chapter 2 but with 0.5,1 and 2 µg of 
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CUG-BP1 antibody incubated with CHO cell extract and RNA transcript overnight ( or for 48 
hours) at 4˚C. 
It would appear from Figure 6.14 that the overnight incubation of CUG-BP1 antibody with 
the radiolabelled RNA transcript + CHO cell extract led to a slight but crucially not 
significant shift (lanes 3-5) in mobility of the complex as the volume of CUG-BP1 increased.  
It would also appear from Figure 6.14 that longer incubation of the complex with specific 
antibody (lanes 6-8) did not create any further shift in formed complex.  In addition, further 
repeats and alteration of experiment’s conditions did not induce a significant shift (data not 
shown).   
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Figure 6.14 Supershift assay with CUG-BP1. Autoradiography image showing the supershift assay result.  
A standard EMSA reaction  was performed by using radiolabelled ∆1-50 RNA transcript and S-100 CHO 
cell extracts incubated overnight with CUG-BP1 antibody (lane 3-5) or 48 hours ( lane 6-8).  Lane 1 
represents the RNA transcript only and lane 2 represents the interaction formed between the RNA 
transcript and S-100 CHO cell extract. 
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The result of supershift assay did not appear to be conclusive and therefore an alternative 
approach was used in which CUG-BP1 was knocked down by siRNA and extracts were used 
in an EMSA reaction to assess whether complex formation with the Albumin 3’UTR was 
impaired.  Since the genome of the Chinese Hamster has not yet been fully sequenced and the 
protein sequence  of CUG-BP1 in the Chinese Hamster was not known, it was decided to 
design the siRNA based on CUG-BP1 mRNA sequence in Rattus norvegicus (Accession 
number:NM_001025421) by using Blok-iTTMRNAi Designer software  (Invitrogen) and then 
perform a blast search for the sequence alignment with Mus Musculus 2 isoforms of CUG-
BP1(Accession number: NM_198683.1 & NM_017368.2), Homo sapian 3 isoforms of CUG-
BP1 (Accession number: NM_006560, & NM_198700 & NM_001025596 and finally 2 
variants of CUG-BP1 in Canis familiaris (Accession number:XM_533186 & NM_855451) to 
find sequence homology and the extent of conservation.  Following identification of the most 
conserved sequence of the CUG-BP1 amongst all the species for known CUG-BP1 
sequences, a specific siRNA (NM_001025421_stealth_1297 (RNA)- 
AAACCUUGGCAGACACGACAUUCCC), (NM_001025421_stealth_1297 (RNA)- 
GGGAAUGUCGUGUCUGCCAAGGUUU) was designed by the Blok-iTTMRNAi Designer 
software (Invitrogen) and this was used in siRNA transfection with CHO cells.  
To determine the extent of CUG-BP1 knock down, CHO cells were treated with specific 
CUG-BP1 siRNA and a negative universal control siRNA (Invitrogen).  As shown in Figure 
6.14, siRNA transfection of CHO cells successfully knocked down CUG-BP1 in the cell 
extracts collected 1-4 days after siRNA transfection.  It appeared from the data that the siRNA 
transfection had knocked down the ~55 KDa CUG-BP1 in cell populations from day 1-4.  
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Recognition of CUG-BP1 by the specific antibody was seen as distinct bands which were 
only present in cell populations treated with the negative universal control siRNA.  
The data also showed that treatment of cell populations with the negative universal control 
siRNA had no obvious negative effect on the CUG-BP1.  It also appeared from Figure 6.15 
that the CUG-BP1 antibody identifies 2 distinct bands which were only observed in cell 
extracts treated with the negative universal control siRNA.  A plausible explanation for 
observing multiple bands is the possibility of the existence of different splice variants that 
share the same epitopes and could be from the same family of protein and therefore could be 
identified by the CUG-BP1 antibody.  Furthermore, it is tempting to consider that the protein 
could have multiple modified forms in vivo as a result of events such as glycosylation, 
phosphorylation, methylation or acetylation. This could have also led to the observation of 
multiple bands seen in Figure 6.15.  
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Figure 6.15 Western blot of CHO cells transfected with siRNA probed with CUG-BP1 antibody.  CHO 
cells were transfected with siRNA for CUG-BP1 and S-100 cell extraction was performed on day 1-4 after 
transfection.  siRNA negative universal control was applied to cells day 1-4  as a negative control.  The 
arrows indicate bands which were only present in cell extracts treated with the negative universal control 
siRNA.  
 
 
Following successful siRNA transfection and CUG-BP1 knock down, it was decided to 
perform the siRNA transfection on stably transfected CHO cells with construct GG*G*Alb 
3∆β.  The aim of this experiment was firstly to visualise siRNA knock down on the stably 
transfected cell line.  Then secondly, to investigate whether is possible to knock down CUG-
BP1 and therefore impair interactions that form between the radiolabelled RNA transcript and 
the CHO cell extract.  
To achieve this, stably transfected cells (GG*G*Alb 3∆β) were transfected with siRNA and 
negative universal control siRNA. Transfection was followed by S-100 CHO cell extraction 
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from a day 3 cell population and western blotting was performed.  The selection of day 3 
samples was based on visual observation of band intensity and the manufacturer’s 
recommendation. 
As shown in Figure 6.16 the specific siRNA transfection successfully knocked down the 
CUG-BP1 whereas treatment of stably transfected cell line with the negative universal control 
siRNA had no obvious negative effect on the ~55 KDa CUG-BP1 recognition by CUG-BP1 
antibody.  
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Figure 6.16 Knock-down of CUG-BP1 in cells stably transfected with GG*G*Alb3delB. S-100 cell extracts 
were prepared from cells transfected with specific siRNA and negative universal control siRNA.  siRNA 
treated stably transfected cells line were probed with CUG-BP1 antibody.  The arrow pointing at bands 
which were only present in cell extracts treated with the negative universal control siRNA but crucially 
not specific siRNA. 
 
 
Interestingly, treatment of the stably transfected cells with specific CUG-BP1 siRNA led to a 
loss in complex formation between the radiolabelled full length Albumin 3’UTR RNA 
transcript and cell extracts (Figure 6.17), firstly confirming that CUG-BP1 knock down 
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affects protein binding to the Albumin 3’UTR and secondly suggesting that it is directly 
involved in complex formation of protein-Albumin 3’UTR. 
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Figure 6.17 EMSA with CHO cell extract from stably transfected cell line (GG*G*Alb 3∆β) treated with 
siRNA specific to CUG-BP1 and negative universal control siRNA (negative control).  The image showed 
that siRNA impairs the complex formation between RNA transcript and CHO cell extract. The arrows 
show the regions where complex formation was affected.  Lane 1 represents the RNA transcript (probe). 
Lane 2 shows the complex formation between the RNA transcript and CHO cell extract obtained from cell 
line treated with negative universal control siRNA.  Lane 3 represents the complex formation between the 
RNA transcript and CHO cell extract treated with specific CUG-BP1 siRNA.  Lane 4 represents the 
complex formation between the RNA transcript and CHO cell extract obtained from cell line without 
siRNA treatment (control). 
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6.2.7 siRNA knock down of CUG-BP1 and its effect on Luciferase activity 
 
Following successful CUG-BP1 knock down, it was decided to investigate the 
negative/positive effects of CUG-BP1 down regulation on Luciferase production and mRNA 
abundance levels in cells transfected with GG*G*Alb 3∆β and GG*G*Alb 3∆β  (∆ 51-100).  
As it was seen previously in this chapter,  UV Cross-linking and EMSA competition assays as 
well as siRNA knock down, revealed evidence of CUG-BP1 binding to the Albumin 3’UTR.  
It was therefore hypothesised that CUG-BP1 knock down would influence Luciferase protein 
secretion and mRNA abundance in the stably transfected cells with construct GG*G*Alb 3∆β 
but not construct GG*G*Alb 3∆β (∆51-100).  CHO cell lines were transfected with the 
siRNA and negative universal control siRNA.  Culture medium sample collection and total 
RNA extraction were performed on day 3 after siRNA transfection.  
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Figure 6.18 Luciferase activity in the culture medium samples shown as percentage of construct 
GG*G*Alb 3∆β (treated with negative universal control siRNA) Luciferase activity.  The data showed 
that measured secreted Luciferase did not increase significantly after treatment with siRNA.  The error 
bars represent the standard error of the mean. 
 
  
 
 
As shown in Figure 6.18 differences in Luciferase activity in cell populations treated with 
specific siRNA and negative universal control siRNA were not statistically significant.  
Interestingly, mRNA abundance level increased significantly after treatment with specific 
siRNA (Figure 6.19).  This was compatible with findings by other groups that CUG-BP1 
destabilises the mRNA targets [202], suggesting that CUG-BP1 knock down significantly 
influenced mRNA abundance level.  The data presented here suggest that although siRNA 
treatment and down regulation of CUG-BP1 stabilises the mRNA targets and result in a 
significantly higher abundance of mRNA compared to the negative control siRNA, the higher 
mRNA level, however, did not correlate with increased protein synthesis as it can be seen in 
Figure 6.20 following the normalisation of Gaussia Luciferase activity to the mRNA level.  
The imbalance between the higher level of mRNA than protein in Figure 6.19 and 6.18 
respectively, could be due to induction of the ER stress responses; the UPR and EOR (see 
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1.2.9 and 1.2.10).  It is speculated for instance that specific siRNA treatment of stably 
transfected cells with construct GG*G*Alb 3∆β leads to the activation of UPR as a result of 
aggregation of unfolded proteins in the ER. Therefore this could lead to PERK-mediated 
phosphorylation of eIF2α and subsequent repression of translation.   
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Figure 6.19 Relative quantification of mRNA abundance in stably transfected CHO cells with construct 
GG*G*Alb 3∆β after treatment with specific siRNA and negative universal control siRNA. The 
quantification of mRNA is relative to the house keeping gene GAPDH.  The data presented here showed 
that the level of mRNA expression was significantly higher after treatment with specific siRNA.  Statistical 
significance relative to the construct GG*G*Alb 3∆β was calculated by using the Mann-Whitney U test 
where **=p≤0.01 and where n=6.  The error bars represent the standard error of the mean. 
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Figure 6.20 The normalisation of Gaussia Luciferase activity to mRNA abundance.  The figure shows that 
reporter activity did not correlate with the mRNA abundance following the siRNA treatment.    
 
 
In contrast to the construct with the full Albumin 3’UTR (GG*G*Alb 3∆β) where siRNA 
treatment did not cause a significant increase in Luciferase activity, siRNA knock down and 
down regulation of CUG-BP1 in a stably transfected cell population with GG*G*Alb (∆ 51-
100) significantly increased the activity of reporter protein (Figure 6.21) and mRNA 
abundance (Figure 6.22).  Normalisation of Gaussia Luciferase activity to the mRNA level 
for cells expressing construct GG*G*Alb (∆ 51-100) clearly showed that reporter activity 
correlated with the mRNA abundance following treatment with the siRNA (see Figure 6.23). 
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Figure 6.21 Luciferase activity in the culture medium samples shown as a percentage of construct 
GG*G*Alb (∆51-100) 3∆β (treated with negative universal control siRNA) Luciferase activity.  The data 
showed that measured secreted Luciferase significantly increased after treatment of the cell line with 
specific siRNA. Statistical significance relative to the construct GG*G*Alb (∆51-100) 3∆β was calculated 
by using the Mann-Whitney U test where **=p≤0.01 and where n=6.  The error bars represent the 
standard error of the mean. 
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Figure 6.22 Relative quantification of mRNA abundance in stably transfected CHO cells with GG*G Alb 
(∆51-100) 3∆β after treatment with specific siRNA and negative universal control siRNA. The 
quantification of mRNA is relative to the house keeping gene GAPDH. The data presented here showed 
that the level of mRNA abundance was significantly higher after treatment with specific siRNA.  
Statistical significance relative to the construct GG*G*Alb (∆51-100) 3∆β was calculated by using the 
Mann-Whitney U test where **=p≤0.01 and where n=6.  The error bars represent the standard error of 
the mean. 
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Figure 6.23 The normalisation of Gaussia Luciferase activity to mRNA abundance. The figure shows that 
Gaussia Luciferase activity correlated with the mRNA abundance following treatment with the siRNA. 
This was in contrast to cells expressing the full length Albumin 3’UTR. 
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6.3 Summary 
 
Overall, in this chapter evidence of protein/s binding to the Albumin 3’UTR was presented. 
Experiments such as EMSA and UV Cross-linking were performed to identify the region/s to 
which protein/s would bind.  Here it was shown that strongest competition for binding to 
protein/s was seen with unlabelled 1-50 deletion variant when it was used as a specific 
competitor against radiolabelled full length Albumin 3’UTR RNA transcript.  Based on 
findings obtained from EMSA and UV Cross-linking competition experiments, to isolate 
protein/s that can bind to the Albumin 3’UTR, it was decided to select deletion construct 1-50 
as “bait”.  Mass spectrometry analysis was used to identify bound protein/s to the Albumin 
3’UTR.  Three proteins were identified by mass spectrometry analysis.  The identified 
proteins were as follows: 
1) Far upstream element (FUSE) binding protein 3 
2) Regulator of differentiation 1 (Rod 1) 
3) CUG-BP1 
To study CUG-BP1 further and confirm the role of CUG-BP1 in CHO cell protein-Albumin 
3’UTR complex formation, siRNA was used to knock down CUG-BP1 expression.  To design 
siRNA for Chinese Hamster CUG-BP1, Blok-iTTMRNAi Designer software (Invitrogen) was 
used and specific siRNA for Rattus norvegicus CUG-BP1 was designed.  Here it was shown 
that CUG-BP1 in CHO cells could be knocked down following siRNA transfection and 
subsequently the effects of CUG-BP1 knock down were investigated.  Here it was shown that 
siRNA knock down of CUG-BP1 leads to severe loss of complex formation between CHO 
cell extracts and the radiolabelled full length Albumin 3’UTR RNA transcript, revealing 
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firstly that protein binding to the Albumin 3’UTR is affected by CUG-BP1 siRNA knock 
down and secondly it is directly involved in complex formation of protein-Albumin 3’UTR. 
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7. Discussion 
 
Prior to this study, a series of gene constructs containing the Gaussia princeps Luciferase as 
reporter were created by utilising a seamless cloning method where the Chymotrypsinogen 
signal peptide was used in combination with either the native Gaussia Luciferase 3’UTR or 
the Albumin 3’UTR. In the present work these constructs were used, and in some cases 
further modified to remove mutations introduced during the earlier cloning, as a basis for 
further changes in the expression vector by which the signal peptide, 3’UTR or both were 
altered.  This led to constructs in which the Albumin 3’UTR was corrected for 5 point 
mutations and in which the Chymotrypsinogen signal peptide was replaced with the Human 
Albumin signal peptide.  The aims were to express these constructs in CHO cells and to 
investigate the extent to which modifications to the signal peptide/3’UTR sequences affect the 
production of recombinant reporter protein and the underlying mechanisms. 
Using the generated constructs it was shown that increasing the hydrophobicity of the 
Chymotrypsinogen signal peptide had little or no detectable influence on protein expression 
when it was used in conjunction with the Albumin 3’UTR (without vector-derived 
sequences).  Since hydrophobicity is recognised as an important factor regarding the 
operational efficiencies of signal peptides [20], one plausible explanation for this observation 
is that the Chymotrypsinogen signal peptide is already sufficiently hydrophobic and therefore 
increasing its total hydrophobicity even further had little or no detectable influence on the 
level of reporter produced.  
The data presented in chapter 4 also showed that the highest level of reporter activity and 
mRNA abundance is achieved when the native or mutated Chymotrypsinogen signal peptide 
is used in combination with the Albumin 3’UTR. On the other hand, replacing the 
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Chymotrypsinogen signal peptides with the Albumin signal peptide significantly reduced the 
level of expression of the reporter protein.  There could be multiple reasons for the lower 
Gaussia Luciferase activity in constructs containing the Albumin signal peptide. The most 
likely reason could be the lower level of Albumin signal peptide hydrophobicity compared to 
the native Gaussia or Chymotrypsinogen signal peptide (see chapter 4).  This could lead to 
inefficient recognition by SRP or the mis-targeting of mRNA transcripts. 
If time had allowed, it would have been interesting to investigate whether increasing the 
hydrophobicity of the Albumin signal peptide improves protein expression.  There are four 
amino acids within the H-domain of the Albumin signal peptide that can be replaced with 
more hydrophobic amino acids.  For instance, less hydrophobic amino acids threonine (1 
residue) and serine (3 residues) could be replaced sequentially with more hydrophobic amino 
acids such as alanine and phenylalanine) using site-directed mutagenesis.  This could produce 
several constructs with different levels of hydrophobicity for the Albumin signal peptide. 
Subsequently, the reporter activity using constructs containing the Albumin signal peptide 
varied with respect to signal peptide hydrophobicity, could be tested and any 
increase/decrease in protein production could be correlated with altered signal peptide 
hydrophobicity.   
It is tempting to speculate that by gradually increasing the hydrophobicity of the Albumin 
signal peptide, protein production should be positively influenced.  However, there will 
possibly be a point where increasing the hydrophobicity would have little or no further 
detectable effect on protein production, as was observed in this study for constructs 
containing the mutated Chymotrypsinogen signal peptide and the Gaussia 
Luciferase/Albumin 3’UTR.  
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The results shown in chapter 4 indicated that the deletion of vector-derived sequences 
significantly improved Gaussia Luciferase activity and mRNA abundance in construct 
GG*G*G 3∆β compared to that of GG*G*G.  This could have been due to the alteration of, 
or conformation changes in the secondary structure of the mRNA transcript following the 
deletion of vector-derived sequences (the partial rabbit β- globin coding region comprising of 
2 exons, one intron and the full rabbit β-globin 3’UTR), therefore leading to a higher stability 
of transcript.  In addition, it is speculated that the theoretical existence of 2 different 3’UTRs 
(the rabbit β-globin 3’UTR and either the Gaussia or Albumin 3’UTR) at the same time in a 
given transcript might cause an unknown interaction between the Gaussia Luciferase 5’UTR 
and the β-globin 3’UTR, as well as the Gaussia Luciferase 5’UTR and the Gaussia 
Luciferase/Albumin 3’UTR.  This could lead to an interaction that reduces the translatability 
of the mRNA transcript generated by a construct containing the vector-derived sequences.  
The data presented in this study also suggested that differences in secreted Luciferase activity 
and mRNA expression between constructs containing various combinations of signal 
peptide/3’UTR were not due to differences in the site of integration.  The pattern of 
Luciferase activity obtained from cells transiently transfected with the various constructs, 
correlated with the pattern of secreted Gaussia Luciferase activity in stably transfected cells. 
It was observed from the data obtained from the transiently transfected constructs that the 
highest Luciferase activity was seen in constructs containing the Chymotrypsinogen signal 
peptide and Albumin 3’UTR (without vector-derived sequences).  This was in agreement with 
the data obtained from stably transfected cells. It was also observed that deletion of vector-
derived sequences (GG*G*G 3∆β) improved protein secretion.  This too was in agreement 
with the data obtained from the stably transfected cells.  Therefore, the differences observed 
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in various constructs are unlikely to have been due to differences in the site of transgene 
integration.  
In the present work it was shown that a construct containing the Albumin 3’UTR (without 
vector-derived sequences) in combination with a sufficiently hydrophobic signal peptide 
(Chymotrypsinogen signal peptide), promotes higher levels of Luciferase activity compared 
to the native Gaussia Luciferase 3’UTR (containing vector-derived sequences).  
To understand the underlying mechanism by which the Albumin 3’UTR influences protein 
production in the context of this study and, in particular, to find out whether a specific region 
or motif within the Albumin 3’UTR is responsible for higher protein production and mRNA 
expression, a series of deletions were made within the first 150 nucleotides of this 3’UTR.  
The data obtained from cell lines stably transfected with the full length Albumin 3’UTR and 
its deletion variants showed that protein production is significantly reduced by the deletion of 
regions containing nucleotides 1-50, 1-100, 1-150, 101-150 (see table 7.1).  However, the 
high-level presence of Luciferase in culture medium samples was maintained following the 
deletion of nucleotide 51-100 and 51-150.  
The reduction of Luciferase activity in cells expressing the deletion construct 1-50 & 101-150 
was also found to be close to significance (p value = 0.055).  Interestingly, the data presented 
in chapter 5 also showed that Luciferase activity in cell extracts from cells expressing the 
deletion constructs ∆1-50, ∆1-150, ∆101-150 and ∆1-50 & 101-150 showed a similar pattern 
to those observed with the culture medium samples in that the Luciferase activity was 
significantly reduced.  The data presented in chapter 5 also showed that the deletion of 
nucleotides 1-50, 1-150 and 1-50 &101-150 significantly reduces the abundance of Luciferase 
mRNA.  
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To test the hypothesis that the differences observed in secreted Gaussia Luciferase activity 
and mRNA expression for the Albumin 3’UTR deletion variants were correlated with the 
ability of the variants to bind trans-acting factor/s, EMSA and UV Cross-linking were 
employed to assess binding to proteins in CHO cell extracts. As shown in chapter 6, there was 
specific binding of proteins to the Albumin 3’UTR.  
The data obtained from the EMSA competition assay and subsequent quantification data 
showed that the strongest competition was observed by the deletion variant 1-50.  This 
indicates that protein binding to the Albumin 3’UTR occurs primarily outside the first 50 
nucleotides.  The data obtained in chapter 5 also consistently showed that deletion of 
nucleotides 1-50 cause a significant reduction in Luciferase activity and mRNA abundance 
(see Table 7.1).  It appeared from the data presented in chapter 6 that little or no competition 
was observed by the deletion variant 1-150.  This indicated that all possible binding 
motifs/sites for the candidate protein/s are located within the first 150 nucleotides.  In 
agreement with the binding data, deletion of nucleotides 1-150 consistently showed the 
greatest reduction in Luciferase activity, both in the culture medium and cell extracts, and in 
mRNA level.  It should be noted that the observed differences in Luciferase activity and 
mRNA expression, are unlikely to have been as a result of the variation in length of the poly 
(A) region due to presence of a polyadenylation signal at nucleotide 166 to 171 of the 
Albumin 3’UTR, the position of which is similar for all deletion variants.  
The deletion variant 101-150 showed the second strongest competition with the radiolabelled 
full length Albumin 3’UTR RNA transcript and significantly reduced Luciferase activity. This 
suggested that potential regulatory motif/s for candidate protein/s are located within 
nucleotides 51-100 of the Albumin 3’UTR.  The binding data also showed a lesser degree of 
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competition with the other competitors (the deletion variant 1-100, 51-100, 51-150 and 1-50 
& 101-150).  This suggested that candidate protein/s may bind to other region/s within the 
Albumin 3’UTR with varying degrees of affinity.  
In agreement with the data obtained from EMSA competition assay, the results of the UV 
Cross-linking experiments also showed that the strongest competition for binding to a protein 
with the molecular weight of ~50 kDa was provided by the deletion variant 1-50.  This 
suggested yet again that the region containing nucleotides 1-50 is not required for binding to 
any candidate protein/s. The deletion region 101-150 provided the second strongest 
competition for binding to the protein/s with a molecular weight of ~50kDa.  This suggested 
that binding motif/s for the candidate protein is probably located in the region that contains 
nucleotides 51-100. 
Therefore, based on the findings from EMSA and UV Cross-linking competition assays 
(chapter 6), the deletion variant ∆1-50 was selected as bait to isolate and subsequently 
identify protein/s that bind to the Albumin 3’UTR RNA transcript.  Three proteins were 
identified by mass spectrophotometry analysis, and these were identified as follows:  
1) Far upstream element (FUSE) binding protein 3 
2) Regulator of differentiation 1 (Rod 1) 
3) CUG-BP1 
In this study CUG-BP1 was studied further, due to the existence of considerable previous 
evidence for the binding of CUG-BP1 to CUG and UG dinucleotide repeats and also due to 
the similarity of a region (nucleotides 75-85) within the Albumin 3’UTR 
(UGUUUUCUUUU) with a reported binding site for CUG-BP1 (UGUUUGUUUGU) .  The 
CUG-BP1 is a member of the CELF/Bruno-like family of evolutionary conserved RNA 
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binding proteins that play essential roles in post-transcriptional gene regulation.  These are 
amongst the most highly conserved RNA binding proteins, all containing three RNA 
recognition motifs [203].  CUG-BP1 was the first member of this family to be identified [198] 
and can act as a regulator for alternative splicing [203-206] , translation and stability [199, 
207, 208] and the deadenylation of target mRNA transcripts [209, 210].  CUG-BP1, was first 
identified as a protein which binds to CUG repeats in the onset of DM1 [208, 211], but 
contrary to its name it is has been shown that CUG-BP1 more readily binds to UG motifs than 
CUG repeats in a yeast three-hybrid system [212, 213].  The binding of CUG-BP1 to the 
CUG repeats could explain the aberrant pattern of splicing which is the hallmark of DM1 
[206].  Interestingly, it was shown recently that a conserved 11-mer nucleotide sequence 
(UGUUUGUUUGU) termed GU-rich element (GRE), regulates mRNA decay by binding to 
CUG-BP1 [202].   
To confirm the role of CUG-BP1 in forming CHO cell protein-Albumin 3’UTR complexes, 
CHO cells were treated with siRNA specific to CUG-BP1 and a negative universal control 
siRNA prior to S-100 CHO cell extraction.  Treatment of the stably transfected CHO cells 
with CUG-BP1 siRNA led to the severe loss of complex formation between the RNA 
transcript and cell extracts revealing that the knock down of CUG-BP1 expression affects 
protein binding to the Albumin 3’UTR, suggesting that CUG-BP1 is directly involved in 
complex formation.  
It was also shown in this study that siRNA treatment of stably transfected cells with the 
construct GG*G*Alb 3∆β did not lead to a significant increase in Gaussia Luciferase activity.  
The opposite was seen following siRNA treatment of stably transfected cells with the 
construct GG*G*Alb (∆51-100) 3∆β, where a significant increase in Gaussia Luciferase 
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activity was seen.  In contrast to the reporter activity, the mRNA expression level was 
significantly higher after siRNA treatment of the stably transfected cells with construct 
GG*G*Alb 3∆β.  In addition, siRNA treatment of stably transfected cells with construct 
GG*G*Alb (∆51-100) 3∆β also led to a significant increase in the mRNA abundance level. 
The mechanism/s which causes the discrepancy between the level of mRNA target and the 
effectiveness of its translation is not yet understood.  The differences in protein production 
and mRNA expression observed after siRNA knock down of CUG-BP1 is speculated to be a 
result of CUG-BP1 binding to its different possible binding sites or motifs within the Albumin 
3’UTR.  
 
Table 7.1 Comparative effects of Albumin 3’UTR deletions on reporter activity, mRNA expression and 
protein binding where ↓* indicates a significant reduction, Ŗ indicates no significant reduction, ↓** 
indicates 2 significant reductions, ↑** indicates increase of 2 significance , ND indicates not determined, ↔ 
indicates maintained activity, - indicates no competition, + + + + indicates the strongest competitor, + + + 
indicates the second strongest competitor, + + indicates the third strongest competitor, + indicates the 
fourth strongest competitor. 
 
Transcript Medium        Cell Extract mRNA EMSA UV Cross- 
linking 
+ siRNA 
(medium) 
+ siRNA 
(mRNA) 
∆ 1-50      ↓**             Ŗ      ↓* ++ ++    + + + +     ND     ND 
∆ 1-100      ↓*         Ŗ      Ŗ     +        -     ND     ND 
∆ 1-150      ↓**         ↓**      ↓**     -        -     ND     ND 
∆ 51-100     ↔         Ŗ      Ŗ   + +        -      ↑**     ↑** 
∆ 101-150      ↓**         ↓**      Ŗ  + + +     + + +     ND     ND 
∆ 51-150      Ŗ         Ŗ      Ŗ    +     + +     ND     ND 
∆ 1-50 & 
10150 
↓close to*         ↓**      ↓*   + +     + +     ND     ND 
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Based on the data obtained from EMSA and UV Cross-linking competition assays carried out 
in this study, it is highly tempting to speculate that CUG-BP1 binds more readily to the 11-
mer nucleotide sequence (UGUUUGUUUGU) termed GU-rich elements within the Albumin 
3’UTR (nucleotides 75-85)  with a greater affinity than to other available binding sites.   
When this binding site is deleted (deletion variant 51-100 or construct GG*G*Alb3∆β (∆51-
100)), CUG-BP1 may bind with a lower affinity to other possible binding site/s or motifs 
within the Albumin 3’UTR.  This, therefore, could be a possible explanation for the observed 
differences in mRNA abundance and protein secretion in Albumin 3’UTR deletion variants.  
It is not evident from this study whether the mechanisms by which the Albumin 3’UTR and 
subsequent protein binding involve mRNA stability or translation of transcripts.  To assess the 
stability of the transcripts (with the full length Albumin 3’UTR and the deletion variants), 
actinomycin could be used to inhibit transcription and measure half-life of various transcripts. 
Such experiments would allow a correlation to be made between the stability of mRNA 
transcript and various deletions within the Albumin 3’UTR. To address the effects of 
Albumin 3’UTR and protein binding on translation of the transcript, the association of various 
mutated mRNA transcripts of the Albumin 3’UTR with ribosomes could be examined by 
separating them on sucrose gradients (polysome profiling) and then analysing presence of 
Luciferase transcripts throughout the gradient [214].   
To summarise, in this thesis evidence for specific protein binding to the Albumin 3’UTR has 
been presented, and its probable binding site has been identified (Figure 7.1).  Furthermore, 
inclusion of the Albumin 3’UTR in a reporter vector (without vector-derived sequences) was 
shown to lead to increased Luciferase activity compared to when the native Gaussia 
Luciferase 3’UTR  was utilised in a vector containing the vector-derived sequences.  The 
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actual relationship between protein binding to the Albumin 3’UTR and the level of protein 
expression need to be explored in depth.  
 
 
Figure 7.1 Schematic representation of probable CUG-BP1 binding sites within the full length Albumin 
3’UTR (A) and the deletion variant 51-100 (B).  The proposed binding sites are underlined.  
 
 
To examine this, various deletions can be made within the Albumin 3’UTR. For instance, the 
CUG repeats and the 11-mer nucleotides UGUUUUCUUUU can be deleted and then the 
interaction between the CUG-BP1 and the Albumin 3’UTR can be examined by performing 
UV Cross-linking and EMSA competition assays.  
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8. Appendices 
8.1 DNA sequences 
 
8.1.1 Gaussia Luciferase 5’UTR:  
GGTACTCAAAGTATCTTCTGGCAGGGAAA 
8.1.2 Gaussia Luciferase signal peptide:    
ATGGGAGTCAAAGTTCTGTTTGCCCTGATCTGCATCGCTGTGGCCGAGGCC 
8.1.3 Gaussia Luciferase coding region: 
AAGCCCACCGAGAACAACGAAGACTTCAACATCGTGGCCGTGGCCAGCAACTTC
GCGACCACGGATCTCGATGCTGACCGCGGGAAGTTGCCCGGCAAGAAGCTGCCG
CTGGAGGTGCTCAAAGAGATGGAAGCCAATGCCCGGAAAGCTGGCTGCACCAGG
GGCTGTCTGATCTGCCTGTCCCACATCAAGTGCACGCCCAAGATGAAGAAGTTCA
TCCCAGGACGCTGCCACACCTACGAAGGCGACAAAGAGTCCGCACAGGGCGGCA
TAGGCGAGGCGATCGTCGACATTCCTGAGATTCCTGGGTTCAAGGACTTGGAGCC
CATGGAGCAGTTCATCGCACAGGTCGATCTGTGTGTGGACTGCACAACTGGCTGC
CTCAAAGGGCTTGCCAACGTGCAGTGTTCTGACCTGCTCAAGAAGTGGCTGCCGC
AACGCTGTGCGACCTTTGCCAGCAAGATCCAGGGCCAGGTGGACAAGATCAAGG
GGGCCGGTGGTGACTAA 
 
8.1.4 Gaussia Luciferase 3’UTR: 
TCCTAATAGAATACTGCATAACTGGATGATGATATACTAGCTTATTGCTCATAAAA
TGGCCATTTTTTGTAACAAATCGAGTCTATGTAATTCAAAATACCTAATTAATTGT
TAATACATATGTAATTCCTATAAATATAATTTATGCAATCC 
 
8.1.5 Human Albumin signal peptide: 
ATGAAGTGGGTAACCTTTATTTCCCTTCTTTTTCTCTTTAGCTCGGCTTATTCC 
 
8.1.6 Human Albumin 3’UTR: 
CATCTACATTTAAAAGCATCTCAGCCTACCATGAGAATAAGAGAAAGAAAATGA
AGATCAAAAGCTTATTCATCTGTTTTCTTTTTCGTTGGTGTAAAGCCAACACCCTG
TCTAAAAAACATAAATTTCTTTAATCATTTTGCCTCTTTTCTCTGTGCTTCAATTAA
TAAAAAATGGAAAGAATCT 
8.1.7 Human Chymotrypsinogen signal peptide: 
ATGGCTTTCCTCTGGCTCCTCTCCTGCTGGGCCCTCCTGGGTACCACCTTCGGC 
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8.2 mFold mRNA secondary structure prediction:  
 
8.2.1 Albumin 3’UTR (wild type): 
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8.2.2 ∆ 1-50:    
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8.2.3 ∆ 1-150:    
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8.3 Sequencing results: 
 
Construct GXG*Alb 3∆β 
 
Query  311   CTCGATGCTGACCGCGGGAAGTTGCCCGGCAAGAAGCTGCCGCTGGAGGTGCTCAAAGAG  370 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  59    CTCGATGCTGACCGCGGGAAGTTGCCCGGCAAGAAGCTGCCGCTGGAGGTGCTCAAAGAG  118 
 
Query  371   ATGGAAGCCAATGCCCGGAAAGCTGGCTGCACCAGGGGCTGTCTGATCTGCCTGTCCCAC  430 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  119   ATGGAAGCCAATGCCCGGAAAGCTGGCTGCACCAGGGGCTGTCTGATCTGCCTGTCCCAC  178 
 
Query  431   ATCAAGTGCACGCCCAAGATGAAGAAGTTCATCCCAGGACGCTGCCACACCTACGAAGGC  490 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  179   ATCAAGTGCACGCCCAAGATGAAGAAGTTCATCCCAGGACGCTGCCACACCTACGAAGGC  238 
 
Query  491   GACAAAGAGTCCGCACAGGGCGGCATAGGCGAGGCGATCGTCGACATTCCTGAGATTCCT  550 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  239   GACAAAGAGTCCGCACAGGGCGGCATAGGCGAGGCGATCGTCGACATTCCTGAGATTCCT  298 
 
Query  551   GGGTTCAAGGACTTGGAGCCCATGGAGCAGTTCATCGCACAGGTCGATCTGTGTGTGGAC  610 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  299   GGGTTCAAGGACTTGGAGCCCATGGAGCAGTTCATCGCACAGGTCGATCTGTGTGTGGAC  358 
 
Query  611   TGCACAACTGGCTGCCTCAAAGGGCTTGCCAACGTGCAGTGTTCTGACCTGCTCAAGAAG  670 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  359   TGCACAACTGGCTGCCTCAAAGGGCTTGCCAACGTGCAGTGTTCTGACCTGCTCAAGAAG  418 
 
Query  671   TGGCTGCCGCAACGCTGTGCGACCTTTGCCAGCAAGATCCAGGGCCAGGTGGACAAGATC  730 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  419   TGGCTGCCGCAACGCTGTGCGACCTTTGCCAGCAAGATCCAGGGCCAGGTGGACAAGATC  478 
 
Query  731   AAGGGGGCCGGTGGTGACTAACATCTACATTTAAAAGCATCTCAGCCTACCATGAGAATA  790 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  479   AAGGGGGCCGGTGGTGACTAACATCTACATTTAAAAGCATCTCAGCCTACCATGAGAATA  538 
 
Query  791   AGAGAAAGAAAATGAAGATCAAAAGCTTATTCATCTGTTTTCTTTTTCGTTGGTGTAAAG  850 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  539   AGAGAAAGAAAATGAAGATCAAAAGCTTATTCATCTGTTTTCTTTTTCGTTGGTGTAAAG  598 
 
Query  851   CCAACACCCTGTCTAAAAAACATAAATTTCTTTAATCATTTTGCCTCTTTTCTCTGTGCT  910 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  599   CCAACACCCTGTCTAAAAAACATAAATTTCTTTAATCATTTTGCCTCTTTTCTCTGTGCT  658 
 
Query  911   TCAATTAATAAAAAATGGAAAGAATCTAATAGTGTGTGGGAATTTTTTGTGTCTCTCACT  970 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  659   TCAATTAATAAAAAATGGAAAGAATCTAATAGTGTGTGGGAATTTTTTGTGTCTCTCACT  718 
 
Query  971   CGGAAGGACATATGGGAGGGCAATCATTTAAAACATCAGAATGAGTATTTGGTTTAGAGT  1030 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  719   CGGAAGGACATATGGGAGGGCAATCATTTAAAACATCAGAATGAGTATTTGGTTTAGAGT  778 
 
Query  1031  TTGGCAACATATGCCCATATGCTGGCTGCCATGAACAAAGGTTGGCTATAAAGAGGTCAT  1090 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  779   TTGGCAACATATGCCCATATGCTGGCTGCCATGAACAAAGGTTGGCTATAAAGAGGTCAT  838 
 
Query  1091  CAGTATATGAAACAGCCCCCTGCTGTCCATTCCTTATTCCATAGAAAAGCCTTGACTTGA  1150 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  839   CAGTATATGAAACAGCCCCCTGCTGTCCATTCCTTATTCCATAGAAAAGCCTTGACTTGA  898 
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Query  1151  GGTTAGAttttttttatattttgttttgtgttatttttttctttAACATCCCTAAAATTT  1210 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  899   GGTTAGATTTTTTTTATATTTTGTTTTGTGTTATTTTTTTCTTTAACATCCCTAAAATTT  958 
 
Query  1211  TCCTTACATG  1220 
             |||||||||| 
Sbjct  959   TCCTTACATG  968 
 
 
 
 
Construct GAG*G 3∆β 
 
 
Query  61   CCTCCGCGGCCCCGAATTCGAGCTCGGTACCCGGGGATCCCCCGGGCTGCAGGAATTCGG  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  94   CCTCCGCGGCCCCGAATTCGAGCTCGGTACCCGGGGATCCCCCGGGCTGCAGGAATTCGG  153 
 
Query  121  CACGAGGGTACTCAAAGTATCTTCTGGCAGGGAAAATGAAGTGGGTAACCTTTATTTCCC  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  154  CACGAGGGTACTCAAAGTATCTTCTGGCAGGGAAAATGAAGTGGGTAACCTTTATTTCCC  213 
 
Query  181  TTCTTTTTCTCTTTAGCTCGGCTTATTCCAAGCCCACCGAGAACAACGAAGACTTCAACA  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  214  TTCTTTTTCTCTTTAGCTCGGCTTATTCCAAGCCCACCGAGAACAACGAAGACTTCAACA  273 
 
Query  241  TCGTGGCCGTGGCCAGCAACTTCGCGACCACGGATCTCGATGCTGACCGCGGGAAGTTGC  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  274  TCGTGGCCGTGGCCAGCAACTTCGCGACCACGGATCTCGATGCTGACCGCGGGAAGTTGC  333 
 
Query  301  CCGGCAAGAAGCTGCCGCTGGAGGTGCTCAAAGAGATGGAAGCCAATGCCCGGAAAGCTG  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  334  CCGGCAAGAAGCTGCCGCTGGAGGTGCTCAAAGAGATGGAAGCCAATGCCCGGAAAGCTG  393 
 
Query  361  GCTGCACCAGGGGCTGTCTGATCTGCCTGTCCCACATCAAGTGCACGCCCAAGATGAAGA  420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  394  GCTGCACCAGGGGCTGTCTGATCTGCCTGTCCCACATCAAGTGCACGCCCAAGATGAAGA  453 
 
Query  421  AGTTCATCCCAGGACGCTGCCACACCTACGAAGGCGACAAAGAGTCCGCACAGGGCGGCA  480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  454  AGTTCATCCCAGGACGCTGCCACACCTACGAAGGCGACAAAGAGTCCGCACAGGGCGGCA  513 
 
Query  481  TAGGCGAGGCGATCGTCGACATTCCTGAGATTCCTGGGTTCAAGGACTTGGAGCCCATGG  540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  514  TAGGCGAGGCGATCGTCGACATTCCTGAGATTCCTGGGTTCAAGGACTTGGAGCCCATGG  573 
 
Query  541  AGCAGTTCATCGCACAGGTCGATCTGTGTGTGGACTGCACAACTGGCTGCCTCAAAGGGC  600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  574  AGCAGTTCATCGCACAGGTCGATCTGTGTGTGGACTGCACAACTGGCTGCCTCAAAGGGC  633 
 
Query  601  TTGCCAACGTGCAGTGTTCTGACCTGCTCAAGAAGTGGCTGCCGCAACGCTGTGCGACCT  660 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  634  TTGCCAACGTGCAGTGTTCTGACCTGCTCAAGAAGTGGCTGCCGCAACGCTGTGCGACCT  693 
 
Query  661  TTGCCAGCAAGATCCAGGGCCAGGTGGACAAGATCAAGGGGGCCGGTGGTGACTAATCCT  720 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  694  TTGCCAGCAAGATCCAGGGCCAGGTGGACAAGATCAAGGGGGCCGGTGGTGACTAATCCT  753 
 
Query  721  AATAGAATACTGCATAACTGGATGATGATATACTAGCTTATTGCTCATAAAATGGCCATT  780 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
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Sbjct  754  AATAGAATACTGCATAACTGGATGATGATATACTAGCTTATTGCTCATAAAATGGCCATT  813 
 
Query  781  TTTTGTAACAAATCGAGTCTATGTAATTCAAAATACCTAATTAATTGTTAATACATATGT  840 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  814  TTTTGTAACAAATCGAGTCTATGTAATTCAAAATACCTAATTAATTGTTAATACATATGT  873 
 
Query  841  AATTCCTATAAATATAATTTATGCAATCC  869 
            ||||||||||||||||||||||||||||| 
Sbjct  874  AATTCCTATAAATATAATTTATGCAATCC  902 
 
 
 
Construct GAG*Alb 3∆β 
 
Query  61   CCTCCGCGGCCCCGAATTCGAGCTCGGTACCCGGGGATCCCCCGGGCTGCAGGAATTCGG  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  77   CCTCCGCGGCCCCGAATTCGAGCTCGGTACCCGGGGATCCCCCGGGCTGCAGGAATTCGG  136 
 
Query  121  CACGAGGGTACTCAAAGTATCTTCTGGCAGGGAAAATGAAGTGGGTAACCTTTATTTCCC  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  137  CACGAGGGTACTCAAAGTATCTTCTGGCAGGGAAAATGAAGTGGGTAACCTTTATTTCCC  196 
 
Query  181  TTCTTTTTCTCTTTAGCTCGGCTTATTCCAAGCCCACCGAGAACAACGAAGACTTCAACA  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  197  TTCTTTTTCTCTTTAGCTCGGCTTATTCCAAGCCCACCGAGAACAACGAAGACTTCAACA  256 
 
Query  241  TCGTGGCCGTGGCCAGCAACTTCGCGACCACGGATCTCGATGCTGACCGCGGGAAGTTGC  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  257  TCGTGGCCGTGGCCAGCAACTTCGCGACCACGGATCTCGATGCTGACCGCGGGAAGTTGC  316 
 
Query  301  CCGGCAAGAAGCTGCCGCTGGAGGTGCTCAAAGAGATGGAAGCCAATGCCCGGAAAGCTG  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  317  CCGGCAAGAAGCTGCCGCTGGAGGTGCTCAAAGAGATGGAAGCCAATGCCCGGAAAGCTG  376 
 
Query  361  GCTGCACCAGGGGCTGTCTGATCTGCCTGTCCCACATCAAGTGCACGCCCAAGATGAAGA  420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  377  GCTGCACCAGGGGCTGTCTGATCTGCCTGTCCCACATCAAGTGCACGCCCAAGATGAAGA  436 
 
Query  421  AGTTCATCCCAGGACGCTGCCACACCTACGAAGGCGACAAAGAGTCCGCACAGGGCGGCA  480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  437  AGTTCATCCCAGGACGCTGCCACACCTACGAAGGCGACAAAGAGTCCGCACAGGGCGGCA  496 
 
Query  481  TAGGCGAGGCGATCGTCGACATTCCTGAGATTCCTGGGTTCAAGGACTTGGAGCCCATGG  540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  497  TAGGCGAGGCGATCGTCGACATTCCTGAGATTCCTGGGTTCAAGGACTTGGAGCCCATGG  556 
 
Query  541  AGCAGTTCATCGCACAGGTCGATCTGTGTGTGGACTGCACAACTGGCTGCCTCAAAGGGC  600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  557  AGCAGTTCATCGCACAGGTCGATCTGTGTGTGGACTGCACAACTGGCTGCCTCAAAGGGC  616 
 
Query  601  TTGCCAACGTGCAGTGTTCTGACCTGCTCAAGAAGTGGCTGCCGCAACGCTGTGCGACCT  660 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  617  TTGCCAACGTGCAGTGTTCTGACCTGCTCAAGAAGTGGCTGCCGCAACGCTGTGCGACCT  676 
 
Query  661  TTGCCAGCAAGATCCAGGGCCAGGTGGACAAGATCAAGGGGGCCGGTGGTGACTAACATC  720 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  677  TTGCCAGCAAGATCCAGGGCCAGGTGGACAAGATCAAGGGGGCCGGTGGTGACTAACATC  736 
 
Query  721  TACATTTAAAAGCATCTCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAAAAG  780 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  737  TACATTTAAAAGCATCTCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAAAAG  796 
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Query  781  CTTATTCATCTGTTTTCTTTTTCGTTGGTGTAAAGCCAACAC  822 
            |||||||||||||||||||||||||||||||||||||||||| 
Sbjct  797  CTTATTCATCTGTTTTCTTTTTCGTTGGTGTAAAGCCAACAC  838 
 
 
 
 
Albumin 3’UTR deletion construct 51-150 
 
 
 
Query  87   GGGGATCCCCCGGGCTGCAGGAATTCGGCACGAGGGTACTCAAAGTATCTTCTGGCAGGG  146 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  68   GGGGATCCCCCGGGCTGCAGGAATTCGGCACGAGGGTACTCAAAGTATCTTCTGGCAGGG  127 
 
Query  147  AAAATGGGAGTCAAAGTTCTGTTTGCCCTGATCTGCATCGCTGTGGCCGAGGCCAAGCCC  206 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  128  AAAATGGGAGTCAAAGTTCTGTTTGCCCTGATCTGCATCGCTGTGGCCGAGGCCAAGCCC  187 
 
Query  207  ACCGAGAACAACGAAGACTTCAACATCGTGGCCGTGGCCAGCAACTTCGCGACCACGGAT  266 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  188  ACCGAGAACAACGAAGACTTCAACATCGTGGCCGTGGCCAGCAACTTCGCGACCACGGAT  247 
 
Query  267  CTCGATGCTGACCGCGGGAAGTTGCCCGGCAAGAAGCTGCCGCTGGAGGTGCTCAAAGAG  326 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  248  CTCGATGCTGACCGCGGGAAGTTGCCCGGCAAGAAGCTGCCGCTGGAGGTGCTCAAAGAG  307 
 
Query  327  ATGGAAGCCAATGCCCGGAAAGCTGGCTGCACCAGGGGCTGTCTGATCTGCCTGTCCCAC  386 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  308  ATGGAAGCCAATGCCCGGAAAGCTGGCTGCACCAGGGGCTGTCTGATCTGCCTGTCCCAC  367 
 
Query  387  ATCAAGTGCACGCCCAAGATGAAGAAGTTCATCCCAGGACGCTGCCACACCTACGAAGGC  446 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  368  ATCAAGTGCACGCCCAAGATGAAGAAGTTCATCCCAGGACGCTGCCACACCTACGAAGGC  427 
 
Query  447  GACAAAGAGTCCGCACAGGGCGGCATAGGCGAGGCGATCGTCGACATTCCTGAGATTCCT  506 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  428  GACAAAGAGTCCGCACAGGGCGGCATAGGCGAGGCGATCGTCGACATTCCTGAGATTCCT  487 
 
Query  507  GGGTTCAAGGACTTGGAGCCCATGGAGCAGTTCATCGCACAGGTCGATCTGTGTGTGGAC  566 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  488  GGGTTCAAGGACTTGGAGCCCATGGAGCAGTTCATCGCACAGGTCGATCTGTGTGTGGAC  547 
 
Query  567  TGCACAACTGGCTGCCTCAAAGGGCTTGCCAACGTGCAGTGTTCTGACCTGCTCAAGAAG  626 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  548  TGCACAACTGGCTGCCTCAAAGGGCTTGCCAACGTGCAGTGTTCTGACCTGCTCAAGAAG  607 
 
Query  627  TGGCTGCCGCAACGCTGTGCGACCTTTGCCAGCAAGATCCAGGGCCAGGTGGACAAGATC  686 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  608  TGGCTGCCGCAACGCTGTGCGACCTTTGCCAGCAAGATCCAGGGCCAGGTGGACAAGATC  667 
 
Query  687  AAGGGGGCCGGTGGTGACTAACATCTACATTTAAAAGCATCTCAGCCTACCATGAGAATA  746 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  668  AAGGGGGCCGGTGGTGACTAACATCTACATTTAAAAGCATCTCAGCCTACCATGAGAATA  727 
 
Query  747  AGAGAAAGAAACTCTGTGCTTCAATTAATAAAAAATGGAAAGAATCT  793 
            ||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  728  AGAGAAAGAAACTCTGTGCTTCAATTAATAAAAAATGGAAAGAATCT  774 
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Albumin 3’UTR deletion construct 1-50&101-150 
 
 
Query  89   GCTGCAGGAATTCGGCACGAGGGTACTCAAAGTATCTTCTGGCAGGGAAAATGGGAGTCA  148 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  82   GCTGCAGGAATTCGGCACGAGGGTACTCAAAGTATCTTCTGGCAGGGAAAATGGGAGTCA  141 
 
Query  149  AAGTTCTGTTTGCCCTGATCTGCATCGCTGTGGCCGAGGCCAAGCCCACCGAGAACAACG  208 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  142  AAGTTCTGTTTGCCCTGATCTGCATCGCTGTGGCCGAGGCCAAGCCCACCGAGAACAACG  201 
 
Query  209  AAGACTTCAACATCGTGGCCGTGGCCAGCAACTTCGCGACCACGGATCTCGATGCTGACC  268 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  202  AAGACTTCAACATCGTGGCCGTGGCCAGCAACTTCGCGACCACGGATCTCGATGCTGACC  261 
 
Query  269  GCGGGAAGTTGCCCGGCAAGAAGCTGCCGCTGGAGGTGCTCAAAGAGATGGAAGCCAATG  328 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  262  GCGGGAAGTTGCCCGGCAAGAAGCTGCCGCTGGAGGTGCTCAAAGAGATGGAAGCCAATG  321 
 
Query  329  CCCGGAAAGCTGGCTGCACCAGGGGCTGTCTGATCTGCCTGTCCCACATCAAGTGCACGC  388 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  322  CCCGGAAAGCTGGCTGCACCAGGGGCTGTCTGATCTGCCTGTCCCACATCAAGTGCACGC  381 
 
Query  389  CCAAGATGAAGAAGTTCATCCCAGGACGCTGCCACACCTACGAAGGCGACAAAGAGTCCG  448 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  382  CCAAGATGAAGAAGTTCATCCCAGGACGCTGCCACACCTACGAAGGCGACAAAGAGTCCG  441 
 
Query  449  CACAGGGCGGCATAGGCGAGGCGATCGTCGACATTCCTGAGATTCCTGGGTTCAAGGACT  508 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  442  CACAGGGCGGCATAGGCGAGGCGATCGTCGACATTCCTGAGATTCCTGGGTTCAAGGACT  501 
 
Query  509  TGGAGCCCATGGAGCAGTTCATCGCACAGGTCGATCTGTGTGTGGACTGCACAACTGGCT  568 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  502  TGGAGCCCATGGAGCAGTTCATCGCACAGGTCGATCTGTGTGTGGACTGCACAACTGGCT  561 
 
Query  569  GCCTCAAAGGGCTTGCCAACGTGCAGTGTTCTGACCTGCTCAAGAAGTGGCTGCCGCAAC  628 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  562  GCCTCAAAGGGCTTGCCAACGTGCAGTGTTCTGACCTGCTCAAGAAGTGGCTGCCGCAAC  621 
 
Query  629  GCTGTGCGACCTTTGCCAGCAAGATCCAGGGCCAGGTGGACAAGATCAAGGGGGCCGGTG  688 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  622  GCTGTGCGACCTTTGCCAGCAAGATCCAGGGCCAGGTGGACAAGATCAAGGGGGCCGGTG  681 
 
Query  689  GTGACTAAATGAAGATCAAAAGCTTATTCATCTGTTTTCTTTTTCGTTGGTGTAAAGCCT  748 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  682  GTGACTAAATGAAGATCAAAAGCTTATTCATCTGTTTTCTTTTTCGTTGGTGTAAAGCCT  741 
 
Query  749  CTGTGCTTCAATTAATAAAAAATGGAAAGAATCT  782 
            |||||||||||||||||||||||||||||||||| 
Sbjct  742  CTGTGCTTCAATTAATAAAAAATGGAAAGAATCT  77 
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 8.4 Programme Settings for Real-Time PCR  
Detection Format                         Block Type                                      Reaction Volume 
SYBR Green                                 96 (LightCycler®480)                           20µl 
Programs 
Programs Name                           Cycle                                                 Analysis Mode 
 Pre-Incubation                                1                                                         None 
Amplification                                  60                                                      Quantification 
Melting Curve                                 1                                                         Melting Curves 
Cooling                                            1                                                         None 
Temperature Targets  
Target (°C)     Acquisition Mode     Hold (hh:mm:ss)     Ramp rate    Acquisition (per °C) 
Pre-Incubation: 
  95                             None                           00:05:00                         4.4                 _ 
  Amplification:  
 95                             None                            00:00:10                         4.4                 _ 
 63                             None                            00:00:15                         4.4                 _ 
72                             Single                            00:00:05                         2.2                 _ 
Melting Curve 
95                             None                             00:00:05                         4.4                 _ 
65                            None                              00:10:00                         2.2                 _ 
97                           Continues                       _                                      _                    5 
Cooling   
4                             None                              00:00:10                          1.5                 - 
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